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Abstract
Cutaneous squamous cell carcinoma (cSCC) is a common skin malignancy. Rates of cSCC in
Australia are the highest in the world, approaching 800 cases/100 000 people per annum in
North Queensland. Between 2-5% of cSCC will metastasise to regional lymph nodes,
representing a higher clinical stage and requiring more aggressive and more morbid
treatment, principally surgery and radiotherapy. Little is known of the molecular mechanisms
of metastasis in cSCC, which makes a stratified method of appropriate surveillance
challenging.
Patients with biopsy proven metastatic cSCC to lymph nodes of the head and neck were
identified and recruited for fresh tumour and whole blood harvest. DNA extracted from 19
nodal metastases of cSCC was sequenced using whole genome sequencing. Following quality
control, in particular verification of tumour cellularity, this number was reduced to 15 for the
purposes of the study. Tumour DNA was compared to DNA from whole blood (germline) to
establish the pattern of somatic variation.
Approaching 98% of the somatic short variants observed were in the noncoding regions of
the genome in all samples. A mutational burden (207/Mb) greater than any other malignancy
previously described underpinned the mutational landscape, characterised by UV implicated
C>T single nucleotide variation in known oncogenes and tumour suppressor genes, a highly
amplified genome and significant structural variation, particularly involving TTC28.
Recurrent high impact short variants were seen in known cancer associated genes including
TP53, CDKN2A and NOTCH1, but also in less well described but emerging genes of interest
including MECOM, PTPRD, PLCB4, PCLO, CSMD3 and FAT4. Non-coding variants were
particularly evident in the TERT promoter region identifying a variant pattern not previously
found in cSCC. Significant amplification of microRNA miR-3147 was seen in all samples.

i

Prominent amplification of cancer associated long non-coding RNAs not previously
identified in cSCC was observed. These included PVT1, MALAT1, HULC and NORAD.
Expression changes resulting from somatic mutation were explored using co-extracted RNA
on the NanoString platform. Prominent overexpression of key genes in cancer progression
and metastasis was observed such as NDRG1, PIK3CA and SOX2.
This work has catalogued the extent and pattern of somatic variation in metastatic cSCC and
has provided potential new targets that can now be investigated for their utility as biomarkers
of progression and metastasis.
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1 Introduction
The perfect storm for cutaneous malignancy would be for a fair-skinned people to occupy a
land with extreme ultraviolet radiation for most months of the year, to serially avoid sensible
preventive strategies to avoid excessive solar skin damage, and to have an excellent health
system which means the majority of the inhabitants live beyond 80 years of age. This perfect
storm is the public health and clinical scenario that has given rise to the tsunami of cutaneous
Squamous Cell Carcinoma (cSCC) in Australia, New Zealand and the US.
For at least 40 years, Australia has been at the forefront of public health campaigns to
promote preventive sun exposure strategies. It is likely these efforts will eventually lead to a
decrease in the incidence of cSCC. But aside from a few examples, our research has centred
on elegantly describing what we see in the clinic and observe during follow up. Very little is
known about the molecular basis of advanced cutaneous squamous cell carcinoma. The era of
massive parallel sequencing has allowed for a deeper understanding of the molecular biology
of many cancers. The accessibility of such processing lead to our employing whole genome
sequencing to further explore the mutational profile of metastatic cSCC. Our challenge, and
responsibility, was to use the opportunity afforded us by our clinical workload to progress the
understanding of the molecular and genetic basis of metastatic cSCC.

1.1 Clinical context
Cutaneous squamous cell carcinoma (cSCC) is the second most common malignancy, after
basal cell carcinoma (BCC), affecting up to 500 000 people in the United States (US)
annually (American Cancer Society 2018). The non-melanoma skin cancers (NMSC) are
more common than all other cancers combined (Fransen, Karahalios et al 2012). The burden
of NMSC is so great that central cancer registries in both the US and Australia specifically
exclude the collection of data on their incidence. Though absolute incidence of NMSC and
cSCC in Australia is simply unknown, current estimates are >176,000 cases per year (Perera
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et al 2015) . In a 2017 review of Australian Health Insurance Commission billing items and
tissue subtypes (Pandeya et al 2017), the incidence of primary cSCC was estimated at 270 per
100 000 person-years.

Figure 1-1. 29 year old male with left lower lip cSCC with metastasis to ipsilateral
upper cervical lymph nodes. Treatment entailed radical excision of lower lip cSCC and
selective neck dissection followed by adjuvant external beam radiotherapy (Ashford
patient).
The highest incidence is observed in Queensland, Australia where the annual age adjusted
incidence of cSCC was determined to be 573/100 000 in males (Pandeya et al 2017).
Lymph node metastases occur in approximately 2-5% of cSCC (Venebles, Autier et al 2018,
Forest, Clark 2010). The majority of cSCC arising in the scalp and face generally show a
predictable pattern of spread predominantly to intraparotid, level II (upper jugular) and
perifacial lymph nodes (Forest, Clark et al. 2010) see also Figure 1-1 and Figure 1-2.
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Figure 1-2. Lymph node levels of the neck. Taken from chapter “Advanced
Developments in Neck Dissection Technique: Perspectives in Minimally Invasive
Surgery” in “Neck Dissection- Clinical Application and Recent Advances” Lee and
Chung (2012)

The pattern of lymph node metastasis from varying regions of the head and neck was first
described in a landmark survey of 209 patients with metastatic cSCC from known primary
locations (Vauterin, Veness et al 2006). Of particular note was the importance of the nodal
basins of the parotid gland and the drainage along the external jugular vein lymphatics
(Figure 1-3). This was the first detailed description of this pattern of metastasis in cSCC in an
Australian cohort.
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Figure 1-3 Patterns of spread to regional lymph nodes depending upon location of
primary, noting the predilection for parotid and external jugular drainage (From
Vauterin, Veness et al 2006)
Limited progress has been made in the management of regionally advanced disease over the
last 15 years. Most patients are managed with parotidectomy, neck dissection and adjuvant
external beam radiotherapy depending on the site and stage at diagnosis (Veness 2005).
Treatment failures are usually locoregional. Durable salvage following locoregional failure
is rarely achievable as there are no effective second line therapies. Options for retreatment in
this setting principally include radical surgical resections and are highly morbid, with
profound physical, functional and psychosocial effects that greatly affect the quality of life
for both patients and their carers. The ageing Australian population also means that there will
be an increase in the incidence of cSCC, principally neglected head and neck cutaneous
primary disease and metastases to the parotid and the regional lymph nodes.
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The Sydney Head and Neck Cancer Institute manages advanced/metastatic cSCC in a
multidisciplinary setting and treats in excess of 80 cases per annum and has published
extensively on the staging, clinicopathological features and outcomes of metastatic cSCC
(Ch’ng 2013, Forrest 2010, Gore 2016). My clinical practice in Wollongong included more
than 30 cases of metastatic cSCC/year over the years 2013-16.

Unfortunately, despite high-level prospective data, the best predictors of nodal metastases
such as tumour thickness and perineural invasion are not sufficiently discriminatory to
change clinical practice because the majority (>85%) of ‘high risk’ tumours will not develop
metastases. In addition, the ‘high risk’ predictors for nodal metastases do not address the
critical group with medium to low-risk local disease where early intervention for nodal
metastases will impact on survival (Ch’ng, Clark et al 2013). This was clearly demonstrated
in the largest series of sentinel node biopsies for ‘high risk’ cSCC where mortality due to
local recurrence out-weighed any beneficial effect (see Gore et al 2016 below).

1.2 Aetiology of cSCC
Ultraviolet (UV) radiation exposure and immunosuppression are the key factors in the
development of cSCC (Alam, Ratner 2001). UVB (280-315nm wavelength) is the dominant
environmental risk factor for cSCC (Armstrong, Kricker 2001). Long term sun exposure
implies an increased risk, particularly in individuals with skin photosensitivity and lower
melanin content as determined by the Fitzpatrick classification of skin phenotypes. This is
more frequent in males and increases with age. UVB induced p53 loss of function is the
index event in cSCC carcinogenesis.
Immunosuppression is a critical risk factor for both the development and metastasis of
cSCC(Euvrard, Kanitakis et al. 2003). Nearly 82% of Australian transplant recipients will
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develop skin cancers 20 years post transplant (Veness, Quinn 1999). The immunosuppressed
population shows higher recurrence rates of cSCC. The rates of metastasis are ten times
greater than immunocompetent individuals. The degree of immunosuppression also confers
greater risk for development of cSCC following transplant. For example, heart transplant
recipients and those who suffer from rejection events within the first year generally require
greater levels of immunosuppression and have higher rates of cSCC than the wider transplant
population (Veness, Quinn 1999).
Rare inherited genetic conditions such as Xeroderma pigmentosa, an autosomal recessive
disorder of DNA repair following UV induced injury, lead to cutaneous malignancy and
death due to melanoma and cSCC (Soufir 2000).

1.3 Staging of cSCC
Staging of solid organ malignancies is according to the American Joint Committee on Cancer
(AJCC) Cancer Staging Manual, currently in 8th edition. This Manual stratifies disease in
clinical and pathological stages in terms of primary Tumour, Lymph Nodes and distant
Metastasis (TNM). The current version for SCC of the head and neck is presented in
Appendix 1. Nodal metastasis confers a five year survival ranging from 55 to 75% (Brunner,
Veness 2013).

It is worth noting that there is no discrimination between mucosal and cutaneous disease,
which has led to criticism as to the utilities of the staging system to act as a prognostic tool
(Liu, Ebrahimi 2017). The limitations of the 8th edition of the AJCC Cancer Staging Manual
with respect to cutaneous head & neck SCC are indicative of our relative lack of
understanding of this disease.
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1.4 Conventional methods for assessment of metastatic potential of cSCC
Traditional means of assessing risk of metastasis in primary cSCC include clinical features
such as location of the primary (lip and ear) and immunosuppression, and histopathological
features such as tumour thickness, poor differentiation, lymphovascular invasion and
perineural infiltration (Peat, Insull et al. 2012). These semiqualitative factors are highly
unreliable predictors of metastatic potential.

Immunohistochemistry (IHC) is a cost effective method of detecting protein expression that
can be easily integrated into the routine clinical diagnostic workup of patients. Differential
protein expression secondary to mutations or post translational changes could be explored in
patients with cSCC.

Currently, there are no reliable immunohistochemical stains that can be used for evaluation of
metastatic potential in routine diagnostic work up of any organ system. Various experimental
stains including focal adhesion kinase (FAK) are being evaluated in gynaecologic and
urologic malignancies with promising results in estimation of metastatic spread (Aust, Auer
2014). Other experimental immunostains such as wingless type receptor homolog 6 (FZD6),
pleiotropin (PTN), cathepsin and matrix metalloproteinases (1,10,13) have been evaluated in
research settings but are not used in clinical practice.

In a well-designed prospective study (Brantsch, Meisner et al. 2008), thickness,
immunosuppression, location on the ear and maximum tumour dimension were identified as
significant predictors of metastasis. Factors predicting for nodal metastases are often
interchangeable with prognostic factors. In a review of 239 patients with established nodal
metastases from cSCC (Ch’ng, Clark 2013), multivariate analysis of the primary tumour

7

including tumour differentiation, margin status, tumour size and thickness found that only
poor tumour differentiation of the primary was associated with shorter disease free survival.
Similarly, Brantsch et al identified thickness >6.0mm and poor differentiation as significant
factors for metastasis. Our study outlined below (Gore, Shaw et al 2016) reporting a large
series of sentinel node biopsies for high risk cutaneous SCC supports the importance of
tumour thickness. Nodal metastases only occurred in tumours more than 4mm thick and the
number of high risk factors (4 or more) was the best predictor of nodal metastases, rather than
any individual clinicopathological variable.

We are not the first group to attempt to establish a link between types of primary tumours and
the likelihood of metastatic disease. Sentinel node biopsy (SNB) is used in numerous
malignancies including breast and penile carcinoma, as well as in melanoma to stage nodal
disease in higher risk primary tumours (Giuliano, Kirgan et al 1994, Kelley, Ollila et al
1998). Sentinel node biopsy allows for the detection of low volume nodal metastasis in the
most likely first echelon node immediately downstream of the index lesion. The facility of
detailed examination of a single lymph node is to allow for multiple and serial sectioning of a
single node not possible in the multiple lymph nodes seen in a larger sample harvested in a
formal neck dissection. The examination of sentinel nodes in high risk cSCC might allow for
the alignment of risk factors beyond those previously described for metastasis.

Our group has published the largest prospective series of sentinel node examination in high
risk cSCC (Gore, Shaw et al 2016). Patients with high risk primary cSCC were prospectively
enrolled to undergo sentinel node biopsy. Full clinicopathological status was documented and
the patients were followed for recurrence and also emergence of occult nodal disease despite
negative sentinel node status (false negative biopsy).
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Inclusion criteria comprised at least one of these characteristics in a patient with cSCC:
1. Tumour size > 2cm
2. Invasion into subcutaneous fat or tumour thickness >5 mm
3. Poorly differentiated tumour
4. Perineural invasion
5. Lymphovascular invasion
6. Local Recurrence in the setting of adequate prior resection margins
7. Ear or lip location
8. Immunocompromise (post-organ transplant, chemotherapy)
9. Carcinoma in pre-existing scar
Enrolled patients received treatment based on the nature of their presentation. Patients who
presented with a high-risk primary or recurrent cSCC were offered wide excision of the
tumour and concurrent SNB. Those who presented following excision of a cSCC that was
subsequently confirmed (by pathological or clinical criteria) to be high-risk were offered
secondary SNB, either alone or along with a wider excision if that were deemed appropriate.

Identification of the likely sentinel node was achieved using both radio-isotope and
intraoperative mapping. Pre-operative lymphoscintigraphy was performed according to local
nuclear medicine department protocols. Intra-operatively patent blue dye or isosulfan blue
was injected intradermally at four points around the middle of the scar, tumour or the edge of
a small skin graft or flap.

SNB was typically performed prior to primary tumour excision, unless the location of the
primary tumour hampered the detection of the sentinel node field in which case the primary
tumour site was resected first. Incisions for SNB were made in appropriately planned sites for
inclusion in potential completion lymph node dissections. Sentinel nodes were identified by
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the combination of the pre-operative lymphoscintigram, the visually identified “blue” node
and the use of a hand-held gamma probe.

Primary tumour resection margins were individualized according to clinicopathological
criteria, in all cases aiming for macroscopic tumour clearance and histologically clear
margins. Wound closure was at the discretion of the operating surgeon.

All Sentinel nodes were cut along their longitudinal axis in 3 mm thick slices and embedded
entirely in paraffin blocks following tissue processing. Four sequential 5μm tissue sections
were cut from each block and stained with haematoxylin and eosin (sections 1 and 4) and
cytokeratins for immunohistochemistry (sections 2 and 3). Each section was examined
microscopically for the presence of metastatic tumour cells by an experienced
histopathologist.

SNB was undertaken in 45 patients (79%) at the time of cSCC resection, of which 17 (30%)
were recurrent tumours. In 12 cases (21%) pathological analysis of the primary tumour
following excision prompted SNB and further wide local excision was performed to achieve
adequate margins.

The mean tumour diameter was 25mm (range 6 - 65mm) and mean depth of invasion was
9.2mm (range 1.0 – 22mm). In 44 cases the tumour was over 5mm thick or was at least
invading to Clark level 4. In 22 patients previous surgery had been performed in the region of
the tumour and 31 patients had been treated for prior non-melanoma skin cancer. The mean
number of sentinel nodes identified on pre-operative lymphoscintigraphy was 2.2 (range 0-6).
Two cases underwent immediate selective neck dissection because of the finding of

10

macroscopic tumour whilst the remaining 55 cases had only sentinel nodes resected. In the 55
SNB cases the number of resected nodes was slightly higher than those identified on
lymphoscintigraphy (mean 2.7, range 0-7). In four cases no nodal tissue was identified on
histopathology despite confirmation with blue dye and intra-operative gamma probe. This
occurred exclusively in patients with prior radiotherapy and scalp primaries with drainage to
retroauricular or occipital nodal basins.

In total, seven patients (12.3%) had subclinical nodal metastasis detected at the time of
planned SNB. In five cases (8.8%) micro-metastatic SCC was detected on pathological
examination and in two cases (3.5%) macroscopic tumour was discovered at the time of
sentinel node biopsy exploration. All seven patients proceeded to therapeutic
lymphadenectomy; the five SNB cases were performed as completion lymphadenectomies
following histopathology results whereas the two patients with macroscopic disease
proceeded to immediate selective neck dissection. Of five patients who had nodal micrometastasis and proceeded to CLND, two had further metastatic disease identified in the neck
dissection specimen (one further positive node in each of these cases).

Median follow up was 19.4 months (range 2.4 - 41 months). At the time of analysis nine
(15.8%) patients had developed recurrence, of which three had subclinical metastasis
detected by SNB. There were six (10.5%) patients who had died of cSCC, of which two had
subclinical metastasis detected, giving a three-year disease specific survival rate of 82%.
There were eight local failures (SNB +ve n=2), two regional failures (SNB +ve n=1) and
three distant failures (SNB +ve n=2) One patient developed regional recurrence after failed
sentinel node biopsy increasing the true number of patients with subclinical nodal metastasis
to eight (14%). This patient underwent preoperative lymphoscintigraphy but although nodal
tissue was removed this was not confirmed to be the sentinel node by standard criteria (blue
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dye / gamma probe count). The patient developed recurrence at the site of exploration. In
addition, one patient developed in-field regional recurrence after positive sentinel node
biopsy, bilateral neck dissection and postoperative radiotherapy. This patient subsequently
died of disease and was the only patient to die with established regional recurrence following
positive SNB. The other five patients who died of disease during the follow-up period
suffered local recurrence (n=4) and /or distant disease (n=2). No episodes of distant
recurrence in the absence of local or regional recurrence have been noted. Patients with
confirmed subclinical metastatic disease had a significantly higher mortality rate than those
whose SNBs were negative for disease (p=0.0082).

In this study the factors associated with a high risk (>20%) of nodal metastasis were depth of
invasion ≥10mm, lymphovascular invasion, perineural invasion, poorly differentiated
tumours, location on the lip, nose or ear, and four (or more) factors combined. On
multivariable analysis the strongest predictors of metastasis were the number of high risk
tumour factors present, the presence of perineural invasion and also the presence of
lymphovascular invasion. Depth of invasion remains an important consideration as all
patients with metastasis had primary tumours more than 5mm thick.
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Figure 1-4. Kaplan-Meier survival analysis of patients with (‘Nodal_Metastases = Y’)
and without (‘Nodal_Metastases = N’) nodal metastasis. Patients with metastasis had
significantly worse survival than those without (p=0.0082).

Our group has recently updated the data on this study to include a total of 105 SNB
procedures were performed on 104 patients, with one patient undergoing two SNB’s for
metachronous lesions 32 months apart (currently under consideration for publication). The
average age at time of SNB was 65 years with a strong male preponderance (male:female =
90:14). The SNB was performed at the time of initial lesion excision on 41 occasions (39%),
after pathological examination of the lesion, with or without further excision to achieve
adequate margins, on 31 occasions (30%) or at the time of recurrent lesion resection on 34
occasions (32%).

In total, 15 patients (14.3%) had subclinical nodal metastases, including 10 patients with a
positive sentinel node (9.5%) and an additional five patients (4.8%) who developed nodal
recurrence on follow up). Macroscopic disease was identified at the time of SNB in four
cases and CLND was undertaken at the time of SNB. Microscopic disease was identified on
pathological examination of the sentinel nodes in six cases with three having CLND as per
protocol. The remaining two patients underwent post-operative radiotherapy and one declined
any further intervention. This patient developed recurrence 11 months after SNB and
subsequently underwent a level II-V neck dissection with 3 of 26 nodes positive. Of the
seven patients who underwent either immediate or staged neck dissection as per protocol, the
median number of nodes removed was 35 (range 6-60) and the median number of involved
nodes was 2 (range 1-14), including nodes removed with the SNB. The negative predictive
value of SNB was 94.7%. Overall sensitivity for SNB was 66.7% with a 100% specificity.
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Median follow up as was 26.2 months (range 0.3-78 months). At the time of analysis there
were 13 local recurrences (four SNB positive), eight regional recurrences (three SNB
positive) and four distant metastases (three SNB positive). One patient developed nodal
metastases more than five years after SNB in the context of multiple subsequent cutaneous
SCC excisions and this was not believed to be related to the index lesion for which the SNB
was performed. Another patient developed distant disease (L2 vertebra deposit) in the
absence of local or regional recurrence. In total, 10 patients died from cSCC during follow up
with a 5-year disease specific survival rate of 83.1%. Patients with subclinical nodal
metastases had a significantly higher mortality compared to those without nodal metastases
(p<0.0001). Of the deceased, death was due local failure in three, regional failure in two,
distant failure in two, local and regional failure in one, local and distant failure in one, and
one patient died with local, regional and distant failure.

On univariable analysis the only significant predictor of subclinical nodal metastases was
depth of invasion. The rate of nodal metastases in patient with DOI ≥ 5mm was 19.7%
compared to 0% in patients with DOI < 5mm (p=0.01). The rate of nodal metastases in
patient with DOI ≥ 10mm was 25% compared to 0% in patients with DOI < 5mm (p=0.001).
However, in patients with both a depth of invasion ≥ 5mm and perineural invasion, the rate of
nodal metastases was 28% compared to 8.2% in patients who did not fulfil both criteria (p=
0.02) The median number of inclusion criteria for patients with subclinical nodal metastases
was four as compared to three for patients without nodal metastases (p= 0.036).

No individual high-risk feature (i.e. inclusion criteria) was significant in predicting
subclinical nodal metastasis on multivariable analysis using logistic regression. Using a
backward elimination method, only the number of inclusion criteria was statistically
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significant (p= 0.035; OR 3.3 for 4 or more compared to 3 or less). When the number of
inclusion criteria was excluded from the model and the depth criteria was set to greater than
10mm (as all positive SNB lesions were greater than 5mm), then the only significant
predictor of subclinical nodal metastases was depth greater than 10mm (p = 0.043; OR 3.2).
Once again the survival data underlines the significant negative prognostic impact of nodal
metastasis.

Figure 1-5. Expanded survival data for patients undergoing sentinel node biopsy. Nodal
metastasis (N=15), no nodal metastasis (N=89). Data taken from Mooney, Martin
manuscript (listed in publications cited earlier)

1.5 Genomic observations
As discussed above, the conventional clinicopathologic prognostic markers in cSCC have
been shown to be highly unreliable predictors of metastasis in our own prospective study of
SNB. Metastasis driver mutations may exist in cSCC that could be used to more reliably
predict metastasis risk in primary high risk cSCC at the time of initial presentation. However,
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relatively little is understood of the molecular and genetic basis of metastasis in cSCC.
Clinically relevant and reproducible molecular signatures that can predict metastatic potential
in the primary cSCC at initial presentation have not been described. An understanding of the
molecular and genetic pathways of metastasis in cSCC has the potential to positively
influence countless lives affected by cSCC in countries with high solar exposure by allowing
for better stratification of risk, more efficient surveillance and the delivery of targeted
therapies that may have lower toxicity and increase potency in patients with recurrent
disease.

Within the genomic examination of cSCC have been papers utilising targeted next generation
sequencing (NGS) and whole exome sequencing (WES) (discussed further below). There are
currently no reports of whole genome sequencing (WGS) being employed in cSCC (primary
or metastatic) and there is no WGS data for cSCC in The Cancer Genome Atlas (TCGA)
(https://portal.gdc.cancer.gov). Reference will be made throughout this introduction to the
techniques used as applicable.

Skin is our first line of defence against environmental assault. The established model for
carcinogenesis (Hanahan, Wienberg 2011) involves genomic instability, cell cycle
dysregulation, induction of telomere maintenance mechanism and an angiogenic switch.
Normal, sun-exposed skin harbours many of the key driver mutations that are seen in cSCC
(Martincorena 2015). This study used targeted NGS and highlighted the breadth and
frequency of UV associated mutations in macroscopically normal skin excised in the course
of blepharoplasty. Common gene mutations included those within the NOTCH family and
TP53, at a frequency about 10% of that seen in cSCC. This underlines the continuum
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between early genotypic changes tolerated in “normal” skin and the phenotypic expression of
atypia, dysplasia and ultimately cSCC.

One of the few publications to cite genetic abnormalities in cSCC highlights the density of
mutations (Durinck, Ho et al. 2011). These authors performed WES of eight primary cSCC
and found approximately 1300 somatic single-nucleotide variations per cSCC exome
(1/30000 base pairs). This is amongst the highest degree of mutation observation for any
cancer described. The authors hypothesize that the constant reinjury to the basal epithelial
cells by UV radiation is at the root of the multiple mutational events in cSCC, including
significant TP53 (100% of samples) and NOTCH1,2 mutations. Variation in established
cancer associated genes are outlined below for cSCC. These include TP53, NOTCH, RAS,
CDKN2A and PTPR.

1.5.1

TP53 family

In cSCC, UVb exposure is implicated in gatekeeper TP53 mutation. This hypothesized
initiating mechanism is seen in both pre-neoplastic actinic keratosis as well as in invasive
SCC in UV exposed skin changes (Benjamin and Ananthaswamy 2006). TP53 (chr17p13.1)
encodes the protein p53 which belongs to a family of transcription factors comprising p53,
p63 and p73. p53 impacts transcription regulation via effects on cyclin dependant kinase
activity. UV-induced mutation of TP53 has long been thought to be critical in loss of
programmed cell death in abnormal squamous cells (Armstrong, Cricker 2001) and
inactivating TP53 mutation has been understood since the 1990s as a cause of cutaneous
malignancy (Basset-Seguin, Moles et al 1994).
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TP53 family mutations can give rise to measurable decreases in expression of other putative
tumour suppressor factors such as IFR6, a member of the Interferon Regulatory function
transcription factors. IFR6 is involved in skin development, due in part to its interaction with
p63. A study comparing cSCC with normal matched skin (Botti, Spallone et al. 2011) found
subsequent downregulation of IFR6 in 71% of cSCC (cell line A431). This analysis
correlated downregulation of IFR6 expression with poor differentiation and increased
invasive potential. Altered expression probably also infers loss of intercellular adhesion, and
perhaps, metastatic potential. Mutation of another tumour suppressor, DICER, has been
suggested to augment the deleterious effect of TP53 mutation (Su, Chakrvarti 2010 and Lyle,
Hoover et al 2014).

1.5.2

NOTCH family

The NOTCH signalling pathway is crucial to epidermal development and maturation.
(Moriyama, Durham et al. 2008). There are 4 families of NOTCH receptors (1-4). The genes
are located at NOTCH1 (chr9q34.3), NOTCH2 (chr1p12), NOTCH3 (chr19p13.12) and
NOTCH4 (chr6p21.32). NOTCH is a transcellular membrane molecule that once activated
transfers its intracellular domain into the nucleus. Intranuclear activation of various genes
are reliant on NOTCH.
NOTCH receptor activation or signalling, depending on the cellular context, can have either
an oncogenic or tumour suppressing role. Whole exome sequencing of head and neck
mucosal SCC demonstrated that up to 15% of tumours show mutation in NOTCH1 receptors
(Agarwal 2011) and loss of NOTCH1 is associated with disease progression. Thus whether it
is inactivation of oncogene action, or loss of tumour suppression function, changes in
NOTCH activity has implications in epithelial maturation and differentiation. NOTCH
expression and activity can be manipulated by commensal human papilloma virus (HPV).
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1.5.3

RAS Family

The RAS gene family comprise 3 RAS genes (H-, K- N-RAS) which encode a family of
small GTPases (Marshall 1996). These genes map to chromosome 11p (HRAS), 12p
(KRAS) and 1p(NRAS). The active form exists with bound GTP (rather than GDP in the
inactive state). RAS activation leads to downstream effects on cellular regulating molecules
such as RAF, MEK and MAPK. Some mutations of RAS can lead to prolonged activation
due to insensitivity to processes that dephosphorylate GTP. Activators of RAS, eg
RASGRP1, a guanine nucleotide exchange factor, have been shown in mouse models to
promote spontaneous cutaneous tumours when overexpressed (Sharma, Fonseca et al. 2014).
Knockout mice also resist tumour formation.

Activating RAS mutations are expected in up to 9% of cSCC. HRAS mutation is more
commonly associated with cSCC than NRAS and KRAS. In a recent German study assessing
focused sequencing analysis of FFPE extracted DNA, only 1/31 cSCC showed a RAS
mutation (Mauerer, Herschberger et al. 2011). Again, the pattern of tumour suppression loss
rather than oncogene activation that typifies cSCC was observed.
In a study of targeted sequencing of DNA from cSCC in 21 patients on the various
vemurafenib trials (Su, Viros, 2012), activating RAS mutations were identified in 60% of the
cancers indicating that the MPAK altering repercussions of BRAF inhibition seem to have a
potent oncogenic influence. In this study, HRAS mutations were most prominent.
1.5.4

CDKN2A

CDKN2A maps to chromosome 9 and encodes for two cell cycle regulatory proteins p16 and
p14, which act via retinoblastoma and p53 pathways respectively. Mutations of CDKN2A
lead to loss of function, and subsequent loss of expression.
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Primary and metastatic cSCC were compared in a study investigating the prognostic
significance of TP53, CDKN2A and HPV status in metastatic cSCC (Kusters-Vandevelde,
Van Leeuwen et al. 2010). This study examined formalin-fixed, paraffin embedded
specimens from both primary and metastatic cSCC, and normal tissue from 35 patients.
Normal tissue was included for exclusion of germline mutations. Highly targeted sequencing
was followed by PCR amplification from extracted DNA to assess TP53 and CDKN2A (both
p16 and 14) mutations. They observed an increased rate of CDKN2A mutation (31%) in the
metastatic tumours when compared to sporadic primary cSCC (Soufir, Daya-Grosjean 2000),
but at similar levels to Xeroderma pigmentosa primary cSCC.

1.5.5

Protein tyrosine phosphatase receptors

PTPRs are cell surface, transmembrane receptors involved in cell signalling via tyrosine
phosphorylation. There are 21 PTPR. Some members of the family of PTPRs function as
tumour suppressors. Loss of function due to mutation may have flow on effects on
downstream signalling. PTRP mutations have been observed in mucosal SCC, and a recent
publication (Lui, Peyser et al. 2014) hypothesizes a role for loss of function of PTPRT
leading to elevated levels of phosphorylated (activated) STAT3(oncogene) in head and neck
(mucosal) SCC. There is no data to support or refute the role of this group in cSCC.
This early exploration of genomic mutations associated with cSCC development barely
begins to explain the complex pathway interaction dysfunction in cSCC. Some of these
mutant pathway modifications will no doubt be responsible for not just cutaneous
carcinogenesis, but will be implicated in the metastatic process, by altered expression of
factors that enhance proliferation, extracellular stromal interaction and ultimately escape
from the primary site.
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1.5.6

More recent genomic observations for cSCC

Pickering et al (Pickering, Zhou et al. 2014) have recently progressed the survey of the
genetic landscape of high risk cSCC. Their group performed WES of DNA extracted from
high risk head and neck cSCC fresh tissue. Their aim was to establish the mutation pattern
and frequency, and to identify driver mutations. They identified a high rate of mutations with
a common pattern of UVB induction (C>T transition), and a strong preponderance toward
inactivating mutations of tumour suppressor genes. Predictable loss of function mutations in
tumour suppressor genes including TP53, NOTCH1 and NOTCH2 were observed. New driver
gene mutations were observed in RIPK4 and RASA1. However, the identification of
actionable mutations in cSCC was thwarted by the predominance of tumour suppressor gene
inactivation as opposed to oncogene activation. Detailed differential mutational patterns in
primary and metastatic cSCC were not explored.

Li, Hanna et al. (2015) examined single nucleotide variation and copy number variation in 29
formalin fixed, paraffin embedded lymph node metastases of cSCC using a 504 cancer gene
panel and categorized mutations as belonging to any of 4 categories: the RAS/RTK/PI3K
pathway, cell cycle pathway (TP53, CDKN2A), squamous differentiation pathway (TP63,
NOTCH) or epigenetic (chromatin remodelling) genes. This is the first genomic analysis
published addressing nodal metastases and offers valuable information. The most recurrently
altered genes seen were TP53 (79% of cases), CDKN2A (48%) and NOTCH 1/2/4 (69%).
They observed activating alterations in the RAS/RTK/PI3K pathways in 45% of samples. An
association was observed between this activation and shorter progression free survival in
their cohort of 29 cases. Other activating mutations in various tyrosine kinase / kinase
pathways, upstream of known significant cell survival augmenting mediators such as MEK
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and mTOR were observed. These included KIT, KRAS and BRAF. All specimens were judged
as HPV negative by p16 IHC and analysis of HPV E6/7 genes. Interestingly, these authors
reported no adverse effects from the challenges of nucleic acid extraction, processing and
interpretation in the setting of formalin fixed specimens.

The substantial mutation rate in the PIK3/Akt/mTOR pathway in the study by Li et al (2015)
suggests a role for this central cascade in the metastatic spread of cSCC. This has been
previously described as a point of difference between gastric cancers with and without
peritoneal metastatic spread (Liu 2010). Using RT-qPCR on extracted RNA they
demonstrated a 5x and 2x higher rate of mutation of the PIK3CA (encoding the catalytic
subunit of p110alpha) in normal gastric and primary gastric cancers, respectively. This
disordered regulation of the PIK3/Akt/mTOR pathway is a potential site of action on
mutations enhancing metastasis.

The identification of deleterious mutations likely to be drivers of carcinogenesis, and
potentially metastasis, is hampered by the high level of background mutation in sun exposed
skin as mentioned above (Martincorena 2015). A prospective study of sentinel node analysis
on high risk cSCC (Gore, Shaw et al. 2016) confirmed non-metastatic cSCC with proven
negative sentinel nodes and long clinical follow-up. In a related collaborative study using
DNA from FFPE primary cSCC using a 48 cancer gene panel a surprising number of likely
deleterious mutations in key driver genes (eg PIK3CA, NRAS, APC) were found when
compared to uninvolved lymph node for germ line control (Zilberg, Lee et al, 2018).

In an analysis of the mutational landscape of metastatic tumour deposits (total n=10000) from
multiple malignancies, Zehir et al included 27 cases of metastatic nodal cSCC all with DNA
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extracted from FFPE samples and subjected to targeted NGS (Zehir, Benayed et al. 2017).
The custom panel of genes targeted included 410 genes that included known oncogenes and
tumour suppressor genes, as well as key non coding regulatory areas like the TERT promoter.
Overall, only 6 % of their samples had insufficient DNA yield to be used, and their average
coverage for the panel was 718X. They found the most frequently observed variant in
metastatic cSCC (indeed in all tumours analysed) was TP53. They did note 32% of patients
harboured TERT promoter variants, albeit in a pattern different from that described by Huang
et al (Huang, Hodis et al 2013) in melanoma.

A recent reanalysis of 40 cSCC (Inman, Wang et al 2018), predominantly in
immunocompromised patients (mostly solid organ transplant recipients) found a new suite of
significantly mutated genes. These included the often reported TP53, NOTCH 1 and 2 and
CDKN2A, but also identified HRAS, MAP3K9, PTEN, SF3B1, VPS41 and WHSC1 as well as
deletion of HRAS. The key finding of this paper was the description of a new mutational
signature (based on the Catalogue of Somatic Mutations in Cancer (COSMIC) signature
patterns) within cSCC related to therapy with the immunosuppressant azathioprine.

1.6 Non-coding RNA – microRNA and lncRNA
There has been emerging interest in the role of both micro RNA and other non-coding but
regulatory RNA elements in cancer. The research interest stems from not just their potential
role in carcinogenesis and progression of malignancy, but also their potential for use as
biomarkers. MicroRNAs are small (22 nucleotide) RNAs transcribed in the nucleus in a
primer form to be activated by Dicer after transport into the cytoplasm (Reinhart, Slack et al
2000). There they act on mRNA to block translation (Almeada, Reis et al 2011).
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In cSCC, a number of studies have examined the role of microRNA (miR). Perhaps the first
of these was an examination of miR in cSCC cell lines, normal skin, actinic keratosis and
frank cSCC (Xu, Zhang et al 2012). By RT pCR and immune fluorescence hybridization, the
authors reported up-regulation of 4 miR (31, 135b, 21 and 223) as well as down-regulation of
54 miR, including 125b, in both cSCC and cell lines when compared to both actinic keratosis
and normal skin which they found by microarray analysis targeted MMP13. They identified
that miR-125b suppressed proliferation and colony formation as well as the migration and
invasive capacity of cSCC cells and that down regulation reduced the deactivation of
MMP13.

miR-203 was found to be inversely correlated with tumour differentiation in cSCC samples
and cell lines (UT-SCC-7 (metastatic) and A341), and was active against c-MYC, effectively
having a tumour suppressor effect (Lohcharoenkal, Harada et al 2016).

Using qPCR on RNA from in situ and invasive cSCC, miR-21, miR-103a, miR- 186, miR200b, miR-203, and miR-205 expression levels were compared (Stojadinovic, Ramirez et al
2016). They found between invasive and in situ disease, both miR-21 and 205 were
significantly upregulated, proposing a role in a more advanced state, by action of downregulation of genes MEIS1, KAT2B, and BLMH.
There is evidence for upregulation of miR-31 in invasive cSCC compared to both actinic
keratosis and normal healthy skin (Wang, Landen et al 2014). miR-31 is thought to oppose
ITGA5, RDX and WAVE3 and RhoTBT1 (Lin, Zhou et al 2017). With the exception of the
inclusion of the (incompletely characterised) metastatic cell line UT-SCC-7, none of the
aforementioned studies of microRNA have examined the metastatic stage of cSCC.
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There is limited evidence for the role of long non-coding RNA (lncRNA) in metastasis of
cSCC. Pipponen et al (2016) analysed the role of the long intergenic ncRNA LINC00162 in
both cSCC and normal skin cell lines. They identified is overexpression in tumour cells (by
RNA in situ hybridization) and not in normal skin cells. Knockdown resulted in suppression
of growth of the tumour cells. They theorised LINC00162, which they renamed PICSAR
(p38 inhibited cutaneous squamous cell carcinoma associated lincRNA), to act by regulation
of ERK1/2 via DUSP6 downregulation.

1.7 Epigenetic changes in cSCC
Epigenetic changes reflect alterations in the histone supports of the nucleic acids. A recent
report identified methylation profile differences in key CpG promoter sites between
metastatic and non metastatic SCC and BCC (Darr, Colacino et al. 2014). DNA extraction
and methylation analysis using formalin fixed and paraffin embedded specimens of 37
primary cSCC (and 5 BCC) showed hypermethylation at CpG sites and thus silencing of
FRZB, TFAP2C and ASCL2 (Goldengate Cancer Panel) in cSCC that developed metastases
as opposed to the cSCC that did not. Pickering et al (Pickering, Zhou et al. 2014) showed an
inactivating mutation of KMT2C in 39 cSCC, which encodes a histone methylation complex
to alter transcriptional regulation. This mutation has been identified in other malignancies and
was associated with increased incidence of bone invasion and a shorter time to recurrence in
cSCC.
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Chromatin accessibility as a result of genomic variants is an important area of interplay
between genomic and epigenomic analysis. An example of this is in the promoter region of
TERT where alteration in ETS binding site motifs with resultant increased affinity for the
transcription factor as a result of somatic variants leads to an increase in histone methylation
and chromatin opening(Liu, Yuan et al. 2016).

1.8 Stromal influences and EMT in the tumour microenvironment
Tumour-stromal interaction is key to the metastatic process. Early invasion in cSCC is
characterized by a desmoplastic stromal reaction. Fibroblasts from the stroma associated with
cSCC have architectural and behavioural differences when compared to normal dermal
fibroblasts (Commandeur, Ho et al. 2011). Increased expression of vascular endothelial
growth factor C has been shown in supraglottic (mucosal) SCC to be predictive of lymph
node metastases (Baek et al 2009). Similarly altered expression of VEGF is seen in the
stromal microenvironment in cSCC (Moussai, Mitsui et al. 2011)

Phenotypic changes may result from pluripotent subpopulations of cells that behave as cancer
stem cells. These cells can exhibit both epithelial-mesenchymal transition (EMT) and
mesenchymal-epithelial transition (MET). The transition between epithelial and
mesenchymal phenotypes may be partial and may also be reversible (Lamouille et al 2014).
The normal junctional integrity and polarity of epithelial cells in skin can, when exhibiting
EMT, be characterised by a loss of E-cadherin expression and an abundance of expression of
N(neural)-cadherin. Even this simple observation and explanation allows an appreciation of
the altered function mediated by transcription factors that are either under or overproduced in
the tumour microenvironment. Transcriptional repressors of E-cadherins include the
mesenchymal markers Snail, Slug and Twist (Thiery et al 2009). Expression of these
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repressors has been shown to be increased in poorly differentiated cSCC when compared to
benign or well differentiated tumours. (Chen, Takahara et al. 2013). Overexpression of the
mesenchymal proteins Twist, Zeb1, Vimentin, beta-catenin and Podoplanin was observed in
metastatic when compared to non-metastatic cSCC (Moussai, Mitsui et al. 2011). TGF-ß
through SMAD activation and intranuclear transport can upregulate EMT by activating
transcription factors and inhibiting repressors, either directly, or through SNAIL to effect Ecadherin expression (Lamouille et al 2014).

Mesenchymal stem cells (MSCs) probably constitute a percentage of tumour associated cell
population but may be attracted by tumour cells into the tumour-stromal interface
(Chamberlain, Fox 2007). Karnoub, Dash et al (2007) described paracrine inducement of
MSCs in the presence of breast tumour stroma, with increased metastasis. The urokinase-type
plasminogen activation (uPA) system is a key component of extracellular matrix and
basement membrane degradation and is overexpressed in more aggressive malignancies
(Ranson, Andronicos 2003). The activation of this system allows for fibrinolysis via the
conversion of plasminogen to plasmin and involves genes including PLAU, PLAUR
SERPINE2 and SERPINB2.

Recently, Laurenzana, Biagioni et al (2015) showed the effect of TGF-ß (canonical SMAD
activation) on uPAR mediated mesenchymal expression within melanoma cells incubated
with MSCs in vitro, as an upregulation of N-cadherin, a-SMA and vimentin, a decrease in Ecadherin and enhanced expression of the E-cadherin transcriptional repressors SNAIL1/2. In
vivo, when bone marrow stem cells were co-injected with melanoma cells in a mouse model,
tumour progression was rapid, however, animals were euthanized due to tumour burden prior
to the exhibition of established metastatic disease. Such growth factor induced altered
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expression with upregulation of pro-EMT mechanisms will be a focus of future research in
metastasis, particularly with the emergence of organotypic culture models.

We have previously published (Morosin et al 2016) a pilot study investigating the presence of
circulating tumour cells (CTC) in the blood of patients with known metastatic cSCC. In this
study, peripheral blood was drawn from patients, with resectable lymph node disease
peripheral circulation prior to any manipulation of the tumour at the time of
lymphadenectomy. Ep-CAM and cytokeratin markers were used to positively identify CTC
after exclusion of circulating cells expressing CD45 (lymphocytes). CTC were identified in
8/10 patients with metastatic cSCC, with tumour microemboli found in 3/10 samples.
Notwithstanding technical considerations around cell surface expression in different EMT
states, this study identified a potential role for CTC analysis in surveillance of patients post
therapy to detect early recurrence.

1.9 Differential expression in cSCC
In a study comparing 2 cell lines of cSCC with a Bowen’s disease (carcinoma-in-situ) cell
line, disease stage dependency dictated the expression of 1895 genes by using organotypic
cultures and IHC, ISH and microarray (Serewko, Popa et al 2002). They found
overexpression of EGFR, but reduced expression of FRA-1, MAPK and MAPKK.

More recently, the predictive utility of inositol polyphosphate 5-phosphatase (INPP5A) was
analysed and measured against biological behaviour in cSCC (Cumsky, Costello et al 2019).
This was built upon earlier work using gene array, FISH and IHC showing loss of INPP5A
may occur early in cSCC evolution (Sekulic, Kim et al 2010). They theorised that deletion of
the short arm of chr10 contributed to the loss. Using IHC, Cumsky et al showed that reduced
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INPP5A expression was also more consistent in more aggressive disease, including in worse
differentiation, LVI and those that metastasised.

The landmark study comparing both transplant requiring immunosuppression induced cSCC
and actinic keratosis with that of normal skin in both the transplanted and other nontransplanted patients (Nindl, Dang et al 2006) compared 22283 genes by microarray and
identified 9 genes over expressed in the tumours. These genes were CDH1, MAP4K4, IL1RN, IL-4R, NMI, GRN, RAB31, TNC, and MMP1. There were 4 genes that were under
expressed including ERCC1, APR-3, CGI-39 and NKEFB.

Garcia-Diez et al (2019) identified underexpression of NEK10 and overexpression of both
FOSL1 and BNC1 when comparing cSCC, actinic keratosis and normal skin in 10 matched
pairs of immunocompetent patients.

Expression of cyclin D1, a member of a family of cell cycle regulatory proteins, increases
proliferation and disorganization of epithelium and is increased in both pre-neoplastic and
malignant skin changes (Burnworth, Arendt et al. 2007). These authors describe a difference
in p16 expression levels between pre-neoplastic and invasive carcinoma in their study cohort,
hypothesizing that decreased p16 was an essential trigger for these preliminary changes to
allow for the invasive progression. They also identified increased telomerase reverse
transcriptase (hTERT) expression in both AK and SCC.

The search for biomarkers of progression in cSCC has thus far borne limited fruit. In a
review of analysis of their own cell lines and FFPE specimens, Kivisaari and Kahari (2013)
highlight extracellular proteases and inhibitors including MMP-7 and SerpinA1 as potential
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candidates. Using genome wide expression profiling comparing cSCC cell lines with normal
keratinocytes they were able to identify expression differences between malignant and benign
conditions ( Farshchian, Kivisaari et al 2011, Kivisaari, Kallajoki et al 2008). They then
utilised rtPCR to validate the expression observations and ultimately used Western blot to
confirm the translated protein effects of these. Primary cSCC FFPE samples were used for
both IHC and also for tissue microarray construction.

Erythropoietin-producing hepatocellular Type B2 (EphB2) is a ligand for a class of receptor
tyrosine kinase. It has been shown to have altered expression in metastasis in colorectal
cancer (Guo, Zhang et al 2006), wherein loss of EphB2 is associated with a more aggressive
phenotype using tissue microarrays from adenomas, colon cancers and their metastases.
Farshchian, Nissinen et al (2015) conversely showed that EphB2 expression promotes
carcinogenesis, invasion and migration in cSCC cell lines and xenografts suggesting it could
be used as a biomarker. This study did not make specific observations of the metastatic
context.
Using two datasets from the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/)
comprising normal skin/cell lines and primary cSCC, Wei, Chen et al (2018) determined that
only EGR3 was consistently and significantly differentially expressed. EGR3 encodes a
transcription factor of the EGR family and impacts up to 330 genes some of which may lead
to progression of malignancy through inflammatory mediators including IL-6 and 8 (Baron,
Pio et al 2015). Once again, the datasets used by Wei, Chen et al did not include any
metastatic tumours or cell lines.
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1.10 Project design, rationale and aims
The design of this project was in response to a clinical question. An ongoing effort within our
clinical research group is to identify the key determinants of metastasis and recurrence in
cSCC. Annually we see more than 100 patients with metastatic cSCC. These patients had all
had primary cSCC, often treated absolutely as per protocol, and yet they had recurred,
commonly presenting with multiple lymph node metastases to the neck. The required
treatment would usually include both surgery and adjuvant external beam radiotherapy, at
significant quality of life cost to the patient, and significant financial cost to the community.
As outlined above, our group had previously published a prospective study investigating the
role of sentinel node biopsy in high risk cSCC with an interest in identifying which types of
primary lesions were most likely to result in metastasis (Gore, Shaw et al 2016) Depth of
invasion and perineural invasion were identified as key predictors of risk of metastasis,
although the actual numbers of metastatic cases were low (15/104 patients enrolled).
Nonetheless, the potential of interrogating the primary lesion by established clinical and
pathological means to determine risk had been surveyed.

In addition to our focus on the primary lesion in a bid to understand the metastatic process in
cSCC, it became an emerging question as to whether looking at the metastatic deposit for
clues would shed further light on a means to establish risk. The theory behind this was that
the clone responsible for metastasis must in part persist as one of the dominant clones in the
metastatic deposit. Sequencing options available for this project included targeted NGS, WES
and WGS. Each modality has advantages and disadvantages including technical and logistic
demands, depth and breadth of coverage and cost of both sequencing and bioinformatic
analysis. Given the discovery nature of the project and the availability of fresh tissue for
sequencing, a determination was made to proceed with WGS. The benefits that were

31

anticipated by this choice included the coverage of non-coding and regulatory regions of the
genome and the ability to make genome wide assessments of mutational burden. Ultimately
this assessment proved valid. To understand the genomic profile of the metastasis, the aim
was to analyse fresh, viable tumour DNA by WGS, as this had never been reported in
metastatic cSCC. We felt that to use this investigative process in a disease which dominated
our clinical practices constituted sound clinical research and offered us an opportunity to
describe for the first time the mutational landscape of this disease.

1.10.1 Aims of this project
Overall aim – to describe the overall pattern of somatic variation in metastatic cutaneous
squamous cell carcinoma and to define particular regions of the genome, patterns of variation
and genes for further analysis in order to facilitate identification of potential biomarkers of
risk for metastasis.

Specific aims
1. Collection of matched samples of blood (germline) and nodal metastatic cSCC
(tumour) and extraction of nucleic acids for downstream analysis
2. Undertake WGS of quality controlled DNA to greater than 60X coverage for tumour
and greater than 30X for germline
3. Subject raw data to manipulation and then bioinformatics analysis to assess overall
somatic mutational burden, structural variation, copy number variation and to detect
short variants across both coding and non-coding regions of the genome.
4. Analyse genes or regions that are either amplified or deleted, or genes that exhibit
high impact or recurrent short variants for altered expression.
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2 Methods
2.1 Patient Recruitment
Patients were recruited according to the protocol contained in the approved ethics application
14/397 UOW/ISLHD HREC and LH 15.047 RPA/LH HREC. The ethics process involved
about 4 months of work and 2 revisions to enable the approval to be granted and the study to
commence.

Recruitment commenced in February 2015. Patients with biopsy proven metastatic cutaneous
SCC scheduled for surgery with a curative intent were eligible for inclusion of tissue for this
study. All patients were initially seen in the consulting rooms of the surgeon and were then
discussed at the local Head & Neck Cancer Multidisciplinary Team (MDT) meeting.
Informed consent for both the procedure and for the collection of blood and tumour samples
was obtained separately and, as per ethics approval, no patients had any parts of their
treatment altered if they were unwilling to be involved in the study.

Recruiting patients was not an issue for the same reason the project was conceived; the
burden of disease is nearly overwhelming. So it was that the flow of patients willing to
contribute to the research effort was plentiful. In the first 18 months of collection of samples,
the patient accrual target of 60 cases had been achieved.

Two centres were involved in sample collection. The Chris O’Brien Lifehouse at RPA
(Camperdown) was the secondary site for sample collection and has had a tumour bank in
place for some time. This is a formal process with a separate consent that allows for a
standardized collection of key tissues, including demographics and sample handling. This is
the ideal arrangement for a study such as this. The primary site for sample collection was
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Wollongong Hospital. This was on the basis of proximity to our wet laboratory facilities and
was particularly useful for the purposes of establishing a cell culture from freshly resected
metastatic cSCC (J.Perry PhD Candidate UOW (Ranson)). At the commencement of the
study, no formal tissue banking arrangement was in place in the Illawarra and Shoalhaven
Local Health District (ISLHD). This meant that the quality control, clerking and storage of
most of the tissue samples for the study fell to us and required a significant amount of time
and technique critical detail. This requirement has now been usurped with the involvement of
the Wollongong Hospital in the CONCERT (Centre for Oncology Education Research
Translation) Biobank (http://concert.org.au/research/research-capabilities/concert-biobank).
This facility is based at the Ingham Institute, but now runs a full service at the Wollongong
Hospital.

Regular reports to the HREC were delivered and there was no departure from the
promulgated protocol. No patients withdrew consent from the study and there were no
complaints identified by our research team pertinent to the research protocol.

Patients were identified for inclusion in the study if they had biopsy proven metastatic cSCC.
Most of these patients had a historical index lesion that had been excised or biopsied. All of
our patient’s index lesions were from head and neck sites.

Resources allowed for the whole genome sequencing of 20 matched whole blood: tumour
pairs to the 30X and 60-90X respectively. Prior to nucleic acid extraction, a snap frozen
tumour sample was subjected to Pathologist review to determine tumour cellularity. Samples
deemed > 30% tumour cellularity were then further processed. Clinicopathological data for
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the patients with metastatic disease from which DNA was used for sequencing is presented in
Table 2.1.
Examples of haematoxylin and eosin histopathological assessment of cellularity are presented
in Figure 2.1.
i

ii

iii

iv

Figure 2.1. Pictures clockwise from upper left (i) 2 x magnification of 35% cellularity
sample moderately differentiated cSCC revealing islands of tumour separated by nontumour fibrous tissue, (ii) Same tumour at 20 x magnification showing more cytological
detail, (iii) 2 x magnification of 70% cellularity sample with less fibrous tissue, (iv) 20 x
magnification of same tumour as (iii) showing cytological detail including higher grade
(poorly differentiated) features.
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Table 2.1 Clinicopathologic data for samples originally included for WGS analysis. Staging is according to AJCC 8th edition. LNY: Lymph
node yield – total number of nodes resected. LNR: Lymph node ratio – number of positive nodes /total number of nodes. ECS: presence of
extracapsular (nodal) spread. R Status: R0 – microscopically clear margin, R1 – Microscopically involved margin, R2 – macroscopically involved
margin. Other: CLL- chronic lymphocytic leukaemia. Liver Txplant- liver transplant recipient on immunosuppression. RA Immunomodulationrheumatoid arthritis on immunomodulation therapy.
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Neck dissection for metastatic cSCC involves not simply the removal of the diseased node/s,
but rather clearance of anatomical regions (levels) of lymph nodes allowing for the capture or
harvest of occult metastases in more distant echelons. This allows for a lymph node yield
that maximizes the accuracy of pathologic staging and is likely to deliver the best curative
effort. Following surgery and pathological reporting, all patients were then again considered
by the local MDT. Herein recommendations were made to the patient about adjuvant
treatment which in most cases consisted of radiotherapy. Following definitive treatment,
patients had regular surveillance in the rooms of the treating doctors.

There was no departure from established protocols for managing metastatic cSCC.
Preoperative blood was drawn at the time of intravenous cannulation, usually by the
attending Anaesthetist. At least 2ml of whole blood was collected in EDTA tubes that were
then transferred to the laboratory for storage at -800C.

2.2 Tissue Handling
On the day of surgery, a sample of the metastatic deposit, approximately 10mm3 was
preserved for storage and downstream analysis. It was critical that the specimen retrieval did
not compromise the work of the Pathologist. The aim was to sample a section of the
metastatic deposit from an area free of macroscopic necrosis and at the leading edge of the
tumour:stromal interface. The specimen was then restored in overall arrangement by suturing
and submitted to normal histopathological processing initially involving fixation in buffered
formalin.
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The harvested fresh sample was stored in cold buffered PBS for transport to the wet
laboratory. Once received at the laboratory, the sample was divided into 30mg cubes and
snap frozen in liquid nitrogen to be stored at -800C.

Prior to any nucleic acid extraction, samples were formally assessed by a Consultant
Pathologist experienced in cutaneous malignancy. One of the 30mg blocks was delivered to
the pathology laboratory on dry ice. Once received, the sample was treated as a normal frozen
section; embedded in medium and sectioned on a cryotome. An estimate of the cellularity of
the specimen (that component comprising viable tumour cells) was made. An arbitrary cutoff of 35% cellularity was used to determine is a sample was to be submitted for further
processing. Almost half of our cases satisfied this cellularity threshold.

2.3 Nucleic Acid Extraction
Samples identified as having adequate cellularity were identified for nucleic acid extraction.
Preparatory experiments for the nucleic acid extraction included comparing automated
techniques of tissue homogenization. Following the homogenization and nucleic acid quality
control application, the Miltenyi Gentle MACS™ system using the RNA01 program was
selected for use with frozen tissue samples. No specific homogenization program for DNA
extraction is supplied on this platform. Tissue was processed in M tubes (a proprietary
canister with an internal blade that is driven by the housing on the Gentle MACS processor),
after the application of 600µl of RLT buffer. The post processing emulsion was then
centrifuged at 4000 rpm for 5 minutes at 4oC.

The resultant solution was then processed to extract both DNA and RNA using the AllPrep
DNA/RNA/Protein Mini Kit (80004, Qiagen), according to the manufacturer’s instructions.
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All resultant DNA and RNA samples were quantified using the NanoDrop (ND1000,
Thermoscientific). The aimed absorbance levels for DNA and RNA were 260:280 ratios of
1.8 (+/-0.1) and 2.0 (+/-0.1), respectively. The results of nucleic acid extraction are presented
in Appendix 2. DNA samples were further analysed using 1% TAE agarose gels. Results of
gel electrophoresis are included in Appendix 3.

2.3.1

Germline (blood) nucleic acid extraction

Whole blood was used for germline DNA. Some samples acquired initially as serum
delivered insufficient DNA even using a kit specifically design for same. It was decided that
whole blood (as per the initial protocol) was the preferred germline source and the
PureLink® Genomic DNA Mini Kit was employed. Samples were quality controlled
quantitatively with Nanodrop and gel electrophoresis.

2.4 Sequencing
The staging of funding allocation necessitated the sequencing of DNA through 2 laboratories.
Both the Macrogen service outsourced through the Australian Phenomics Facility at the
Australian National University and the inhouse sequencing provided by the Kinghorn Centre
for Clinical Genomics (KCCG, Garvan Institute of Medical Research) utilised an Illumina Hi
Seq X platform.
Specifically, the process at Australian Phenomics Facility (ANU) included:
1.

Sample initial QC using nanodrop, agarose gel electrophoresis and Picogreen

assay and sample final QC check using SNP arrays.
2.

WGS reads were generated on HiSeq X (Illumina Inc, San Diego, CA) as

follows:
a. Library Kit Type: Truseq Nano DNA kit 350bp insert
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b. 150bp Paired End; 60X mappable and 45X mappable (sequencing depth)
c. Expected Output: >100Gb per lane at raw data level
3.

Raw data was delivered in FASTQ, although both BAM and VCF were

available.
The KCCG service only differed in the sequencing depth, this being 90X for tumour DNA
and 30X for germline DNA.

2.5 Bioinformatic Workflow
The process of turning WGS raw data into interpretable events is always complex. This is
made moreso by an increased mutational burden. Prior to this study, melanoma had been
identified as having the highest mutational burden, averaging in the order of 49 mutations per
megabase for cutaneous melanoma (much greater than for variants including uveal and acral
lentiginous) (Hayward, Wilmott et al. 2017).

The process from sequencing to files able to be interpreted by a non-bioinformatician is long
and expensive. For a single matched (tumour and germline) DNA sample undergoing WGS,
the cost from eluted DNA to output data in 2018 was in excess of $10000. And beyond
output files, significant bioinformatic interpretation and formatting for presentation is
required.

The pipeline consists broadly of variant calling from aligned reads, establishing the effect of
variants, determining copy number (ploidy) of individual spans of reads, and interrogating
break points to determine structural variation.

40

Seave, a bespoke Gemini-based program for searching and collating genomic variation across
all forms had been previously used by co-workers to investigate the mutational landscape of
lung cancer (Gayevskiy, Roscioli et al 2019). This set of applications runs in-series analysis
across multiple bioinformatic file types and allows the user to dictate not just what type of
variant is being sought, but also the parameters of confidence and incidence required for
reporting.

2.5.1

Sequencing outputs

Sequencing provides short reads (up to 200 bases long) as an output FASTA file (Pearson,
Lipman 1988). When the FASTA also includes quality data in the form of a Phred score, it is
termed FASTQ. This is the usual output form for subsequent alignment to the reference
genome.

Following alignment to the reference genome (in our case GRCh37/hg19) files are in 2
forms, SAM (Sequence Alignment Map) (Li, Handsaker et al. 2009) and BAM (the binary
form of SAM). Both file types include sequencing data aligned to the genome from which
can be made an index file to tag the relative positions of sequence within the entire genome.
BAM is the input used for the Integrated Genome Viewer (IGV) (Broad Institute). IGV is the
basis for confirming a mutation or anomaly seen on some other platform. It allows for
assessment of the entire genome and can also enable very localized assessment and can
review reads/point mutations and even breakpoint areas. To navigate around IGV using BAM
files, the Index file (.bai) must be loaded concurrent with the .bam. IGV is not a discovery
tool, but rather a means by which outputs from bioinformatics analysis can be checked for
veracity.
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Sequenza (Favero, Joshi et al. 2015) was employed to calculate cellularity and copy number
variation, a process dependant on adequate read depth in the region of interest. Less
confidence in the output, as always, is the result of analysis of regions with poor coverage.

Manta was the principle program utilized for structural variant analysis. Like Sequenza, it
uses BAM files to look for breakpoints, and identifies insertions, deletions, inversions and
translocations. SV analysis was further interrogated by using Mobile Element Locator Tool
(MELT) (Gardner, Lam et al 2017). This tool enables the identification of somatic
breakpoints built upon local sequence identifiers and the degree of confidence of the call for
Mobile Element Insertions (MEI).

Maftools (Mayakonda, Koeffler 2016) was used to derive Mutation annotated format (maf)
files from Variant Calling Format files (see below). Thereafter, visual representation of short
variants, and copy number variants were delivered in oncoplot form.

Circos plots were generated to display an overall genomic variant profile, including structural
variants using Purple. PURPLE is a purity ploidy estimator. It uses the read depth and
tumour BAF to estimate the purity of a sample and generate a copy number profile.
(https://github.com/hartwigmedical/hmftools/tree/master/purity-ploidy-estimator). PURPLE
is one of a number of tools that can be utilised to provide relatable information as a function
of copy number and sample purity. The 5 basic steps in the computation of values form
PURPLE include (Preistley, Baber et al 2017)
1. Calculate BAF in tumour at high confidence heterozygous germline loci
2. Determine read depth ratios for tumour and reference genomes
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3. Segmentation – the division of the genome into uniform Copy Number (CN) regions,
within the limits of breakpoints and chromosomes
4. Purity Fitting – relates ploidy and BAF to determine reliability of CN calls
5. Smoothing – reduces outlying small variances in CN to related regions not including
those broken by segmentation
Diagrammatic representation of bioinformatic outputs were conceived in collaboration with
and refined by Bioinformatician Dr M Gauthier.

2.6 Scoring Variant Effects
Variant calling, and subsequent variant effect prediction is the process whereby the aligned
reads are subtracted from the germline, within ascribed confidence limits to identify somatic
variants. Strelka was used as the variant caller (Saunders, Wong et al 2012) . The output of
Strelka is a .vcf file (variant calling format). The effect of the variant can be measured (or
scored) by algorithms, including SIFT, Polyphen and CADD, to provide evidence regarding
the likely impact of variants to help understand the biological effect.

2.6.1

SIFT (Sorting Intolerant From Tolerant)

SIFT (Ng, Henikoff 2001) predicts the likely impact of an amino acid substitution due to a
somatic variant in the coding genome. It uses the genomic information of a missense variant
as input. SIFT scores range from 0-1 and a score less than 0.05 means the amino acid change
is likely to be damaging, based on probability. Between 0.05 and 0.1, the biological effect of
the change in protein function due to the amino acid change is judged to be possibly
damaging.
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2.6.2

PolyPhen

PolyPhen (Adzhubei, Schmidt et al 2010) uses a similar mechanism to predict the effect of
missense variants in the coding genome. It uses protein information to arrive at an assessment
of biological effect. The possible outputs are probably damaging, possibly damaging and
benign, all given with a confidence score, where closer to 1.0 is the highest level of
confidence.

2.6.3

CADD (Combined Annotation Dependent Depletion)

CADD (Kirsher, Witten et al 2014) is a more recent addition to the predictive tools for
genomic variants. CADD combines other scoring systems (including SIFT and PolyPhen)
with integration with both large genomic datasets (such as 1000 Genome) to cover both
coding and non-coding regions. CADD scores imply that for a score of 10, the variant is in
the most damaging 10%of variants, and a score of 20 means the variant is in the highest 1%
of damaging variants. Both raw and scaled CADD scores may be derived. Raw CADD scores
are best to compare overall effect between 2 groups, eg control and study, whereas scaled
scores are more useful for looking between small groups or individuals.

Without translated data, these numerical interpretations of implied biological effect are not
entirely accurate as identified in a recent review of this topic (Misoge, Field et al 2015).
Nonetheless, these parameters serve as an independent measure of risk of biological impact.

For each significant short variant reported, IGV was used to confirm the coverage in the
region and the true nature of the variant in a given sample to trust the finding. Some GC rich
areas seen in our samples had problems with coverage due to the challenges of genome
assembly on the Illumina platform. Because coverage effects the reporting of variant allele
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fractions and because coverage can be affected by such bias, high variant areas, or areas that
we would expect to show variation but didn’t need to be reviewed for each sample to
establish the reliability of the individual call. This is a manual process and took some time to
learn and subsequently complete.

2.7 Gene Expression Analyses
Gene expression was explored using the NanoString nCounter Sprint system using the 770
gene PanCancer Progression panel with 25 ng of RNA extracted as above from fresh frozen
tumours as per the manufacturer's instructions (NanoString Technologies). Nanostring uses a
hybrid probe to allow RNA in solution to be identified with a capture probe and subsequently
reported by a reporter probe. This highly automated process delivers molecule counts for
each gene of interest as a measure of expression. The molecule counts are compared and
calibrated to that of housekeeping genes. Results were analysed using NanoString nSolver
4.0 and Advanced Analysis Module, which normalizes gene expression to a set of positive
and negative controls genes built into the platform. The housekeeping genes selected for
Content Normalization are selected based on low level of overall change in reads across the
samples and also represent low, medium, and high expression levels. Differential expression
of key gene pathways was compared between specimens. The parameters for constructing
heatmaps were derived in NSolver Basic Analysis program. These included background
subtraction of the geometric mean of negative controls and including only those
housekeeping genes with an average numerical count of greater than 50. Variation in
expression between samples for given genes was expressed across Z-scores (how many
standard deviations below or above the population mean a raw score is).
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3 Clinicopathological characteristics and broad genomic
characterisation
3.1 Tumor cellularity and clinicopathological parameters
As outline in Methods, funding allowed for 20 matched pairs of blood and tumour to undergo
WGS. Despite review of case notes and pathological specimens, 1 of the 20 cases identified,
processed and sequenced was ultimately found to have be inaccurately categorised, and was
actually a large primary tumour which had no nodal spread following neck dissection. This
left us with 19 sequenced blood; tumour pairs. Initial bioinformatic analysis using Sequenza
to derive cellularity (as part of the overall bioinformatic pipeline “Refynr”) revealed
significant variance between the histopathological yield (purity) and the bioinformatic (Table
3.1) Furthermore, despite attention to quality control, ultimately 4 of the 19 specimens were
not useful for somatic variant analysis due to poor cellularity as judged by Purple. The
discrepancy between the histopathological yield, that derived by Sequenza and that derived
by Purple was the subject of much analysis.

So far as the difference between the yield determined by the Histopathologist and Sequenza,
the specimen used for DNA extraction can never be the same as that used by the Pathologist
for cellularity estimation, they can at best be adjacent, which invites microscopic variance
between the two. As a result, the potential exists for a specimen used for DNA extraction to
have less viable tumour, more stroma or even non-cellular areas of necrosis.

Strategies for decreasing the likelihood of this in future experiments of this kind could
include using a block tissue as samples for cellularity estimation on either side of the block of
tissue used for nucleic acid extraction, or by using a SNP array to identify suitability of the
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tumour tissue for downstream processing. The SNP array would incur further processing
costs, but perhaps only 10% of the costs associated with WGS.

Table 3.1 : Variance between histopathological cellularity and that defined by Sequenza
100% = tumour only. 0% non tumour only. * no histopathological cellularity estimate
measured.

Furthermore, in samples where the true cellularity was very low (in the order of 10-20%)
Sequenza tends to overcall variation. In these cases, Purple was a more reliable determinant
of the true cellularity, ultimately exhibited by almost no somatic variation, either as short
variants or CNV.

The 4 cases that were judged by Purple to be of inadequate cellularity had all passed quality
control measures as part of the routine initial assessment of cases worthy of inclusion in that
tissue quality and tumour cellularity within the specimen was assessed as adequate by a
Specialist Histopathologist highly experienced in cutaneous malignancy. Nonetheless,
ultimately it became clear that the cellularity as determined by the bioinformatics algorithms
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was significantly different to the clinical and histopathological assessment, and these tumours
were judged as having cellularity that was too low (less than 20%) to allow for calling of low
variant allele mutations, and therefore could not be relied upon to faithfully represent the true
mutational status of the original tumour. The clinicopathologic data of these 15 cases is
summarised in Table 3.2.

Table 3.2. Clinicopathologic data of 15 specimens cleared for bioinformatic analysis.
Staging according to AJCC 8th edition: (Grade 1: Well differentiated; Grade 2: Moderately
differentiated; Grade 3. Poorly differentiated. Tumour mutational burden is genomic. Units
mutations/Megabase.)
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One sample initially designated as metastatic was found at a later time to have been from a
primary cSCC with no evidence of metastasis. This specimen, and its matched whole blood,
underwent WGS to 60X/45X prior to its status being understood. As such, it was not included
in this analysis, but the variant calls and all data from this analysis will be used by a
collaborator who is mirroring this overall study design, but in the primary cSCC setting.

3.2 Sequencing coverage
Of the 15 samples that passed quality control, sequencing coverage is presented in Table 3.3.
Overall tumour coverage was 78.5X and germline was 34.4X. Coverage and tumour
cellularity combines to enable confidence in variant calling, and the ability to also identify
low VAF variants.
Table 3.3 Sequencing coverage for each sample tumour and blood(germline).

3.3 Mutational burden and signatures
Across the 15 cases with matched metastatic cSCC and matched whole blood for germline, a
striking incidence of mutational burden was observed (Figure 3-2) with an average mutation
load of 207.8 mutations/Mb. This is greater than previously published data from primary
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cSCC where the mutational burden was 45.2 mutations/Mb(Chalmers, Connelly et al. 2017).
No mutational burden data for a cohort of metastatic cSCC has previously been published.
Mutational burden of our cohort compared to previously published data is presented in figure
3.1 and is now also published (Mueller et al 2019).

Figure 3-1. A comparison of tumour mutational burden across a variety of tumour
types. SKCM – skin cutaneous melanoma. LUSC – Lung small cell. LUAD – lung
adenocarcinoma. BCLA – breast lobular carcinoma. This figure is derived from data
from Chalmers et al (2017) and data herein.

The scale of the variants identified within this cohort is significant. In total, WGS identified
14681149 variants. Of these, 5801 were classified High Impact (including Stop gained,
Splice site, Frame shift or Stop lost) on the basis of either functional or algorithmic (CADD,
SIFT, Polyphen) implication. A further 74612 were classified as being of medium impact. Of
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these, 45067 had a CADD > 15. A CADD score of 20 means the variant is within the top 1%
of deleterious variants in the entire genome, a CADD of 30 put the variant in the top 0.1% of
the most deleterious variants (Kircher, Witten et al. 2014). All high and medium impacts
were in the coding genome, as non-coding variants are classified low impact on the
established scoring systems.

For each specimen, it was possible to report on the percentage of nucleotide variants that best
fit one of the 30 COSMIC mutational signatures (Alexandrov, Nik-Zainal et al. 2013) (Figure
3-2). Cosmic signatures are derived from major catalogues of cancer associated exome and
genome level sequencing. Where tumours are predicted to have a clear aetiological
relationship with some known or unknown factor, they are grouped on the basis of
predominant nucleotide variants. For some of the mutational signatures, the aetiological agent
is known and ascribed, for other groups of tumours with a recurrent pattern of mutations, the
agent is unknown. For instance, Signature 4, seen in tumours of the head and neck (mucosal),
liver, lung and oesophagus, which is characterized by C>A mutations, and CC>AA
dinucleotide substitutions has tobacco mutagens as its proposed aetiological agent. Signature
7, seen in skin cancers, is characterized by C>T, and CC>TT dinucleotide substitution, and is
ascribed ultraviolet radiation as its proposed aetiology. The predominant mutation signature
in our disease cohort was Signature 7 (Figure 3-2). As predictable as this may sound, this
finding has not been reported in metastatic cSCC and confirms the metastatic process does
not overly influence the underlying likely mechanism and pattern of nucleotide variation.
Compared to other tumour groups, the percentage of mutations showing concordance to the
underlying signature is striking. On average, greater than 65% of variants seen in our cohort
were C>T, or CC>TT. The fit with Signature 7 is somewhat clouded by the similarity
between it and Signature 11, ascribed to the exposure to alkylating agents (first described in
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exposure to temozolomide). Temozolomide acts by its ability to alkylate or methylate DNA,
particularly on guanine residues. This effect triggers apoptosis.
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Figure 3-2 Mutation density and signature analysis across the cohort of 15 cSCC lymph
node metastases. (Top) Base change mutation distribution at single base level shows
predominance of CàT transitions. (Middle) Boxplot showing median number of
mutations per megabase (Mb) in the coding and non-coding DNA. Mutation burden per
patient in coding and non-coding DNA. (Lower) Signature profiles using the updated
signature repertoire by Alexandrov et al. (Alexandrov et al., 2018).
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3.4 Discussion
Tumour mutational burden is a complex and potentially confusing descriptor. Traditionally,
TMB has been described as the rate of mutations/Mb of the coding regions, either as a
percentage of the total coding region, or as a percentage of the entire genome. This rule is not
universally followed. The melanoma genomic analysis paper (Hayward, Wilmott et al 2017)
cites TMB for various subtypes of melanoma. The authors used TMB in a genomic context,
ie looking at mutation across the entire genome. This is different to most previous TMB
papers, although truly is a measure of genomic instability. In our paper describing TMB in
metastatic cSCC (Mueller, Lauthier et al 2019), TMB is reported as both non-coding (noncoding mutations/Mb of the entire genome) and coding (coding mutations/Mb of the entire
genome) to illustrate the predominance of non-coding variants within our samples. In this
paper, we report coding TMB as 1.2 mutations/Mb and non-coding TMB as 206.6
mutations/Mb. If we report the same dataset as TMB of the coding region with the total Mb
of the coding region as the denominator, the result is 43.0 mutations/Mb. Similarly, if we
report non-coding TMB with the non-coding genome as the denominator, the result is 212.5
mutation/Mb. It is therefore important to compare like with like, and to establish the
parameters of TMB prior to drawing conclusions.

Whilst we suspected the genomic mutational burden in metastatic cSCC (total mutations of
any type across the entire genome) would be high, at an average of 207.8 mutations/Mb, this
figure vastly eclipses the rates of any other malignancy, including metastatic melanoma and
primary cSCC. UV associated melanoma and primary cSCC had the highest rate of
mutations/Mb described. In a study outlining the genomic landscape of subtypes of
melanoma, sun exposed skin occurring melanoma had an overall tumour burden averaging 49
mutations/Mb. Non UV associated tumours (uveal and acral) showed far lower rates of
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overall mutational burden(Hayward, Wilmott et al. 2017). Rates for a mixed cohort of cSCC
(including 7 cases of metastatic cSCC) were 61.2 mutations/Mb (Pickering, Zhou et al. 2014)

The UV associated signature of pyrimidine substitution (C>T) was strikingly consistent
throughout our samples. This confirms the penetration of the UV associated genomic base
substitution through EMT, with subsequent genotype of the metastatic clone/s closely
mirroring the predicted effect.

We assume that the increased mutational load in metastatic cSCC is due to the ongoing and
prolonged burden of UV associated damage. However, it is clear from analysis of
microsatellite instability (MSI) in non-polyposis colorectal cancer, that mutation rates are
higher in so called MSI-High (MSI-H) tumours (Pawlik 2004). These cancers in HNPCC are
the result of germline mutations in mismatch repair genes, in particular MSH2, MLH1,
MSH6, PMS2, and PMS1.

The unprecedented level of mutational burden seen in our tumours makes the case for the use
of checkpoint inhibitors as probable therapeutic agents in this disease. Whilst the
consideration of therapies is well beyond the scope of this project, the utility of any therapy
needs to be based on scientific observation, and it is established that tumours with a greater
mutational burden should respond with greater effect to checkpoint inhibition (Yarchoan,
Hopkins et al. 2017). The authors describe response rates to checkpoint inhibition as a
function of coding (exomic) TMB. According to the formula established by Yarchoan et al
for assessing predicted response rate to PD-1 inhibition, Response rate = 10.8 x loge(X)-0.7,
where “X” is the mutational burden (mutations/Mb), our cohort should have a 39.6%
response rate. The results of the phase 2 EMPOWER CSCC-1 trial of a monoclonal antibody
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to PD-1 Cemiplimab which showed that about half of patients responded to therapy with a
mean follow-up of 7.9 months, have lead to the release of this drug in the US in the advanced
cSCC setting, for both metastatic and locally advanced disease (Midgen, Rischin et al 2018).
Our mutational burden findings support the use of PD-1 inhibitors in metastatic cSCC.

55

4 Major structural variation including copy number
variation
4.1 Overview
Structural variation (SV) covers major chromosomal events including inversions,
translocations, large deletions and amplifications. Visual representation of SV events can be
figuratively exemplified in Circos plot format - a means by which multiple data points and
types can be represented on a single figure able to recreate the full, in this case, genomic
picture. Each circus plot is built upon data derived from variant and structural analysis
through the bioinformatic pipeline. Each circus plot thus also contains information relating to
short variants including allele frequency, copy number variation as well as major structural
variants. Such a format allows for a comparison within a cohort of the extent of genomic
variation, and for each sample, can guide areas of the genome for interrogation with respect
to a given category of variation. After exploring a number of formats to represent our
structural variant data in circos, Purple, a bioinformatics program that estimates purity and
copy number by using read depth and tumour variant allele frequency, was chosen. This
allowed for the most accurate visualisation of all the elements deemed useful.

4.2 Major structural variation
4.2.1

Results

As outlined above Circos plots provide an overall impression of the somatic genome of an
individual sample, in comparing between samples, or identifying congruence between
versions (tumour, cell line, passages) of a single sample. An annotated example of a circos
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plot derived by Purple is presented in Figure 4-1. Circos plots of all 15 specimens, with a
clinicopathologic summary are presented below.

1.
2.
3.
4.

5.

6.

Chromosome
Purity adjusted allele
frequency of SNV by
colour
Type of indel
(deletion:red,
insertion:yellow)
Copy number changes,
both focal and
chromosomal. Copy
number losses are red,
green shows copy
number gain. A dot
above green shows
CN>6
Minor allele copy
number, losses orange,
gain is blue. Scaled
from 0 (LOH) to 3,
high level gain
Structural variants –
translocations in blue,
deletions in red,
insertions in yellow,
duplications in green
and inversions in black.

Figure 4-1 Circos plot sample 4699. Cellularity 52%

The utility of the circos plot is to enable an overview of all categories of variants within a
sample’s genome. Sample 4699 is from a 78 year old male who had a right pinna cSCC
treated with cryotherapy only and developed ipsilateral nodal disease. The patient eventually
developed contralateral neck disease from a forehead cSCC moderately differentiated with no
LVI or PNI, treated with surgery and adjuvant RT. He eventually succumbed to soft tissue
recurrence within the RT field and developed lung metastasis (DOD).
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The overwhelming majority of the second shell (SNVs) of the circos shows C>T (red). When
compared to Figure 5-1, detailing Indels, shell 3 in the circos appears mostly insertions. The
contrast between these colours could be improved to allow for greater resolution. CNV is
demonstrated in the 4th shell and is able to be constrained by block size. The minor allele CN
in shell 5 here shows, for example, amplification of both major and minor allele in 5p. The
proximity of 4q and 5p are useful for displaying a copy number gain despite the loss of the
minor allele(4q) and a copy number gain of both major and minor allele (5p). In 8p, a CN
neutral LOH is seen due to loss of the minor allele. The inner shell herein shows both
inversions and translocations. Particular concentration is seen in the proximal long arm of 15
and in 8q.

58

Figure 4-2: Circos plot of sample 9120. Cellularity 27%.
Sample 9120 is from a 66 year old male. The patient initially had an excision of recurrent
scalp tumour of 8.5mm thickness, moderately differentiated with clear margins and no LVI or
PNI. The patient developed metastases in the draining posterior scalp lymph nodes and
posterior triangle 12 months following the initial excision. Currently the patient is alive with
no evidence of disease 2 years post lymphadenectomy.
Striking within this circos plot is the deletion of chr3p, chr4, chr11 and chr18 and loss of
copy number. There was an oscillating CN artefact identified during SV analysis. This
artefact resulted in, within established parameters as above, an excessive CNV count which
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was not consistent with the actual CN and can be seen in the difference between Figures 4-1
and 4-2 in the green track.

Figure 4-3: Circos plot sample 33432. Cellularity 70%.
Sample 33432 is from a 69year old male with a background of rheumatoid arthritis treated
with pharmacologic immunosuppression (Azathioprine). The patient in initially had a
temporal scalp SCC. He underwent surgery and adjuvant RT and then had recurrence of
poorly differentiated metastatic cSCC. This patient died of disease. The lack of significant
CNV and SV in this sample is striking.
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Figure 4-4: Circos plot of sample 34366. Cellularity 26%.
Sample 34366 is from an 86 year old male. Metastatic cSCC to parotid treated with surgery
and then adjuvant RT. Thereafter recurred in soft tissues within radiated field. Died of
disease.
Prominent loss of minor allele copy is demonstrated across much of the genome in this
sample, as well as areas of very high overall CN gain (chr2q and chr18p). Inversions are
more common than translocations in this sample.
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Figure 4-5: Circos plot sample 34934. Cellularity 73%.
Sample 34934 is from an 87 year old male who previously had a maxillary mucosal SCC.
Subsequently he developed a scalp cSCC and left parotid metastasis. Surgery revealed a
single metastatic deposit. He underwent post operative radiotherapy and was alive with no
evidence of disease 2 years later.
Once again, despite being high cellularity there is relatively less amplification in this sample.
CN loss is once again the predominant CNV despite some area of amplification (chr14). This
sample has a very low indel incidence (shell 3).
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Figure 4-6: Circos plot sample 35562. Cellularity 46%.
Sample 35562 is from a 66year old male, 15 years post liver transplant on tacrolimus and
prednisone for immunosuppression. He initially had excision of 20mm forehead skin lesion
(moderately differentiated cSCC 7mm thickness, with both LVI and PNI) with right neck
dissection. Neck dissection 2/29 lymph nodes in parotidectomy and neck dissection. Post
operative radiotherapy. Alive with no evidence of disease at 2 years.
Whether the formal immunosuppression has impacted the CNV in this case is not clear. Apart
from chr8q, there are not large scale amplifications, but areas of CN loss and LOH.
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Figure 4-7 Circos plot sample 35649. Cellularity 46%.
Sample 35649 was from a 63 year old male with chronic lymphocytic leukaemia. Recurrent
scalp cSCC with metastases to parotid and neck. Primary mod differentiated 8.5mm thick
with LVI but not PNI. Post operative radiotherapy with early recurrence. Died of disease.
Again this sample, although having more areas of amplification, including with very high CN
in an isolated area of chr4p, is more characterised by CN loss with LOH. A focus of
translocation is in chr19.
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Figure 4-8 Circos plot sample 35818. Cellularity 69%.
Sample 35818 is from a 69 year old male. Underwent a right radical parotidectomy
(including sacrifice of facial nerve and reconstruction) and then had post operative
radiotherapy. Late recurrence ipsilateral lymph node level Ia/b junction. Clinically very high
risk for recurrence but alive with no evidence of disease.
This circos is more typical of the trend with widespread CN gain with some areas of CN
neutral loss of minor allele (chr8p, chr5q). Most of the areas of CN gain have contribution to
overall CN by amplification of the minor allele (blue in shell 5). Note also the concentration
of inversion in chr1q and chr5p.
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Figure 4-9 Circos plot sample 38532. Cellularity 24%.
Sample 38532 is from a 78 year old male with Protein S deficiency. Nasal cSCC with
prominent PNI. Metastasis to left parotid and eventually right neck. Post op radiotherapy.
Alive with evidence of disease 1year post op.
Isolated regions of amplification can be seen with total CN>10 in chr3 and 7. Overall limited
amplification across the genome. Prominent CN loss with LOH in chr3, 8, 12 and 15.
Amplified area of chr3 also corresponds to a concentration of both inversion and
translocation.

66

Figure 4-10 Circos plot sample 48585. Cellularity 28%.
Sample 48585 is from a 78 year old female (note sex chromosomes) with multiple recurrent
cSCC bilateral forehead and face. She had an acceleration of cSCC over the last 5 years of
her life without formal immunosuppression. This patient developed bilateral neck node
metastases from different primaries. This invites the potential for her having a predisposing
germline or acquired immunodeficiency. She eventually succumb to left sided recurrence at
skull base post salvage surgery and radiotherapy.
This is a heavily amplified sample. Some of the amplified regions have minor allele loss. A
focus of translocation in chr22 is typical of that seen with the TTC28 transposon (see below).
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Figure 4-11 Circos plot sample 183410. Cellularity 35%.
Sample 183410 if from a 30 year old male with limited UV exposure history. Left lip cSCC
excised with emergence of ipsilateral Level Ib metastasis. Post operative chemoradiotherapy.
He developed tinnitus with cisplatin and was switched to cetuximab. Alive with no evidence
of disease 2 years post treatment.
This sample had an average ploidy of 4. This is a heavily amplified genome, with only very
few areas of minor allele loss. This sample has the highest incidence of CN >10 (4th shell
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with circle on top of green CN gain). Additionally, significant SV with again a focus of
translocation in chr22.

Figure 4-12 Circos plot sample 184577. Cellularity 60%.

Sample 184577 is from a 78 year old male. Right ear cSCC to ipsilateral parotid. Nodal
deposit 45mm poorly differentiated with positive margin on facial nerve. Post op RT. Alive
with no evidence of disease beyond 3 years.
This is a similar plot to 183410 except for the extent of translocation. Some areas of LOH
(chr10q and 13). Again some concentration of SV in chr22 (TTC28) is observed.
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Figure 4-13 Circos plot sample 193958. Cellularity 34%.
Sample 193958 (Parent tumour of cell line UW01- Jay Perry) is from a 74 year old male.
cSCC from right ear excised. Eight months later emergence of parotid metastasis. 50mm
deposit with PNI and 2 other positive nodes. Clear margins. Post op radiotherapy. Alive with
no evidence of disease 3 years post treatment.
This circos shows significant amplification across most of the genome. There is widespread
loss of the minor allele, often occurring as CN neutral, but often with an overall CN gain. A
focus of SV (both inversion and translocation) can be seen in the short arm of chr7.
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Figure 4-14 Circos plot sample 200971. Cellularity 34%.
Sample 200971 was from a 65 year old male who initially had a lower lip cSCC (6mm
moderately differentiated) with metastasis to level Ib at 14 months post surgery to the
primary. Moderately differentiated disease. Post op radiotherapy. Succumbed to pulmonary
metastases within 3 years.
This sample shows isolated regions of CN gain with even more isolated regions of loss of
minor allele.
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Figure 4-15 Circos plot sample 321773. Cellularity 33%.
Sample 321773 was from a 78 year old male who initially had a Left forehead cSCC with
widespread PNI. Post op radiotherapy to the primary site but not to draining nodal basins.
Metastasis to left parotid 19 months post surgery. Parotidectomy and neck dissection with
adjuvant radiotherapy to left neck and parotid bed. Alive with no evidence of disease at 3
years.
Loss of minor allele and CN loss entire chr13. Otherwise a significantly amplified genome.
SV including chr22 (TTC28) and complex pattern of SV in chr8.
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4.2.2

Discussion

Just as for short variants, the identification and characterization of structural variants in a
highly mutated genome is challenging. As stated earlier, the mutational burden of our
samples is greater than any previously published series, at 207.8 mutations/Mb. Complex
bioinformatics and computational analysis is required to overcome this genomic noise, and to
filter spurious findings.

Structural variants may be between non-coding or coding regions. They may involve large
scale deletions or duplications, or breakpoints which then reconnect with a remote part of the
genome, either intrachromosomal (inversion), or interchromosomal (translocation). Large
deletions may include areas coding or impacting on transcription of tumour suppressor genes,
thus promoting a carcinogenic stimulus. In addition, and often as well, large duplications
(usually with overall CN >5 and block size >5000 base pairs) may include regions coding for,
or impacting the transcription of oncogenes, once again with potential for malignant genomic
effect.

In addition to simple descriptions of SV events (inversion, translocation, deletion,
duplication), more complex patterns of structural rearrangement have been described. In a
cohort of prostate cancers, Baca et al (2013) describe a pattern of translocation associated
with deletion breakpoints, but also giving rise to observed deletion bridges from one
chromosome to another. They termed this phenomenon “chromplexy” (pleko : “to weave” or
“to braid”). Chromoplexy is thought to occur throughout the progression of a cancer and is
characterized by tens of chromosomal structural variants, effecting different loci and
probably occurring at multiple timepoints. Such large scale chromosomal rearrangement is
relatively common, particularly in prostate cancer (Shen 2013). This is in contrast to
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chromothripsis. Chromothripsis entails a very localized disruption of the genome, often
entailing hundreds of structural variant events, and is thought to occur as a once off
phenomenon (Stephens 2011). Such a massive genomic crisis event gives rise to oscillating
copy number states between one or only a few chromosomes and may include cancer causing
fusions.

Within our structural variant analysis, there are no convincing episodes that can be easily
labelled chromothripsis. This observation may be clouded by the volume of SV events, and it
is possible that both chromoplexy and chromothripsis are occurring in the same samples, both
inferring a tumour clonal evolution by different means and chronologies.

4.3 Gene fusions
4.3.1

Results

Break points within coding regions of the genome can lead to fusions with other genes or
non-coding regions. Such coding impacts are called gene fusions and may have unpredictable
effects on the transcribed RNA. We identified 2004 gene fusion events structural variants
having any gene involvement (gene:intron or gene:gene) across our 15 cases. Break points
(including those leading to gene fusions) occurred in more than 1 sample in only 5 genes as
listed below. By far the most frequently involved gene was TTC28 which showed significant
structural variation in the first intron.
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TTC28
Ten of fifteen samples (66%) had a SV in TTC28. In our series, the TTC28 first intronic
transposon (between coordinates 22:29064630-29066160) is inserted into a number of genes
as depicted in Figure 4-16.

Intergenic regions 1,2,4,5,8,9,11 &12
ARMC4 (16th intron) chr 10

TTC28

(first intronic transposon)

NELL1 (13th intron) chr 11
ESRRG (1st intron) chr 1
Upstream of 1st exon FUT9 chr 9
ADGRB3 (13th intron) chr 6
KANSL1L (3rd intron) chr 2
LEMD3 (8th intron) chr 12
linc00534 chr8
NR2F1-ASI/NR2F1 chr5

Figure 4-16 TTC28 transposon structural variants

Additionally, the following genes had break points in their coding regions: MYLK (2/15
samples); PDE4D (3/15 samples); EPHB1 (2/15 samples).PTK2:SLA2 gene fusion occurred
in 1/15 samples.
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4.3.2

Discussion

TTC28 (chr22:28,374,002-29,075,853) is described having recurrent chromosomal
translocations in colorectal, small cell lung and liver cancer (Fujimoto et al 2016). The
pattern of the structural variants we have observed involving TTC28 is most in keeping with a
phenomenon known as somatic retrotransposition. The resulting genomic feature is an
example of a retrotransposon in the form of a Long Interspersed Element 1 (LINE-1 or L-1).
A known retrotransposon is within the first intron of TTC28. Retrotransposon insertion may
also happen in the germline.

It is unusual for the same region in a chromosome in the same sample to be widely dispersed
in a structural variant or translocation event. The model of a LINE-1 dispersion to “random”
locations, even within one sample was identified and characterized during the assessment of a
new bioinformatics application (MELT) looking at data from 1000 Genomes Project
(Gardner, Lam et al 2017). This tool identifies and characterises LINE-1, Short interspersed
nuclear elements (SINEs) and other major and structural variant events caused by mobile
elements. The use of MELT with our data supports this hypothesis of LINE-1 transposon
“rearrangement”.

In our study, the only gene to show a fusion with TTC28 is ESRRG. ESRRG has recently been
identified as playing a role as a tumour suppressor gene in gastric cancer (Kang, Choi et al
2018) by its impact as a suppressor on the Wnt signaling pathway, as evidenced by the down
regulation of key Wnt genes in ESRRG overexpressing tumours.

Otherwise there appear no key known cancer genes in our observed structural variants
interacting with TTC28. This process of somatic retrotransposition has been questioned by
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others (Pitkanen, Cajuso et al 2017) as potentially over-calling the role of such LINE-1
elements, particularly so since in the oesophageal SCC series, no demonstration of an
expression change was demonstrated. Nonetheless, this pattern is repeated in numerous
cancers, and it will be illustrative to review once we have completed a parallel project
looking at WGS within primary cSCC, and also to examine the transcriptome affect once our
RNA Seq project is complete across cSCC cohorts.

MYLK; Functionally MYLK has transferase activity, transferring phosphorus-containing
groups and protein tyrosine kinase activity. MYLK and MYL9 were found in NSCLC to be
downregulated in Stage 1 and II cancers but upregulated in III and IV cancers (Tan, Chen
2014). This suggests not only a role in carcinogenesis, but also in metastasis.

PDE4D; a phosphodiesterase that degrades cAMP thus disrupting activation of the cAMP
pathway. Interaction with Focal Adhesion Kinase (FAK) (which we did not see as a gene
fusion) may promote melanoma invasion (Delyon, Servy et al 2017) and conversely the
blocking of this interaction reduces invasion.

EPHB1; This gene codes for a receptor tyrosine kinase. Decreased expression of EPHB1 has
been identified in renal cell carcinoma (Zhou, Wang 2014)

PTK2:SLA2 translocation occurred in only 1 sample. PTK2 is a protein tyrosine kinase
which if activated is an important promoter of downstream signalling processes. SLA2 is a
member of the SLAP family of proteins, that play a role in downregulating inflammatory
cascades, but that are also active in cancer. Silencing of SLAP promotes tumour progression
in colorectal cancer, while overexpression inhibits tumour growth and invasiveness (Marton
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2015). Indeed, one of the SLA2 protein domains actively binds to phosphorylated tyrosine
residues.
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4.4 Copy Number Variation
4.4.1

Results

Copy Number Variation detection was principally derived by Sequenza (as described earlier).
Sequenza walks through the genome in 50Mb segments to identify copy number variation
and variant allele frequency and is highly dependent on cellularity. Low cellularity specimens
(where tumour yield was ultimately found to be low), or areas of low coverage can both
impact on reliability of CNV data.

Chromosomal amplification and deletion across the entire cohort is presented in Figure 4-17.
Amplification is predominant although some areas of the genome do not show amplification,
and other areas are commonly and recurrently deleted.

Figure 4-17 All samples genome view of amplification vs deletion as percentage of
samples (y axis) for each chromosomal arm (x axis). Amplification shown as blue bars;
Deletions shown as red bars.

An output of Sequenza includes the genome view of copy number and allele frequency. An
example output of a single sample with high frequency alterations is shown in Figure 4-18.
Obvious alterations in this example include a large CN gain in the long arm of Chr3 (with a
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CN of 1 in the beta allele), and a CN neutral (CN = 2) loss of heterozygosity (B allele CN=0)
in the long arm of Chr5.
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Figure 4-18 Genome view of CNV sample 4699. Chromosomes are listed on the X axis.
Copy number along the Y axis. The colours within each chromosome represent the total CN
(red) and the CN of the minor variant allele (blue).

Figure 4-19 shows CNV of a low cellularity specimen. CNV is essentially non-existent and
resembles the genome of normal (blood), and thus this specimen most likely represents
mainly normal tissue DNA (only minor changes from the germline). A genome view with
little departure from the normal is thus one of the clues to low cellularity.
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Figure 4-19 Genome view of CNV of low tumour cellularity sample 4777
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Figure 4-20 shows CNV for commonly effected samples with total events for each gene at
the top of the figure. Amplification events were recognised if they had adequate size (base
pairs > 104 ) and with total copy number >5. Deletion events were also of the same minimum
size and either had loss of both alleles or a loss of heterozygosity event with complete loss of
minor allele regardless of total CN.

Below are listed common gene (Fig 4-20) and chromosomal band (Fig 4-21) CNV across as
many samples as they are shared by. This is the reason not all samples are included as there is
a tail of less common events which are not shared by many samples. Common genetic and
chromosomal amplification is a relatively more common phenomena, as compared to
commonly occurring deletion, a can be seen by only DCC and SMAD4 reaching any common
threshold across samples that also shared common amplification. This is also mirrored by the
overall finding of combined samples in Fig 4-17, which demonstrates the prominence of
amplification in CNV analysis.

81

0
1
2
3
4
5
6

25
20
15
10
5
0
NDRG1

60%

PIK3CA

60%

SOX2

50%

ABL1

50%

ASXL1

50%

BAI1

50%

CAP2

50%

COL5A1

50%

CYC1

50%

DSP

50%

EDN1

50%

EGFL7

50%

EIF2S2

50%

DUP

60%

EPHB3
EPPK1

50%

FAM129B

50%

FAM166A

50%

FOXA2

50%

ID4

50%

JAG1

50%

MME

50%

MYC

50%

NOL7

50%

NUP214

50%

PLEC

50%

RXRA

40%

DCC
SMAD4

193958
35818
321773
4699
183410
34366
200971
38532
48585
184577

30%

DEL

50%

Alterations

Amplification

Deletion

Figure 4-20 Genes with most frequent Copy Number Variation with minimum
Duplication (CN>4) and Deletion (CN=1) for 10 samples with common shared CNV.
Histogram at top: number of events for each sample for the group of genes. Histogram
at right: number of samples (of 10) with CNV for given genes.
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Figure 4-21 Recurrent CNV of chromosome bands. Histograms as per Figure 4-20. As
per Figure 4-20, represented are common chromosomal band CNV with CN>4 or =1.

Specimen 9120 was unable to be included in CNV analysis due to an oscillating CN artefact
identified during SV analysis. This artefact resulted in, within established parameters as
above, an excessive CNV count which was not consistent with the actual CN when inspected
using Integrated Genome Viewer. This is most instructively seen in Figure 4-22 below, when
comparing the CN track (green) of the circus plots of samples 4699 versus 9120.
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Figure 4-22 Circos plots of samples 4699 (left) and 9120 (right). A comparison of the CN
track (green) and also the minor allele CN (blue/orange) track in circos plot for 9120
shows an oscillating artefact represented by smaller blocks of CNV. This disallowed
9120 to be included in the CNV analysis.

4.4.2

Discussion

Overall picture is of a highly somatically amplified genome. Gene amplification has been for
some time regarded as a driver of both carcinogenesis and of clonal expansion within
tumours (Albertson 2006). A recent study of amplification of driver genes across multiple
cancer types identified a group of 6 genes (from a total of 138 candidate oncogenes (n=64)
and tumour suppressor genes (n=74)) commonly amplified across multiple cancer types (not
including cSCC) (Ohshima, Hatakeyama et al 2017); MDM2, MYC, MYCL, MYCN, NKX21and SKP2.
Recurrent CN amplification of 3q and 5p were identified across various SCC sub types in a
recent review comparing TCGA data and mutational signatures (Campbell, Yau et al 2018).
Within 3q, which showed frequent CNA in our samples are included PIK3CA, TERC, TP63
and TP73, and SOX2 (see below). 5p includes TERT, TRIP13 and FASTKD3. The role of
TERT (in the context of TERT promoter variants) in our cohort is detailed in Chapter 6.
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TRIP13 can promote error prone non homologous end joining, cell proliferation, survival,
and resistance to cisplatin in head and neck (mucosal) SCC. Twelve of 15 samples in our
cohort had copy number gains of TRIP13 with an average CN of 4.8 across the amplified
samples. FASTKD3 has prosurvival affects probably via inhibition of the intrinsic
mitochondrial cytochrome-mediated cell death pathway (Simarro, Gimenez-Cassina et al.,
2010) was amplified again in (the same) 12/15 samples as TRIP13, with an average CN of
4.6. With an average block size of 1900Mb, the amplifications encompassing these 2 genes
were the same events. Notwithstanding the observed 5p and 3q amplification, in our cohort,
there were also consistently amplified segments in 7p, 8q, 14q and 20q (Figure 4-17).
In a census of amplified and overexpressed genes in cancer, the gap between amplification
and over expression is highlighted (Santarius, Shipley et al. 2010). An amplification may be
within a gene, or, given a cutoff of not less than 5000 BP, more often includes multiple genes
over upward of 100 000BP. Within such regions, driver genes may be identified, but coamplified genes (eg DDX1 in the amplification of MYCN) could potentially play a role in any
expression effect.

4.4.2.1 Recurrently amplified genes
The following genes were amplified in percentage of samples outlined in Figure 4-20.
NDRG1 (N-Myc Downstream Regulated 1) chr8:134,249,414-134,314,265 encodes a
cytoplasmic protein involved in stress response. It is generally regarded as a tumour
suppressor, but levels of the protein are prognostically unfavourable in liver, renal and brain
malignancy (proteinatlas.org).

PIK3CA chr3:178,865,902-178,957,881 is a key participant in cellular signalling in response
to the binding of numerous ligands to receptor tyrosine kinases. Whilst hotspots for mutation
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at codons 542/545 and 1047 are described (Vorkas, Poumpouridou et al 2010), we did not see
any examples of this SNV. Only 2 samples had missense mutations. By far the greatest likely
impact on PIK3CA was amplification, which, in keeping with its role as an oncogene with
AKT and mTOR pathway impacts, offers an opportunity for potential therapeutic
intervention.

SOX2 chr3:181,429,712-181,432,224 involved in embryonic development, stem cell
maintenance in the central nervous system and for expression of gastric epithelial expression.
There is no clear role for its amplification being a driver in cancer, although it thought to
have a role in adult stem cell differentiation (Karamboulas and Ailles 2013). With 11/15
samples showing amplification, with an average CN of 4.3, SOX2 is a good example of the
3q amplification characteristic across various subtypes of (non-cutaneous) SCC(Campbell,
Yau et al. 2018)

ABL1 chr9:133,589,268-133,763,062 encodes a protein (non-receptor) tyrosine kinase and is
a proto oncogene, highly expressed in many cancers (proteinatlas.org). We observed no
major structural variations in ABL1 as described in other cancers including the BCR-ABL1
fusion in chronic myeloid leukaemia (CML).

ASXL1 chr20:30,946,147-31,027,122 encodes a chromatin-binding protein which binds and
then disrupts chromatin in specific regions to enhance transcription. Its expression in
endometrial cancer in a negative prognostic indicator, and conversely provides a favourable
prognosis in head and neck (mucosal) SCC (proteinatlas.org) (Chung, Guthrie et al 2015).
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BAI1/ADGRB1 chr8:143,530,791-143,626,370 encodes a protein which acts as an inhibitor
of angiogenesis, perhaps as a member of the secretin receptor family. Its transcriptional
regulation is by p53. It has low levels of expression in cancer (proteinatlas.org).

CAP2 chr6:17,393,447-17,558,023 probably plays a role in actin binding and ectoderm
differentiation. It is not normally expressed in skin (proteinatlas.org). There is no reported
association with skin malignancy although overexpression in hepatocellular carcinoma may
indicate a poor prognosis (Fu, Li 2015).

COL5A1 chr9:137,533,620-137,736,689 encodes for collagen type V alpha chain. Type V
collagen is found with type I collagen (fibrillary collagen found in most tissues) and this gene
helps regulate fibre assembly (proteinatlas.org).

CYC1 chr8:145,149,930-145,152,428 encodes a protein involved in mitochondrial respiratory
chain electron transfer, Upregulation of this process may help the cell overcome the
deleterious effects of oxidative phosphorylation and overexpression has been identified in
breast cancer cell lines as a marker of worse prognosis and metastasis (Han, Sun et al. 2016).

DSP chr6:7,541,808-7,586,950 encodes a protein that anchors desmosomes in the internal
surface of the cell membrane. Mutations are associated with keratoderma, or abnormal
thickening of the skin. It has been shown to be underexpressed in some Non small cell lung
cancers (NSCLC) and its antitumoural properties might be the result of its impact on the
expression of Wnt/ß-catenin genes Axin2 and MMP14(Yang, Chen et al. 2012).

EPPK1 chr8:144,935,822-144,952,632 encodes a protein which is a member of the plakin
family, generally involved in cytoskeletal architectural organisation, exclusively in epithelial
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cells. This enables normal epithelial differentiation but may also effect cell migration in
injured tissues as part of repair (Yoshida, Shiraki et al 2008).

EDN1 chr6:12,290,529-12,297,427 encodes a preprotein that is then converted to a
vasoactive peptide, enabling vasoconstriction. Its is overexpressed in colorectal cancer
probably by interaction with ß-catenin (Kim, Xiong et al 2005).

EGFL7 chr9:139,553,308-139,567,130 also encodes for a vasoactive peptide. Most
malignancies show expression and overexpression carries an unfavourable prognosis in
colorectal and renal carcinoma (proteinatlas.org).

PLEC chr8:144,989,321-145,050,913 Plectin is an important cytoskeletal structural protein.
It is known to be expressed in skin cancers, and its expression predicts a worse prognosis in
renal, lung and colorectal cancer (proteinatlas.org).

MYC chr8:128,747,680-128,753,680 encodes a proto-oncogene that complexes with MAX to
act as a transcription factor and impacts cell cycle, apoptosis and cellular transformation. It
may also bind to VEGFA promoter to drive transcription and subsequent angiogenesis.
Known to be amplified in cancers, can also shows translocation in both Burkitts Lymphoma
and Multiple myeloma. Samples from both proteinatlas.org and from COSMIC from TCGA
skin cancer (melanoma samples) suggest that overexpression is not universal or profound.

4.4.2.2 Recurrently deleted genes
DCC (Deleted in Colon Cancer) encodes for a protein which is a membrane receptor for
netrin-1 (dependence receptor). When not activated by netrin-1, DCC has a pro-apoptotic
effect. Once bound, it can block apoptosis by activation of MAPK pathway and by Caspase
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3. As outlined above DCC in our cohort was most significantly effected by LOH events in
8/15 samples.

SMAD4
SMAD4 is a member of a family of signal transduction proteins and is a tumour suppressor.
Activated by TGF-ß binding to serine protein kinases on the cell surface, the products of
SMAD4 accumulate in the nucleus to regulate target gene transcription. Deletions have been
associated with pancreatic malignancy, neuroendocrine tumours (Simbolo, Vicentini et al.
2018), juvenile polyposis syndrome, and hereditary haemorrhagic telangiectasia syndrome.
Alternative splicing which also leads to decreased expression due to the predominance of an
inactivated isoform has recently been described in a keratinocyte cell line subject to UVB
radiation exposure (Ullah, Liao et al. 2018).
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5 Short Variants
5.1 Results: Short variants
The overwhelming number of short variants detected were single nucleotide variants (SNV)
in non-coding regions (including introns, 5’ and 3’ UTR and regulatory regions) (See Figure
3-2). The overwhelming majority of coding SNVs were missense mutations, where the
resultant codon encodes for an alternate amino acid (Figure 5-1). The next most common
class of short variant was a nonsense mutation, where the altered codon results in premature
shortening of the resultant transcribed and translated protein (eg due to the introduction of a
stop codon). This class of mutations represents less than 5% of the missense class.

The predominant pattern of SNV was C>T (refer to Figure 3.2). This made up more than
80% of SNV and is consistent with the dominant effect of UV radiation on pyrimidine bases,
in keeping with our general findings on mutational signature (Section 3.3) and recently
published (Mueller, Gauthier et al 2019).

Figure 5-1: Coding short variant classification. Short coding variants were assessed for
rates of recurrence and likely impact on the basis of various predictors using SIFT, PolyPhen
and CADD (see Chapter 2.6). These tools provide evidence of the likely impact of variants
on biological activity and are best used in combination.
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A gene list was collated that included known tumour suppressor genes, oncogenes, other
genes falling within genomic hotspots in other cancer surveys (Gonzalez-Perez, PerezLlamas et al. 2013) and genes of specific relevance to surveys of cutaneous malignancy(Su,
Viros et al. 2012). In total, 1365 genes comprised the list that was used to assess for variants
within genes (coding and non-coding regions) using the Seave platform. The gene list used
for identifying short variants, copy number variation and structural variant effects of the
coding genome is listed in Appendix 3. Other lists of specific non-coding regions, including
specific promoter regions, long non-coding RNA and micro-RNA are described separately
below.

5.2 Highly recurrent somatic mutations
The most highly recurrent short somatic variants with scaled CADD >10 are represented,
combined with concomitant CNV in Figures 5-2 and 5-3. Two figures are presented
combining single nucleotide variation and copy number variation in the same samples for the
same genes/chromosomal bands. These two figures differ in thresholds for calling of variants
and the filtering applied in Figure 5-3 to include those genes with at least 4 COSMIC
variants and to exclude larger genes (eg MUC16, CSMD3) where variant frequency is high
but may not be as meaningful (Lawrence, Stojanov et al. 2013).
.
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Figure 5-2 Recurrent short variants in genes also subject to CNV– including PCLO,
CSMD3 and MUC16. Top histogram: short variant events per sample colour coded.
Histogram at right: Number of samples effected. Colour coding shows type of
alteration.
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MUC16. Histograms as per Figure 5-2.
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Following is a detailed description of the types of mutation for each of the genes listed in
Figures 5.2 and 5.3.

TP53 (chr17:7,565,097-7,590,863). In our cohort, a mixture of high impact variants as well
as copy number events were observed. A total of 79 SNV were identified across the cohort,
31 with a CADD >20.

CDKN2A (chr9:21,967,751-21,995,300). Eight samples showed high impact (mostly stopgained) SNV, all within the coding region and in 4 cases occurring in multiple samples. All
of these high impact variants had COSMIC IDs and had an average scaled CADD of 36. A
further 6 examples of medium impact SNV were seen in CDKN2A including a missense
variant occurring in 3/15 samples.

MECOM chr3:168,801,287-169,381,563). The predominant pattern of variation in MECOM
was amplification. It was also the most highly amplified oncogene with 10 samples (66%)
harbouring a CNV with average CN of 4, and no evidence of any LOH. Of the 6 samples
with high and medium impact SNVs, one sample (4699) had a stop gained (COSMIC IDs
COSM1420480, COSM4948202, COSM5829617) and the others were missense mutations.
Of these variants, the average scaled CADD was 20.53.

NOTCH1 chr9:139,388,896-139,440,314 Like MECOM the predominant pattern of variation
in NOTCH1 was amplification. Notwithstanding this, numerous high impact SNV were
observed including 5 samples with stop-gain mutations in the second half of the gene
(negative strand), and numerous significant medium impact missense and splice region
variants.
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PTPRD chr9:8,314,246-10,612,723 In our series, PTPRD showed a mixture of variants,
dominated by high impact (inactivating) SNV, and CNV, predominantly by deletion and
LOH. When filtered for impact, SNV in PTPRD were the most plentiful of any in our study,
with 293 variants with a CADD > 20 across all samples.

PLCB4 chr20:9,049,410-9,461,889 Within our cohort, one specimen had both a stop gained
and a splice acceptor SNV with high impact. In total, 56 SNV with a scaled CADD > 20 were
identified across all samples. We identified amplification in 9 of 15 samples, to an average
CNV of 4. Two samples had LOH with CN =1.

PCLO chr7:82,383,321-82,792,246). The predominant pattern of variation for this gene was
SNV, with a single sample showing amplification. Of the SNV, 4 samples displayed stop
gained, while one other sample had a high impact splice variant as well as two high impact
frameshift deletion events.

PPP6C chr9:127,908,852-127,952,218 A single stop-gained SNV and 5 other missense SNV
were identified in our series for PPP6C.

FAT4 chr4:126,237,554-126,414,087). FAT4 SNVs were observed in 5 samples. Of these
short variants, there was a single high impact stop-gain, and 57 other mutations with a
minimum scaled CADD of 20. CNV analysis revealed 2 samples with LOH (CN =1), both
samples also harbouring missense SNV.
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CSMD3 chr8:113,235,157-114,449,328). Five samples had a stop gained SNV in this gene,
effecting codons 22-67/71. One stop gain mutation effected 2 samples. This mutation has 2
COSMIC IDs: COSM1721763, COSM1721764. These catalogue to melanoma and rectal
adenocarcinoma, across 5 curated samples. A further 152 SNVs with a minimum scaled
CADD of 20 were identified. These included both coding and non-coding regions.

SYNE1 chr6:152,442,819-152,958,936 A single sample in our study showed 3 high impact
mutations in this gene, including a stop gained and 2 splice acceptor variants. A further
sample had a stop gained (high impact). In total 50 SNVs were identified in 12/15 samples
with a CADD > 20. A single LOH event effecting SYNE1 was noted in one sample. There
were 8 amplification events, only one of which had a CN >4.

PTCH1 chr9:98,205,262-98,279,339 PTCH1 mutations were common, but it was the least
effected by high impacting variants. Only 3 variants with a CADD > 20 were identified, all
were missense SNV, and none were classified as “probably damaging”.

DCC chr18:49,866,542-51,062,273 In our cohort, SNV in DCC was prominent with a stop
gained truncating mutation in one sample, but in all other samples another 60 variants with
scaled CADD >20. Of particular note, DCC in our cohort was most significantly effected by
LOH events in 8/15 samples.

AMPH chr7:38,423,297-38,671,167 We observed prominent amplification of this gene with
10 samples having duplications with CN form 3-5.
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MUC16 chr19:8,959,520-9,092,018). MUC16 was subject to a high rate of inactivating
mutations, including a stop gained in 8/15 cases, and another 9 cases of coding variants with
CADD >20, including a missense SNV 9:8997432 (glutamate to lysine) effecting 2 samples
with COSMIC ID COSM4546866/7, catalogued by COSMIC in the context of aggressive
cSCC (Pickering, Zhou et al. 2014, South, Purdie et al. 2014), although not mentioned in
these publications. We identified 6 samples with duplication events.

NRXN1 chr2:50,145,643-51,259,674 High impact missense variants were identified in 8/15
samples, including with COSMIC ID COSM 4475612 seen in high risk cSCC (Pickering,
Zhou et al. 2014).

USH2A chr1:215,796,236-216,596,738). Three samples with a total of 5 stop gained SNVs
were identified for this gene with another 46 missense variants with CADD > 20 evident.
Within cutaneous malignancy, USH2A variants have been documented in multiple COSMIC
samples, predominantly melanoma, but also in a cSCC (COSM4547692) (Pickering, Zhou et
al. 2014). COSMIC data shows an overwhelming proportion of variants of USH2A to be C>T
(94% of 15408). We would have expected this to be the same, but only 25/46 (54%) were
C>T. This anomaly, given the overwhelming nature of SNV being C>T in the overall cohort,
is difficult to account for.

SEMA3D chr7:84,624,869-84,816,171 Only one sample had a stop gained and splice
accepter high impact variant, and another 6 samples exhibited 10 separate missense SNV,
including 7:84628811 C>T which is shared by 4 samples. This variant has a COSMIC ID
COSM170328, seen in cSCC (Pickering, Zhou et al. 2014), melanoma, prostate and bowel
carcinoma. It has a scaled CADD of 29 and is probably damaging as assessed by PolyPhen.
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NAV3 chr12:78,224,685-78,606,790 One sample had a stop gained, 8 samples showed
missense SNV (19 SNV events ie most samples had more than 1 missense variant) and a
further 15 non-coding short variants of high impact (CADD > 20), 6 of which were short
deletions for this gene. CNV revealed 2 samples with large deletion events.

5.3 Other genes of interest based on known association with metastasis
PLAU chr10:75,668,935-75,677,259 encodes the protein urokinase plasminogen activator
which converts plasminogen to the broad spectrum serine protease plasmin responsible for
the degradation of extracellular matrix and tumour migration and proliferation (Ranson and
Andronicos 2003). There were no coding short variants in PLAU in any sample. There were
numerous large amplification events on Chr10 spanning the entire gene (Figure 4-17) and see
also circos plots 4699, 9120, 35649, 35818, 48585, 183410, 184577, 193958, 321773
above.

FGFR2 chr10:123,237,844-123,357,972. FGFR2 encodes for a cell surface growth factor
receptor, which when upregulated can activate both the RAS-MAPK pathway and the PI3KAKT pathway. FGFR2 variants with scaled CADD scores > 20 were largely missense
variants. Coding SNV resulting in codon changes were seen at codon numbers:
216 – S > L (Sample 9120) within the Ig-like C2-type 2 domain
572 – G > E (Sample 4699) within protein kinase domain
591 – H >Y (Sample 183410) within protein kinase domain
654 – S > F (Sample 48585) within protein kinase domain
778 – S > L (Sample 9120) within the cytoplasmic domain
All were assessed as Deleterious on Provean and Damaging on SIFT.
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RIPK4 chr21:43,159,529-43,187,266 RIPK4 has been postulated as a potential driver gene in
cSCC (Pickering, Zhou et al. 2014), by activation of Wnt/Hedgehog/Notch signalling
pathways. Five samples (33%) showed medium impact SNV, including COSM21051 which
annotates a C>T substitution at 21:43176851 with a scaled CADD score of 28.6.

RASA1 chr5:86,563,705-86,687,748). RASA1 probably acts as a tumour suppressor gene by
its inhibitory regulation of the Ras-cyclic AMP pathway (Pickering, Zhou et al. 2014). Three
samples (20%) showed inactivating missense SNV with scaled CADD scores >25 for this
gene.

HRAS (chr11:532,242-537,287). See above in Chapter 1.5.3. Four samples (27%) showed
damaging and deleterious missense SNV. Only 1 sample harboured an amplification CN >=
5.

PARD3 chr10:34,398,488-35,104,253 High impact short variants (1 stop gained and 1 splice
acceptor region variant) were identified in 2 samples for this gene. Five samples showed
missense SNV (all with scaled CADD > 20), with one of these samples also showing an
inframe deletion. One of the missense SNV had a COSMIC ID catalogued to BCC. All
samples showed at least one non-coding but scaled CADD > 10 SNV. There were no
examples of amplification in this cohort and two samples had large scale deletion events.
Neither of these large deletions were in samples with inactivating missense coding SNV.
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Table 5-1 Mismatch repair gene SNV/Indel and CNV

5.4 Mismatch repair genes
To identify susceptibility to microsatellite instability (MSI) due to mutations in mismatch
repair genes, we analysed variation in a subset of genes included in a review of MSI in
melanoma (Chae 2016). These genes were the top 10 mutated DNA repair genes when
comparing COSMIC and TCGA data for diseases including lung, breast, liver, large intestine
and skin(melanoma). The variant data for these 10 genes is presented in Table 5-1. All genes
had some degree of inactivating variant. A large and significant amplification of TP53BP1
was seen in a single specimen (4699).
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5.5 Discussion
5.5.1

Short Variants

The overwhelming majority of short variant events in metastatic cSCC are non-coding (Figure
3-2). This underlines the utility of WGS in this study compared to the largest previous study
of aggressive and high risk cSCC which employed WGS(Pickering, Zhou et al. 2014), and a
recent major work using targeted NGS analysis of 10 000 tumours including metastatic cSCC.
The conclusion could be drawn from our findings that it is simply our ignorance of the noncoding genome that limits the application of WGS to this disease and has little to do with the
mutational landscape.

5.5.2

Recurrent SNV

Somatic SNV identification was one of the key aims of this project. We were interested in a
metastatic cohort to establish the mutational landscape of cSCC. As with BRAF v600e, we
wondered whether a single variant might be recurrent and provide an avenue for therapy in
this disease. Of note, there were no BRAF coding SNV in our series.

The extent of somatic variation in “normal” UV exposed skin (Martincorena 2014) is
significant. Nonetheless, the burden of mutation and variants seen in cancer associated genes
is different between their cohort and ours, being at either end of the range of sun exposed and
UV implicated pathologies. What is to be made of the extent of SNV and how can we best
make sense of short variants in the face of the mutational burden in metastatic cSCC? The
answer is obviously to more mindfully interrogate hotspots of impact in the non-coding
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genome, some of which are known, and some will depend on findings from transcriptome
analysis of our cohort.

The short variants that were recurrent and high impact (coding, scaled CADD >10) included
many known tumour suppressors or other genes previously described in the cancer context.
These genes and their known roles in carcinogenesis and metastasis include:

TP53 was the gene in which most mutations occurred. TP53 encodes a protein (p53) that acts
as a tumour suppressor, with effects on apoptosis and cell cycle regulation, including by p21,
GADD45 and 14-3-3 activation. Germline mutations cause Li Fraumeni Syndrome,
characterized by early onset of many varieties of malignancy. Somatic variations in TP53 are
seen in all cancer types. Mode of variant may be large scale impact such as frameshift or
premature stop codons, or by missense mutation.

CDKN2A– Cyclin-dependant kinase inhibitor 2A (p16) acts as a tumour suppressor, acting
by inhibiting cyclin-dependant kinases. It is capable of inducing cell cycle arrest in G1 and
G2. Its actions are many and can be related to its effect on p53 degradation (by binding to
MDM2), or independent of p53 (by activation of cyclin complexes). The usual mechanism
of inactivation is via deletion, but this was not the case in our series, whereby SNV was
predominant. CDKN2A (p16) expression acts as a surrogate marker for HPV infection and is
of particular interest in mucosal oropharyngeal SCC. It is thought that p16 expression may be
a marker of disease more sensitive to therapy. The application of this theory is currently the
subject of numerous clinical trials. Its role in cutaneous malignancy is less clear. There is
good evidence that p16 expression in the lymph node metastases of cSCC is common
(Beadle, William et al. 2013). Practical application of this finding supports a sceptical
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approach to the routine attribution of p16 +ve SCC in cervical lymph node metastases to an
occult mucosal primary.

MECOM– a gene involved in haematopoiesis. It has at least three transcribed isoforms,
MDS1-EVI1, EVI1 and EVI1Δ324. Generally MDS1-EVI1 behaves as a tumour
suppressor, whereas EVI1 and EVI1 324(commonly co-expressed with EVI1) act as oncoproteins, binding as transcription factors to ETS binding sites(Sayadi, Jeyakani et al.
2016), and are associated with aggressive cancers with poor prognosis. MECOM is a
transcriptional regulator and oncogene which plays a role in development, cell proliferation
and differentiation. It has anti-apoptotic effects by suppressing the JNK-1 mediated
phosphorylation of c-Jun. c-Jun is usually activated (phosphorylated) in response to UV to
protect against UV associated apoptosis. The role of an amplification (and therefore overexpression) of MECOM could be to decrease c-Jun activity in UV exposed cells and to
impact on normal apoptotic regulation. MECOM overexpression is associated with worse
prognosis in glioblastoma multiforme (Hou, Zhao et al. 2016). Translocations of this gene
with AML1 can occur in Acute Myeloid Leukaemia. In a study of irinotecan resistant
colorectal cancer cell lines, MECOM was identified as a differentially expressed gene, acting
through evasion of apoptosis and the MAPK pathway, to worsen prognosis in this therapy
resistant group.

NOTCH1 encodes a transmembrane protein with EGF like receptors which, once ligand
bound, releases an intracellular component which has numerous roles in the regulation of
transcription and subsequent proliferation, differentiation and apoptosis. The Notch signalling
pathway is upregulated in murine mammary oncogenesis, and increased expression of Notch
receptors has been associated with many malignancies.
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PTPRD encodes a protein of the protein tyrosine phosphatase receptor family, that have roles
in cell growth and differentiation and oncogenic transformation, their action opposing that of
the tyrosine kinases. Large scale genomic events impacting CDKN2A can also affect PTPRD
due to their proximity. PTPRD dephosphorlyates STAT3, deactivating its tumourogenic
activity. STAT3 hyperactivation is associated with decreased survival and resistance to
EGFR-targeted therapy (Peyser, Du et al. 2015). PTPRD inactivation was demonstrated to
significantly increase levels of STAT3 in HNSCC. PTPRD is a tumour suppressor that
exhibits putative inactivating somatic variants in >50% of GBM and between 10-20% of head
and neck mucosal SCC (Veeriah 2009).

PLCB4 encodes for a protein that catalyses the formation of inositol 1,4,5-trisphosphate and
diacylglycerol from phosphatidylinositol 4,5-bisphosphate. Amplification of PLCB4 and
subsequent overexpression has been associated with overall more aggressive disease and
worse prognosis in primary GIST (Li et al 2017). PLCB4 is also one of a group of genes
frequently mutated in uveal melanoma.

PCLO encodes Piccolo, which is a presynaptic cytomatrix protein. There is evidence for its
role stabilising and preventing breakdown of EGFR, and in the progression of disease in
oesophageal SCC (Zhang 2017). In. this study, in both a knockdown mouse model, as well as
using a monoclonal antibody targeting PCLO, tumour progression was inhibited. As such, in
oesophageal SCC it behaves as an oncogene.

PPP6C encodes a catalytic subunit of the protein phosphatase that regulates IL2 receptor
stimulation by removing phosphate groups and activating the cytoplasmic receptor tyrosine
kinase. This gene was recently identified as altered in review of BCC, occurring in 15% of
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primary tumours(Bonilla, Parmentier et al. 2016). Herein it is cited as an inhibitor of Cyclin
D1. Loss of regulation or inhibition of Cyclin D1, and its overexpression is established in
many cancers, including head and neck SCC (mucosal).

FAT4 encodes a protocadherin that plays a role in regulating planar cell polarity, the Hippo
signalling pathway, the Wnt signalling cascade and the expression of YAP1. In gastric cancer
cell lines and in a mouse xenograft model, FAT4 downregulation increases lymph node
metastasis and worse survival, and increases growth and invasion of gastric cancer cells, with
over expression of mesenchymal markers and decreased epithelial phenotype (Cai, Feng et al.
2015).

CSMD3 encodes a transmembrane protein with CUB and Sushi Multiple Domains. Available
data from multiple sources supports a tumour suppressor role for CSMD3 and the other
CSMD genes. Loss of function mutations of CSMD3 were identified in a knockout airway
epithelial cell line model to increase cell turnover and probable role in lung tumourogenesis
in a non-small cell lung cancer model(Liu, Morrison et al. 2012).

SYNE1 encodes for a spectrin repeat containing protein that localises to the cell membrane
and assists in maintaining subcellular spatial organisation. It has influence in both meiosis
and cell cycle pathways. Cutaneous melanoma exhibits SYNE1variants in 24% of samples,
while HNSCC shows SNV in 18% (Intogen : Barcelona Biomedical Genomics
Lab(Gonzalez-Perez, Perez-Llamas et al. 2013)).

PTCH1 encodes a transmembrane protein receptor (Patched) for Sonic Hedgehog (SHH).
Unbound, it suppresses the activity of Smoothened (and keeps it cytoplasmically bound
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within and endosome), but once bound by SHH, it releases SMO to promote cell proliferation
by nuclear GLI gene activation. Indeed, upon SHH binding, Patched is degraded. PTCH1 is a
key component of the Hedgehog pathway, and its protein’s action on SMO is the key event in
contemporary Hedgehog pathway inhibition. Indeed, vismodegib acts to bind and inhibit
SMO in effect, similar to the action of Patched.

DCC encodes for a protein which is a membrane receptor for netrin-1 (dependence receptor).
When not bound, DCC has a pro-apoptotic effect. Once bound, it can block apoptosis by
activation of MAPK pathway and by Caspase 3.

AMPH encodes a protein (amphyphysin) associated with the cytoplasmic surface of synaptic
vesicles. There is a potential role for AMPH expression changes in cancer. A subset of
patients with Stiff-Person Syndrome and breast cancer have autoantibodies to amphyphysin.

MUC16 encodes CA-125, which is a transmembrane 0-glycosylated protein which helps to
protect the apical aspect of epithelial cells. MUC16 interacts with mesothelin (MSLN) to
activate matrix metalloproteinases to enhance invasion in pancreatic cancer (Chen, Hung et
al. 2013). CA-125 is used as a marker of disseminated disease in the blood of ovarian cancer
patients, and its role in other malignancies is emerging. Its cancer association is generally
assumed to be by overexpression, probably as a result of amplification. Given the role of
MUC16 in invasion is likely to be by amplification, expression of MUC16/CA-125 and
MSLN relative to MMP is likely to determine any role in this disease.

NRXN1 encodes for neurexin-1-beta, which is a cell-surface protein that binds to neuroligins
and is involved in synapse communication between cells, and likely plays a role in cell
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adhesion interactions. Deletions in this gene are associated with neurodevelopmental and
neurobiological abnormalities (genecards.org).

USH2A encodes for a protein involved in hearing development. It has been implicated
(perhaps as a tumour suppressor) as a result of observations of missense mutations of this
gene in HCC, and its related genes GPR98, PCDH15 and MYO7A in a review of 88 HCC by
WGS. (Kan, Zheng et al. 2013).

SEMA3D encodes a protein involved in axon guidance in neural development and diseases
associated with SEMA3D deactivating SNV include Meniere and Hirschsprung Disease.

NAV3 is another gene involved in axon guidance and neurone development and impact IL2
production by T cells (Karenko, Hahtola et al. 2005) and in neural regeneration. Additionally,
it plays a role in microtubule regulation and in a breast cancer xenograft model with NAV3
knockdown, metastasis was increased, and patients with breast cancers expressing normal
levels of NAV3 show longer survival.

FGFR2 encodes a critical receptor tyrosine kinase, one of four for FGFR. FGF plays a role in
cell division, regulation of growth and maturation, angiogenesis and wound healing. Targeted
next generation sequencing in a cohort of non-metastatic primary cSCC identified variants in
FGFR2 to be exclusively seen in tumours with perineural infiltration (PNI) of tumour cells
(Zilberg, Lee 2018). Histopathology of lymph nodes infrequently displays PNI due to the
absence of neural tissue which makes this finding difficult to correlate in our cohort.

RIPK4 encodes a key serine/threonine protein kinase involved in keratinocyte and stratified
epithelial differentiation. It is involved in both NK-kappaB signalling interactive and
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Wnt/Hedgehog/Notch signalling pathways. Five samples (33%) in our series showed medium
impact SNV, including COSM21051 which annotates a C>T substitution at 21:43176851
with a scaled CADD score of 28.6. This variant was also seen in a series of RIPK4 in primary
head and neck cSCC (Pickering, Zhou et al. 2014). In that series, RIPK4 variants were
identified in 28% cases. They found variants only in exon 2 and 8, whereas in our cohort,
they included 2, 5,7 and 8.

RASA1 encodes an inhibitory regulator of the Ras-cyclic AMP pathway, acting via weak
GTP-ase action to derive the inactive GDP bound RAS on the cytoplasmic extent of RTK. It
thus acts as a tumour suppressor. In our cohort, three samples showed inactivating missense
SNV with scaled CADD scores >25. This is in keeping with previously reported findings in
cSCC (Pickering, Zhou et al. 2014).

HRAS encodes for one of the Ras activating genes, involved in signal transduction and the
MAPK pathway. It is classified as an oncogene.

PARD3 encodes an adaptor protein involved in asymmetrical and cell polarization processes.
It is involved in epithelial tight junctions (Chen, An et al. 2017) and may also targets PTEN
to the same tight junctions. Inherited defects have been implicated in neural tube defects as a
result of the disruption of neuroepithelial morphogenesis. Its role in cancer has mostly been
described as a tumour suppressor in breast cancer. Recently, evidence for a role of decreased
expression of PARD3 in facilitation of the invasion of malignant cells within the breast
tumour microenvironment by enhancing the sliding property of tumour cells within
stroma(Milano, Ngai et al. 2016). In our samples, high impact short variants (1 stop gained
and 1 splice acceptor region variant) were identified in 2 samples. Five samples showed
missense SNV (all with scaled CADD > 20), with one of these samples also showing an
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inframe deletion. One of the missense SNV had a COSMIC ID catalogued to BCC. All
samples showed at least one non-coding but scaled CADD > 10 SNV. There were no
examples of amplification in this cohort and two samples had large scale deletion events.
Neither of these large deletions were in samples with inactivating missense coding SNV.
These data support a high incidence of inactivating short variants potentially enhancing the
metastatic process.

With such a range of high impact short variants (as well as CNV and SV) within our cohort,
the question is how to interpret this against what we understand to be drivers of cancer. A
recent update to the COSMIC database is the Cancer Gene Census (Sondka, Bamford et al
2018). This is not new data but a review and representation of existing COSMIC data and
revision of the original paper (Futreal, Lachlan et al 2004).

Within the census, genes are categorised according to Tiers. Tier 1 genes possess documented
activity relevant to cancer, along with evidence of mutations in cancer which change the
activity of the gene product in a way that promotes oncogenic transformation. COSMIC also
reviewed the existence of somatic mutation patterns across cancer samples in COSMIC. For
instance, tumour suppressor genes often show a broad range of inactivating mutations and
dominant oncogenes usually demonstrate well defined hotspots of missense mutations. Genes
involved in oncogenic fusions are included in Tier 1 when changes to their function caused
by the fusion drives oncogenic transformation, or in cases when they provide regulatory
elements to their partners (e.g. active promoter).

Tier 2 genes are those that, whilst being implicated in cancer, have less robust evidence and
often relate to genes that are more recent targets of interest.
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Within our cohort, Table 5-2 represents those genes for which we observed either significant
SV, CNV or high impact SNV compared to the same genes annotation within the Cancer
Gene Census.
Of note is that for our reported SNV, we have a minimum scaled CADD of 10 for
predominantly missense variants. Other higher impact short variants including stop gained,
frameshift and splice donor or acceptor variants are also present. The same is not the case for
the data from the CGS. No such minimum impact is required. Rather, for each gene,
following a search of the COSMIC database and the available literature, data is compared
from multiple reported series (at least 2), and each piece of evidence must satisfy at least 2
expert (post-doctoral scientists) reviewers. The gene is then ascribed a Tier.
Within the CNV/SV group, concordance in this comparison is seen within SOX2, MYC,
DCC, SMAD4, PDE4D. Additionally, most of our high impact (missense) SNV share this
observation with the CGS annotations.
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Table 5-2 Comparison of metastatic cSCC CNV/SV genes and high impact SNV with
annotations from COSMIC Cancer Gene Census.
CNV/SV

SNV

GENE
NDRG1

Met cSCC
Amp

CGS (Tier)
Trans (1)

GENE
TP53

PIK3CA

Amp

Mis SNV(1)

CDKN2A

SOX2
ABL1

Amp
Amp

MECOM
NOTCH1

ASXL1

Amp

BAI1
CAP2
COL5A1

Amp
Amp
Amp

Amp (1)
Mis SNV/
Trans (1)
FS, Mis/Non
SNV (1)
-

CYC1

Amp

-

FAT4

DSP
EPPK1
EDN1

Amp
Amp
Amp

-

CSMD4
SYNE1
PTCH1

EGFL7
PLEC
MYC

Amp
Amp
Amp

Amp/Trans
(1)
Mis/Non
SNV Del (1)
FS Mis/Non
SNV Del (1)

AMPH
MUC16
NRXN1

DCC
SMAD4

TTC28
MYLK
PDE4D
EPHB1
PTK2

Mis SNV
/Del
Del

Trans
Trans
Trans
Trans
Trans

PTPRD
PLCB4
PCLO
PPP6C

Trans
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Met cSCC
CGS (tier)
FS Splice
Mis/Non SNV
Mis SNV
FS Trans (1)
FS Mis SNV Del/FS/Splice/
Mis/Non SNV
(1)
Mis SNV
Trans (1)
Mis SNV
Trans Mis
SNV (1)
FS Mis SNV Del Mis/Non
SNV (1)
Mis SNV
Mis SNV
Mis SNV
Mis/Non SNV
(1)
Mis SNV
Mis/Non SNV
(1)
Mis SNV
Mis SNV
Mis SNV
FS/Splice/
Mis/Non SNV
(1)
Mis SNV
Mis SNV
Mis SNV(2)
Mis SNV
-

USH2A

Mis SNV

-

SEMA3D

Mis SNV

-

NAV3
FGFR2
RIPK4
RASA1
HRAS
PARD3

Mis SNV
Mis SNV
Mis SNV
Mis SNV
Mis SNV
Mis SNV

Mis SNV (1)
Mis SNV(1)
-

5.5.3

Mismatch repair genes

Mismatch repair defects give rise to microsatellite instability (MSI) due to hypermutation.
Microsatellites are small recurring repeats, usually one to six base pairs in length. MSI was
originally described in Lynch syndrome, a non-polyposis colorectal cancer, the phenotype
having mainly right sided cancers occurring in the 6th decade and having a signet ring
histopathology (Thibodeau 1993). This disease is characterised by germline mutations in the
MSI genes MSH2, MLH1, MSH6, PMS2, and PMS1 (Pawlik 2004). In particular SNPs in
MSH2 and MLH1 were seen most frequently in tumours exhibiting MSI.
A comprehensive review of somatic mutations, CNV and expression frequencies of DNA
repair genes within COSMIC identified recurrently somatically varied genes in melanoma
(Chae 2016). The top 10 genes associated with subsequent MSI in melanoma were TP53,
KMT2C, POLQ, ATM, ATR, BRCA2, SLX4, TP53BP1, PRKDC, CENPE. Somatic variants
within our cohort across these genes is presented in Table 6-3.
As stated earlier, in a series of high risk cSCC, Pickering et al reported inactivating mutations
of KMT2C in 39 cSCC, which encodes a histone methylation complex to alter transcriptional
regulation. This mutation has been identified in other malignancies and was associated with
increased incidence of bone invasion and a shorter time to recurrence in cSCC (Pickering,
Zhou et al. 2014). Once again, in our series, it was a key MMR gene with a high rate of
inactivating mutations. This confirms the earlier findings of a likely role in advanced and
metastatic disease.
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5.5.4

Pathway impacts from short variants

5.5.5

Canonical Wnt/ß-catenin and Hippo interaction

The canonical Wnt/ß-catenin pathway is one of 3 Wnt pathways (canonical, non-canonical
(cell polarity and calcium homeostasis). Wnt signalling is responsible for many regulatory
and growth limiting effects with obvious cancer implications. Canonical Wnt pathway is
activated via Wnt ligand binding to the Frizzled receptor (Fz) with subsequent
intracytoplasmic accumulation of ß-catenin and translocation into the nucleus to act as a
transcription factor for genes including c-myc and cyclin D1. When the Wnt ligand is not
bound, ß-catenin does not accumulate, but rather is phosphorylated and ubiquinated to be
degraded by proteasomes.

Hippo is a pathway that acts to regulate the size of organs. It is impacted by cell density and
so in a high cell density is in the activated state. Such a state is meant to regulate further cell
division and organs growth. This is ultimately by phosphorylation (and degradation) of
YAP/TAZ, the final drivers of anti-apoptotic and proliferation genes including diap1 and
cyclin E (Kim and Jho 2014).

Mechanisms for interaction between Wnt and Hippo pathways include the blocking of ßcatenin’s nuclear localization (and therefore activation of regulators of proliferation) by
YAP/TAZ, remembering that YAP/TAZ activation (non-phosphorylation and escape from
degradation) occurs in the low-cell density state. Additionally, ß-catenin levels, and their
ubiquitinisation complex levels may also impact on the levels of TAZ in the cytoplasm
(Azzolin Cell 2012). FAT4 is one of the previously unknown upstream activators of Hippo.
Its deactivation should lead ultimately to less phosphorylation of YAP/TAZ with less
resultant degradation. This would then replicate the low-cell density state and drive anti-
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apoptotic and proliferative genetic drivers. As reported earlier, FAT4 showed significant
missense SNV in our cohort. Conversely, we have identified an amplification of DSP which,
in NSCLC acts as tumour suppressor by inhibiting the Wnt/ß-catenin pathway.

5.5.6

Notch signalling

Of the 4 NOTCH receptor encoding genes, NOTCH1 showed the most variation in metastatic
cSCC. Activation of the NOTCH pathway is highly conserved, and binding of ligands and
activation of the transmembrane NOTCH receptor transfers the Notch Intracellular domain
(NICD) to the nucleus to activate transcription of specific target genes and activation of
downstream targets including PI3K, AKT and p21.

5.5.7

Hedgehog pathway signalling

PTCH1 was recurrently varied in metastatic cSCC although perhaps not to the same
deleterious biological effect of some of the other highest impacting genes by SNV.
Nonetheless, there is a degree of variant activity in this gene which is likely to impact on its
role as a key transmembrane receptor in the Hh pathway. Inactivation of PTCH1 to disallow
reception of the Hh ligand will impact disinhibition of SMO. SMO affect to induce expression
and post translational modification of GLI zinc finger transcription factors (Karamboulas and
Ailles 2013).

5.5.8

Cell Cycle

Genes in the cell cycle pathway predominate in the most recurrent single nucleotide variants
in our samples. TP53 and CDKN2A are genes most impacted by high impact (eg stop gained
and splice region) and missense variants. SMAD4 is the gene with the second highest rate of
large scale deletion events. Crossover effects to the regulation of apoptosis magnify the loss
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of not just the cell cycle but also programmed cell death as a result of these inactivating
mutations.

Figure 5-4 Cell cycle Kegg diagram highlighting TP53, CDKN2A and SMAD4
interaction. Source https://www.kegg.jp/kegg-bin/show_pathway?hsa04110

5.5.9

MAPK and MEK inhibition

The Ras-Raf-MEK-Erk pathway starts with the bindings of a receptor tyrosine kinase and
ends with the activation of transcription factors in the nucleus to drive cell growth,
differentiation, proliferation, apoptosis and migration functions. Key genes within the
pathway showing somatic variation in our cohort include the tyrosine kinase regulator
PTPRD and PPPC6. In recognised key MAPK genes DUSP4, DUSP6, MAP2K1, MAP3K1,
MAP3K2, MAP3K3, MAP3K7, MAP3K9, MAPK1, MAPK3, MAPK8, MAPK12, MAPK14 we
found multiple missense variants across 10 of 15 samples. These were most prominent in
DUSP4, MAP3K1, MAP3K3, MAP3K9 and MAPK14. No such mutations were seen in
DUSP6, MAPK1 or MAP2K1.The usual targets of MEK pathway inhibition, BRAF and RAS
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did not show significant variation, and there were no examples of V600E (or V600K)
mutation in our samples.
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6 Results: Non-coding regions
6.1 TERT promoter variants
TERT promoter mutations (TPM) were seen in 13 (93%) metastatic tumours (Figure 6-1).
These included common and widely reported classic mutations C228T (chr5: 1295228) (n=3)
and C250T (chr5:1295250) (n=8,), but also the less common but described variants
A161C(chr5:1295262), C205T(chr5:1295205) (n=7), C242T(chr5:1295242),
C243T(chr5:1295243) and C252T(chr5:1295252). Of those cases with TPM, 85% showed
either C228T or C250T, but none showed both.

The classic TPM C228T was seen in 21% of all samples and 23% of those with TPM. In this
series the previously infrequently observed mutation C205T, was seen in 50% of all samples
and 54% of samples with TPM (Figure 6-1).

Amplification (CN=>4) of TERT itself was demonstrated in 13/15 samples (Figure 6-1), with
a minimum block size of 5000bp.
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33432
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Figure 6-1 TERT promoter variants by sample and prevalence. Percentage of samples
exhibiting TP variant (blue) left of main body. Copy number variation of TERT below
main figure (green).
In order to understand whether any of the observed TPM impacted on telomerase expression,
paraffin blocks of all metastatic tumour samples were cut and stained for
immunohistochemical (IHC) assessment (TERT Antibody (A-6), Santa Cruz Biotechnology,
California). Of those cases that had TPM, only 25% stained positive for telomerase (Figure 62). The greatest association between TPM and positive IHC was for the C205T variant,
whereby 75% of cases that stained positive had this mutation, and 43% of the C205T cases
stained positive. Only 1 out of 8 cases with C250T stained positive, with this case also having
C205T TPM. There was no correlation between positive IHC and clinicopathological
features. Vinagre et al found a trend toward higher TERT expression as assessed by IHC in
gliomas with TPM, but this failed to reach significance. Furthermore, there was no
association between TPM or amplification pattern, and differentiation of tumours, nodal
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ratio, resection status or survival in our cohort. Thus, telomerase IHC is unhelpful in
considering TPM effect.

Figure 6-2 Immunohistochemistry analysis showing positive telomerase staining in
tumour cells of sample 35818 with no staining (negative control) of stroma evident. 35818
had a TERT CN of 9 and was the only sample with C205T and A161C. TERT (A-6): sc393013 Santa Cruz Biotechnology Inc

6.2 NFKBIE
Across the NFKBIE promoter co-ordinates 6:44233377-6:44233437, SNVs were identified in
9/15 specimens (60%), with 5 of these samples having more than one promoter variant.
Chr6:44233400 C>T was seen in 5/15 (33%) samples with an average VAF of 0.25.
In total, more than 50% of cases showed an amplification, one in combination with an LOH
event.

Noteworthy is that all samples with a CNV other than 48585 also had a promoter variant. 48585
herein shows a major amplification over 370000bp with a CN of 6 (5:1).
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6.3 MicroRNA
We selected a group of microRNA(miRNA) that had been identified in SCC of the vulva
(Melo-Maia, Lavorato-Rocha et al 2013) and cervix (Ding, Wu et al 2014) as potential
biomarkers for progression of disease and also as potential serum biomarkers. These miRNA
included miR-1246, miR-20a, miR-2392, miR-3147, miR-3162-5p miR-4484. To assess a
wider block size (5000bp) than confined only to the miR co-ordinates (in the region of 22
nucleotides each), manual co-ordinates were entered into Seave for analysis. These coordinates were:
miR-1246 Chr 2: 176817825-178208520
miR-3147 Chr 7: 56738644-58335801
miR-4484 Chr 10: 125523232-125649350
miR-3162 Chr 11: 59265408-59409255
miR-20a Chr 13: 91984898-92091600
miR-2392 Chr 14: 101233633-101308604
Copy number analysis of the regions spanning these miRNA showed both CN loss and gain.
miR-3147 showed deletion in 5 samples (33%). This same miRNA was duplicated in 100%
of samples with an average CN of 4.6 and average block size of 19.7 Mb. 13/15 samples
showed a duplication of miR-2392 with an average CN of 3.7.

A selection of microRNA implicated in cSCC (miR-21, miR-184, ,miR-31, miR-203 and
miR-205) (Dziunycz, Iotzova-Weiss et al 2010) were analysed for CNV and SNV in our
cohort. (Table 6.2). As discussed in Chapter 9.5.3, miR-203 and 205 are heavily amplified in
our samples. In particular, miR-203 showed highly consistent amplification (in all but 1
sample) and no evidence of deletion. Within this group miR-31 (known to suppress growth,
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invasion and colony formation in metastatic cSCC cell lines (Wang, Landen et al 20140) had
the highest average CN in those samples showing amplification.
Table 6-1 cSCC associated microRNA Copy number variation.
microRNA

Amplified (n)

miR-21
miR-184
miR-31
miR-203
miR-205

6/15
5/15
6/15
14/15
10/15

Ave CN
amplification
3.5
3.9
4.5
3.7
3.6

Deleted (n)
4/15
2/15
2/15
3/15

6.4 Long non-coding RNA
A number of cancer associated lncRNAs , including HOTAIR, LINC00568, TERC,
LINC00657 (NORAD), TCF7, TINCR, MALAT1 (Schmitt and Chang 2016) PVT1, HULC,
,RP11-65J3.1(Xie, Jiang et al. 2018) and PICSAR (LINC00162) (Pipponen et al 2016)were
analysed for both SNV and CNV. SNV (with minimum scaled CADD >5) were common
across all samples (Table 6-2). 200971 was the least varied sample with only 2 SNV of
lncRNA PVT1 and TINCR.

Table 6-2 Frequency of lncRNA SNV in 15 metastatic cSCC specimens. Scaled CADD
>5
lncRNA
HOTAIR
LINC00568
TERC
LINC00657
TCF7
TINCR
MALAT1
PVT1
HULC
LINC00162
RP11-65J3.1
MIRLET7A1

SNV
# samples (of 15)
5
2
1
9
9
5
12
15
2
0
11
1
121

Average scaled CADD
10.8
9.3
6.7
8.7
9.1
9.5
9.9
7.7
9.1
6.9
16.3

CNV of these lncRNA was predominantly amplification (Table 6-3). In particular 13 of the
15 samples had amplification in PVT1 with an average CN of 4.8 and no deletions.

Table 6-3 Copy number variation long non-coding RNA
lncRNA

CN

Amplification

Ave Size BP
for Amp (Mb)

Deletion

# samples (of

# samples (of

15)

15)

HOTAIR

3.5

8

24.61

2

LINC00568

3.9

9

19.13

2

TERC

4.1

11

14.47

0

LINC00657
(NORAD)
TCF7

4.2

9

12.88

1

3.2

5

36.12

3

TINCR

3.2

8

9.89

2

MALAT1

3.9

11

13.01

2

PVT1

4.8

13

20.80

0

HULC

4.0

10

19.13

0

RP11-65J3.1
(linc01503)
MIRLET7A1

4.0

8

15.64

0

4.0

8

32.02

0

LINC00162

3.6

6

5.81

3

6.5 Discussion: Non-coding Regions
Most of the genome is non-coding. Non-coding regions include 3’ and 5’ untranslated
regions (UTR), promoter and other regulatory regions, long non-coding RNA, introns, either
in genes or intergenic with no clear functional role. Interrogating non-coding regions is a
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mammoth task. This task is most sensibly approached either in piecemeal fashion targeting
known hotspots or regions with transcription factor binding sites, or in conjunction with
expression data which identifies over or under expressed regions not obviously the result of
coding variants. And just as not all somatic variants are coding, not all expression changes
will be the result of genomic variance, highlighting the impact of epigenetic modulation and
stromal interaction.

Non-coding regions discussed here are as a result of assessment of genes in interest only and
are not presented as comprehensive. A further review of non-coding regions will follow a
more thorough analysis of the expression pattern in cSCC generally. Promoter and enhancer
variants probably impart effect by changing the affinity of transcription factor binding sites.
Promoter and enhancer (regulatory) regions are rich in transcription factor binding sites.
University of California Santa Cruz (UCSC) genome browser includes a track which includes
TFBS in regulatory regions. From this resource, each TFBS can be interrogated for the
evidence behind each claim, including the cell line or disease in which the enhancement is
seen. Given the lack of genomic assessment of cSCC (moreover for metastatic cSCC), the
application of data derived from ICGC or 1000 Genomes is not always clear.

6.5.1

TERT promoter mutations

Telomerase is a ribonucleoprotein polymerase, maintaining telomere ends by addition of the
telomere repeat TTAGGG. In most normal somatic cells, telomerase is repressed allowing for
progressive shortening of telomeres and eventual senescence. Telomerase is made up of an
internal telomerase RNA template (encoded by gene TERC chr3) and the enzyme, telomerase
reverse transcriptase (encoded by gene TERT chr5). The TERT promoter spans the
coordinates chr5:1295154-1295376 (50-270BP upstream from the transcription start site).
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Deregulation of telomerase expression in somatic cells may be involved in oncogenesis, and
TPM are perhaps the most common variants in cancer.

Vinagre et al (2013) evaluated the presence of TERT promoter mutations (TPM) across a
number of malignant cell lines and tumours. They identified rates of TPMs in various
malignancies; glioblastoma (49%), urothelial carcinoma of the bladder (59%), differentiated
thyroid cancer (10%) and melanoma (29%). Corresponding upregulation of expression was
noted in these groups. In the same study, no mutations were found in renal cell carcinoma,
GIST or phaeochromocytoma. Within melanocytic tumours, only sun exposed cutaneous
melanoma showed recurrent mutations, with no such evidence in either benign neavi or
ocular melanoma. Huang (2013) in a study of 329 cell lines form various tissues and
pathologies found a high rate of recurrent TERT mutations C228T and C250T within the
melanoma group. Most mutations observed were either C250T or C242T. Hugdahl,
Kalvenes et al (2018) recently described the rate of TPM in matched primary and metastatic
melanoma. They found a rate of 68% and 64% respectively, with 24% of mutations being
discordant.

Some telomerase activity persists in normal skin. Burnworth (2007) observed that over the
spectrum from normal skin, through keratoacanthoma to invasive SCC, TERT expression was
equally upregulated. In a focused examination of TERT promoter variants of SCC from
various sites Cheng et al (2015) showed a similar pattern of recurrent and mutually exclusive
mutations to that reported by Huang, but most marked in UV associated tumours. These
mutations had no impact on clinicopathologic behaviour. Scott et al (2013) surveyed TPM in
primary skin cancers compared to benign skin conditions, without matched normal germline
control. They found the highest rate of mutations in basal cell carcinoma (78%). Mutations
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were found in SCC (50%) and Bowens Disease (cSCC insitu) (9%), but no TERT promoter
variants were found in benign skin. Zehir (2017) in 27 cases of metastatic nodal cSCC all
with DNA extracted from FFPE samples and subjected to targeted NGS (including TERT
promoter) found 32% of patients harboured TERT promoter variants; however, none of the
patients exhibited C228T or c205T. TPM have been identified (Jung, Kim et al 2017) as a
negative prognostic indicator in Non Small Cell Lung Cancer, being associated with both
regional lymph node metastasis and worse overall survival.

This mutual exclusivity of C228T and C250T was first described by Huang (2013).
Breakpoint analysis showed no translocations or inversions effecting either promoter or
TERT in any samples. One sample showed a 3Mb tandem duplication of TERC.

The classic TPM C228T has not been previously described in metastatic cSCC. Herein it
was seen in 21% of all samples and 23% of those with TPM. In this series the previously
infrequently observed mutation C205T, was seen in 50% of all samples and 54% of samples
with TPM. In their collection of a variety of solid organ metastases, Zehir et al observed
C205T mutation in only 0.05% of all cases (5 of 10336) and 0.4% of those cases with TPM
(5 of 1232).

TERT regulatory variants outside of the promoter region (total co-ordinates span
chr5:263002-2208200 [Ensembl.org]) were identified in all samples with promoter region
mutations. Some of these variants occurred in multiple samples. These occurred in Enhancer,
TF, CTCF (CCCTC-binding factor) bindings sites, open chromatin and Promoter Flanking
regions. Of the 6 cases without TPM, 2 also had a variant in an open chromatin TERT
regulatory region.
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This high rate and novel pattern of TPM may be in response to the high mutational burden
and may give rise to the high level of structural variation, including chromothripsis, although
this paradoxical theory of telomere crisis is theoretical. Telomere crisis is characterised by
the shortening of telomeres due to increased cell division (unregulated growth occurring early
in carcinogenesis) to the extent that telomeres are completely lost to expose the chromosome
proper (Chin, de Solorzano et al. 2004). Subsequent replication of isolated chromosomal
fragments may give rise to chromothripsis and katagesis (Maciejowski, Li et al. 2015).

ATRX can act to reduce telomere shortening via an alternate mechanism to the action of
TERT. Its loss, by either mutation or deletion, might lead to telomere length loss. This
process is described in glioma(Wiestler, Capper et al. 2013) to be mutually exclusive to TPM.
In our series, this was not the case and the only coding mutation in ATRX was seen in a single
sample that also had C250T TPM. Nonetheless, the missense mutation (C>T) with amino
acid change (leucine to phenylalanine) seen was probably deleterious and had a scaled
CADD of 29.8, and has been described in cholangiocarcinoma with COSMIC ID
COSM4767440, COSM4767441.

6.5.2

NFKBIE

NFKBIE is a gene with 2 isoforms (Shain, Garrido et al. 2015). The longer isoform is present
mainly in brain tissue, whereas the shorter isoform is present in all other tissues. Shain et al
identified mutation hotspots within the promoter region of the shorter isoform, particularly in
desmoplastic melanoma. One of these variants is chr6:44233400 C>T (G>A on coding
negative strand). The mutation hotspots within the promoter of NFKBIE are within consensus
binding sites for multiple transcription factors. Across the promoter co-ordinates 6:44233377-
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6:44233437, we identified SNV in 9/15 samples (60%), with 5 of these samples having more
than one promoter variant. Chr6:44233400 C>T was seen in 5/15 (33%) samples with an
average VAF of 0.25. In the original paper outlining this finding, 2 of 20 samples of
desmoplastic melanoma also showed NFKBIE amplification.

6.5.3

microRNA

MicroRNA are small (19-25nt) fragments of the genome that are transcribed to a primer and
then pre miRNA before exiting the nucleus as mature miRNA. In the cytoplasm they are
activated by Dicer and then interact with mRNA in a complex known as the RNA-induced
silencing complex (RISC). The effect of the RISC can be to either completely silence the
translation of the mRNA or to reduce its expression and enhance its degradation, depending
on the match of the miRNA and the 3’ UTR of the target gene/mRNA. The first human
miRNA (let-7) was discovered in 2000 (Reinhart, Slack et al 2000). miRNA are often located
in close proximity to genes (eg TP53 and miR-34) a trait that enables or augments their
activity to reduce protein expression and in turn to potentially play a role in pathology.
miRNA can be thought of in much the same fashion as cancer associated genes, ie having
proto-oncogenic or tumour suppressing effect. Because miRNA through the RISC opposes
gene expression by disabling mRNA (a miRNA may be involved in the RISC for a number of
different genes), an over expression of a miRNA that bind to a tumour suppressor gene will
have a pro-cancer effect, and similarly, under expression of a miRNA that binds to the
mRNA of an oncogene will have the same effect. The converse would be the same in the
tumour suppressing context. So miRNA are of interest in their interaction with cancer
associated genes and might be able to be used as a biomarker or potentially as a therapeutic
target. Not insignificant in assessing impact of miRNA in disease is the identification of the
target genes for each.
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Matched tumour and serum miRNA were investigated in oral SCC (OSCC) (Schneider,
Victoria et al. 2018). They found amongst a group of 48 miRNA differentially expressed
between healthy tissue and OSCC (25 down and 23 up-regulated), 30 were also able to be
identified in the serum samples. They promoted the utility of miR-32 as it was up-regulated
in both states compared to healthy tissue. miR-32 was identified as associated with colon,
pancreas and prostate cancer in one of the earliest studies matching miRNA with solid
tumour types (Volinia, Calin et al 2006). miR-32 is located on the long arm of chr1, near
PTPN3, a protein tyrosine phosphatase which has been implicated in numerous solid organ
malignancies, both to inhibit and to promote (Gao, Zhao et al. 2014, Li, Lai et al. 2015). In
this context of liquid biopsy biomarkers, the microRNA miR-1246, miR-20a, miR-2392,
miR-3147, miR- 3162-5p miR-4484 were identified as serum markers of metastatic cervical
SCC(Chen, Yao et al. 2013). These miR cluster together in pathways by using miR-Path
(Vlachos, Zagganas et al. 2015)

In our cohort, copy number analysis of the regions spanning these miRNA showed both CN
loss and gain. miR-3147 showed deletion in 5 samples (33%). This same miRNA was
duplicated in al 100% of samples with an average CN of 4.6 and average block size of 19.7
Mb. 13/15 samples showed a duplication of miR-2392 with an average CN of 3.7.

A study of HPV negative vulval cSCC described overexpression of miR-3147 in cancers
compared to non dysplastic adjacent skin. Levels of overexpression were proportional to
depth of invasion, but not metastatic spread (Yang and Guo 2018).
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We also identified a highly amplified state of miR-203, a miRNA previously identified as
under-expressed in cSCC when compared to normal skin (Dziunycz, Iotzova-Weiss et al
2010). This report did not analyse metastatic cSCC. Indeed in our samples, of the five
miRNAs analysed in Dziunycz et al (miR-21, miR-184, miR-31, miR-203 and miR-205)
miR-203 stood out due to there being no deletion events but having sizeable amplification in
14/15 specimens. In SNV terms, miR-203 showed downstream SNV in 10/15 samples,
though of debatable impact without total RNASeq data.

This amplification of miR-203 in metastatic cSCC is at odds with most of the body of
evidence surrounding this microRNA. In colorectal cancer for example, depletion of miR-203
is associated with a higher grade and lymph node metastasis (Deng, Wang et al 2016).
Conversely, overexpression was associated with improved survival and suppression of
growth in vitro on CRC cell lines. Using a bioinformatic algorithm called TargetScan, Deng
et al inferred the target of the miR-203 blockade was EIF5A2. Expression of miR-203 and
EIF5A2 were essentially opposite. The one exception from the published series is that of
epithelial ovarian cancers, which generally displayed the opposite effect, that miR-203 levels
are proportional to aggressiveness and are prognostically adverse (Iorio, Versone et al 2007).
In our cohort, with significant amplification of miR-203, we found that EIF5A2 (located on
3q – a highly amplified region – see above) was amplified in 11/15 samples with an average
CN of 4.2 in the amplified samples. There were no deletions of this gene. This is not the same
as either transcription influence or protein translation, but the amplification of both seems to
suggest there is more to this story, particularly in our cohort.

TP63 is a target of miR-203 in effect reducing p63 expression (Yi, Poy 2008). This means
that in vitro it reduces stemness in the suprabasal epithelial layers and promotes

129

differentiation. Conversely, miR_205 is thought to target E-cadherin expression, and in doing
so, be associated with a less well-differentiated form. In comparing miR-203 and miR-205
and their expression in high risk cSCC, again, miR-203 was more likely to be expressed in
better outcome disease, when compared to miR-205, which was associated with more
aggressive biology in terms of recurrence and locoregional metastasis (Canueto, CardenosoAlvarez et al 2017). Again, in terms of purely genomic observations of amplification and
deletion, this difference is not seen in our cohort, with amplification of miR-203 being the
most prominent amplified cSCC associated microRNA. Total RNA Seq will qualify and
quantify any expression difference.

Also within the list of miRNA of Dziunycz is miR-31. It has been further analysed by Wang
et al (Wand, Landen et al 2014) wherein they describe its apparent role in both primary and
metastatic cSCC, utilizing a previously described metastatic cSCC cell line UT-SCC-7. They
found that blocking of miRNA expression reduces invasion, migration and colony formation
of UT-SCC-7. miR-31 was not overexpressed in normal tissue or actinic keratosis. Within
our samples, miR-31 amplification was seen in 6/15, with an average CN of 4.5 (Table 6-1),
perhaps providing genomic evidence of over-expression.

6.5.4

Long non-coding RNA

lncRNA are a type of noncoding RNA that have transcripts greater than 200 nucleotides in
length without protein coding function. These are thought to be highly specific to
differentiated tissues and diseases including cancer. lncRNA influence gene expression by a
variety of mechanisms. The physiological and pathological mechanism of miRNA action is
more fully understood and there are a number of miRNA inhibitors and mimics currently
being developed for use in cancer and chronic diseases (Matsui and Corey 2017). lncRNA
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situated between genes are referred to as long intergenic ncRNA, and there is a subclass of
lincRNA that is termed very long intergenic non-coding RNA as their size is greater than
50kb.
PVT1 (lincRNA) upregulation is associated with worse prognosis and a more aggressive
phenotype in many cancers. It shares a locus with the known oncogene MYC on chr8. There
is significant correlation between amplification of PVT1 and MYC due to their close
proximity. In breast cancer, PVT1 may interact with the miRNA-200 family to promote early
disease events (Colombo, Farina et al. 2015). It may exert its role in gastric cancer by
interfering with the ubiquitinisation of STAT3 to reduce it degradation, and in doing so, to
promote angiogenesis (Zhao, Du et al 2018).

In this study, we have shown amplification in chr8q24.21 which includes both MYC and
PVT1. In addition, CNV identified PVT1 as amplified (to an average CN of 4.8) in 13/15
samples of metastatic cSCC (87%). There was no evidence of any deletions in this lincRNA.
The highest rate of amplification frequency seen in TCGA data is for ovarian cancer at 43%
(Colombo, Farina et al. 2015). Of note is that all samples with amplification of PVT1 showed
corresponding amplification of MYC presumably due to the block size (average size of
amplified element affecting PVT1 20.80 Mb) covering both regions in the long arm of chr8.
PVT1 holds some promise, not just in cSCC, as a potential biomarker of disease and/or
progression.
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7 Germline variants
While the focus of this study has been an analysis of the landscape of somatic variants in
metastatic cSCC, we have, in the process of interrogation of genes of interest, identified a
number of recurrent inherited variants that may be implicated in the development of cSCC,
and may play a role in the progression of cSCC.

7.1 Mismatch repair genes

In our cohort, significant germline events were identified in 14/19 whole blood samples. The
most recurrent of these variants, seen in 9/20 samples, was a splice region SNP of MSH2
(chr2:47641560 (A>C) (dbSNP ID rs11309117), with a scaled CADD of 11.63. This SNP
was not identified in any of the more than 4000 genomes sequenced in the Medical Genome
Reference Bank healthy elderly adult germline database, compiled and curated by the,
Kinghorn Centre for Clinical Genomics/Sydney Genomics Collaborative.
(https://www.garvan.org.au/research/kinghorn-centre-for-clinical-genomics/researchprograms/sydney-genomics-collaborative/mgrb). One other SNP, effecting one specimen,
had a probably damaging and deleterious variant in PMS2 (chr7:6045634 T>C) rs63750123
(scaled CADD 26.9), seen in 1% of MGRB samples. This SNP also has a COSMIC ID
(COSM601786), catalogued as a missense somatic variant in tumour sample of a sample of
metastatic cSCC (Li, Hanna et al. 2015)

7.2 TERT promoter

Germline analysis of all included samples reveals recurrent Chr5p15.33 SNPs. We identified
3 recurrent and novel variants in the TERT/CLPTM1L super-enhancer SE_66421 in 16 of 19
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samples. The incidence of these events in normal elderly healthy adult genome library
(MGRB – as discussed above) (n=5678) are 43%, (rs466502/Chr 5:1325767 A>G), 40%
(rs31488/Chr 5:1342156 A>G) and 44% (rs27070/Chr 5:13465303 G>C). This combination
of SNPs has not been previously described and they have neither independently nor in
combination been described in cSCC.

These germline events occur less than 1500BP upstream of the TSS of CLPTM1L, which in
turn is immediately upstream of TERT. They also sit within the bound region of
ENSR00000177543 which is the CLPTM1L regulatory element with binding sites for
promoting transcription factors including PKNOX1 and ATF1.

Germline analysis reveals 93% of our cases have a G>C SNP at 5:1346303 (rs27070), less
than 1500BP upstream of the TSS of CLPTM1L, within the TERT associated super-enhancer
SE_66421. This SNP also sits within the bound region of ENSR00000177543 which is the
CLPTM1L regulatory element with binding sites for promoting transcription factors including
PKNOX1 and ATF1. This SNP is present in 43% of 5678 sequenced germlines in our
database of healthy subjects. SNPs in the TERT/CLPTM1L.

7.3 Discussion

Much effort in this analysis of cSCC has been on tumour variation. We know, using
xeroderma pigmentosum as a model (see above Chapter 1.2) that predisposing inherited
conditions can mirror the effect of drug induced immunosuppression in increasing the
incidence of cSCC. There has been previously no investigation into whether novel inherited
predisposing genetic factors might play a role in determining a landscape for either a more
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aggressive form of cSCC or for disease which readily metastasizes. These initial results
suggest peculiarities in the germline of this cohort of patients with metastatic disease and
offers an avenue for a more formal interrogation. This idea is supported by recent work by
Ioannides and Wang et al (2018) who have identified through genome wide and
transcriptome wide analysis loci of likely predisposition for cSCC. These genes include
CTSS, HORMAD1, GOLPH3L and ANXA9 at 1q21, CASP8 at 2q33, AHI1 at 6q23, HAL at
12q23, and ORMDL3 at 17q21. Further analysis of larger germline samples within an
expanded group of our cases will allow some insights into any relevance of these genes in
susceptibility in the metastatic disease setting.
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8 Expression analysis
The Nanostring platform using the Pancancer Progression Gene Panel for multiplex gene
expression analysis was used. This catalogue of cancer associated genes (n=770) was selected
to match best with predicted patterns of variants associated with the metastatic process. The
genes analysed in the panel are listed in Appendix 6 and are known drivers of carcinogenesis,
metastasis or epithelial mesenchymal transition.

8.1 Results
Expression data for across all 770 genes is shown in Figure 8-1. The samples and genes are
clustered in an unsupervised manner and show considerable variation in gene expression
across all genes and specimens.

Within each of the following heatmaps, sample 34943 shows significant difference from the
remained of the cohort. This sample is from a patient who had left sided parotid lymph node
metastasis. Of all the patients included, this patient was the only to have previously had a
mucosal SCC, in addition to the included metastatic cSCC. They had undergone a
contralateral maxillary resection for an alveolar SCC 6 years prior to the emergence of their
cutaneous disease. It is unclear as to the significance of the observed expression difference
and how much previous treatment may have influenced subsequent behavior of a new,
anatomically related, malignancy.
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Figure 8-1 Heatmap analysis of expression of all 770 genes in the Nanostring Pancancer
Progression panel for all 15 metastatic cSCC specimens. Lower panel shows (log2)*gene
expression.

Next, gene expression analyses of tumour samples based on genes with recurrent short
variants across our cohort (refer to Figure 5-2) that are also included in the Nanostring
Pancancer Progression Panel was performed (Figure 8-2). For each of these genes, there was
demonstrable expression changes for high impact SNV. Within TP53, the only samples with
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high impact SNV (eg stop-gained or deletion) were 321773, 48585 and 4699. Conversely,
193958 had no high or medium impact SNV in TP53. With respect to PTPRD, while 38532
has evidence herein of decreased expression, and while it does have a high/medium impact
variant is a missense SNV, the SNV is classified as benign and tolerated, but with a scaled
CADD of 23. Within each sample, SNVs can be implicated in some of what is observed in
the expression analysis, but certainly not all. This supports the conventional wisdom that

200971
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184577
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9120

expression is the summation of multiple influences including both genetic and epigenetic.

Figure 8-2 Heatmap analysis of expression of genes with recurrent short variants across
15 metastatic cSCC specimens. Lower panel shows (log2)*gene expression
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Expression of those genes that are included in the Nanostring Pancancer Progression Panel
with significant CNV as reported in Figure 5-3 is shown in Figure 8-3. DCC and SMAD4

Figure 8-3 CNV and expression effect for the genes listed in Figure 5-3 that were
included in the 770 gene Cancer Progression Panel. Samples with SMAD4 and DCC
deletions listed beneath the heatmap. The samples in which SMAD4 is deleted include
321773, 183410 and 184577. The samples which showed deletion of DCC include 34366,
321773, 183410 and 184577.
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show recurrent deletions, all other genes were amplified.

As discussed earlier (Chapter 1.8), many genes are potentially implicated in EMT.
Expression differences in these genes are not necessarily driven by genetic variants.
Epigenetic influence may be a key driver of EMT. We examined a group of genes previously
identified as exhibiting expression differences in cSCC animal models (Pastushenko,
Brisebarre et al. 2018). This study defined tumour cells on the basis of their expression of
EPCAM markers CD61, CD51 and CD106, and differential expression of genes including
CDH1, EPCAM, KRTN14, ASPN, MMP1, TWIST1, VCAM, ZEB1, LOX.

Figure 8-4 Expression of EMT genes
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The expression heatmap of these genes across our cohort is presented in Figure 8-4.

MYLK, EPHB1 and PTK2 were amongst the genes that were shown to have gene break points
in more than one sample. To examine the effect of these coding break points and/or gene
fusions, all samples were tested for MYLK, EPHB1 and PTK2, as these genes were amongst
the 770 genes included in our Nanostring Pan Cancer Progression Panel. The findings are
presented in Figure 8-5.

Figure 8-5 Expression of genes with breakpoints (samples with breakpoints highlighted
in blue for given gene). Samples with MYLK breakpoints were 9120 and 184577.
Samples with EPHB1 breakpoints were 4699 and 321773.Samples with PTK2
breakpoints were (including sample 34934 which had gene fusion with SLA2). These
expression differences are inconclusive.
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8.2 Discussion
It is ultimately expression that determines a biological effect. Variants in the genome may be
transcribed and translated in an altered fashion to affect a pathological outcome. Various
methods exist for the correlation of genomic observations with gene expression. These
include formal sequencing of the entire transcribed RNA (transcriptome), a more limited
coding RNA sequencing, PCR (polymerase chain reaction) of isolated regions of transcribed
RNA by identification using primers, newer digital counting technologies and more clinical
means such as immunohistochemical assessment and in situ hybridization. There are pros and
cons to each platform, derivatives mainly of cost and technical demands, and within any
experiment, one or more of these may be applicable to different components of the analysis.

NanoString NCounter technology uses a hybrid probe to allow RNA in solution to be identified
with a capture probe and subsequently reported by a reporter probe. This highly automated
process delivers molecule counts for each gene of interest as a measure of expression. The
molecule counts are compared and calibrated to that of several housekeeping genes.

The extent of intracohort variability for selected genes with either CNV or high impacting
SNV was significant. Some of these findings were counterintuitive. For example, in Fig 8-2,
the sample with the least expression of TP53, relative to other samples, was 48585, which
showed TP53 amplification. However, it is worth noting that this sample also harboured a
high impact SNV, so the expression affect could be due to, for example, a premature stopgained or a splice variant curtailing transcription. The correlation between our identified
genomic events and the NanoString expression is not linear, and ultimately the employment
of RNASeq to more accurately measure the entire transcriptome will provide for greater
assurance around discrepancies. There are other instances where a clear expression change
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cannot be accounted for with only genomic data, without an understanding of transcriptional
translational influences beyond the observed variation.
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9 Conclusion and reflections
9.1 Conclusion
Cutaneous squamous cell carcinoma (cSCC) ranks as the most common lethal malignancy.
Primary cSCC ranks second only to BCC in prevalence, and together they comprise more
numbers than all other cancers combined. But most cSCC are able to be treated with simple
excision with clear margins. This is made more complex in head and neck regions, given
anatomical constraints and aesthetic considerations. Nonetheless, less than 5% of cSCC will
ever metastasize.

There are no clinicopathologic predictors of risk of metastasis. Large databases of high risk
and metastatic cSCC, such as that maintained at the Sydney Head & Neck Cancer Institute,
support the idea that tumours of the lip and ear are more likely to spread to cervical lymph
nodes. However, by no means do all tumours behave in this aggressive way, and therefore
most can be treated simply and not subjected to rigorous surveillance, other than for further
primary cutaneous lesions.

The impact of metastasis on the patient with cSCC is profound. Spread to lymph nodes
usually requires multimodal treatment including the surgical resection of effected lymph node
basins and adjuvant external beam radiotherapy. A large study of the effect of such therapy
reveals the quality of life costs (Wang, Palme et al 2013). The issue is not the metastasis per
se, but rather that most patients with metastatic disease have not been the subject of
surveillance to risk and with the aim of identifying regional disease spread. This is not due to
some dereliction of care, but rather that no reliable means of prediction of risk, and therefore
application of surveillance, has been established. The result of this clinical dilemma impacts
not just the individual patient, whereby lymph node metastases are often only identified at an
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advanced stage, but also the community, where effective strategies for surveillance and preemptive management could save not just morbidity to individuals but could more effectively
and efficiently use public money and resources.

The gaps in our knowledge of the genomic landscape of cSCC have lagged behind that of
many other less common cancers. In particular, as a marker of activity, publications in cSCC
compare unfavourably to those on melanoma (Figure 9.1) despite far greater prevalence.

Figure 9-1 Publication rates per year for the last 10 years comparing cSCC, Skin SCC
and Melanoma (PubMed).

This project is the first dedicated examination of the whole genome in metastatic cSCC. This
disease has the highest somatic genomic mutational burden of any disease ever described.
The overwhelming majority of this variation is in the non-coding genome. Within the coding
genome, the observed mutational burden provides evidence for the application of checkpoint
inhibiting immunotherapeutics. Metastatic cSCC is characterized by a highly disrupted
genome with significant structural variation. The predominant structural variation is
amplification. Within the coding genome, a pattern of highly impacting and recurrent SNV of
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both tumour suppressor genes and oncogenes is evident. Within the non-coding genome,
novel patterns of variation have been identified within the TERT promoter and also within
noncoding RNA.
This project is an exploration of the genomic landscape of metastatic cSCC. This subject
underpins the work now commenced on looking at expression changes in metastatic versus
primary disease, with a view to eventually providing validated biomarkers to discriminate
cancer behaviour and identify those tumours at greatest risk of metastasis from those at little
risk.
The suite of genes with high impact variants, and subject to copy number variation and or
structural rearrangement is significant, both in terms of synergy with other disease, and for
their potential to provide both a measurable biomarker, and a potential for therapy for
advanced or unresectable disease, or indeed for distant metastatic disease.

The subjects of investigation that have become obvious future areas if interest from this work
include:
Interrogation of non-coding variants- of note was the extent to which WGS illuminates the
variation in the non-coding genome. We have herein identified some noteworthy regions
which have stemmed from findings in other diseases, including the TERT promoter and
miRNA and lncRNA. This is however by no means an exhaustive list and a concentration on
these findings as well as other known hotspots of influence must be undertaken.
Analysis of germline variants – this project was not designed as an investigation of the
germline looking for predisposing inherited variants. However, even within the
CLPTM1L/TERT super-enhancer, we were able to identify SNPs of unusual combination and
recurrence. We understand the role of the immune system in predisposing to cSCC. It would
therefore seem illogical to imagine that components of the genetic makeup of individuals
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could not play a role in predisposing to an exaggerated effect of UV exposure, either through
innate immunodeficiency or through stromal variation.
Transcriptome analysis – this work must be combined with a thorough analysis of the
transcription and expression of the genomic events we have discovered. Outside of using
circulating DNA remnants as a biomarker of disease, an examination of the genomic state of
tumours does not provide any targets of use as a tool for assessing risk. Certainly the
discoveries herein provides clues to targets, but the transcriptome will potentially provide a
more useful picture of high risk and metastatic cSCC.
Already planned future work with this dataset will include the abovementioned transcriptome
analysis and integration and will also need to be enhanced by increasing the overall numbers
of both primary and metastatic deposits, including those cases that have synchronous primary
and metastatic disease.

9.2 Reflections
It has not been possible to extrapolate from the genomic analysis of 15 samples any particular
clinicopathologic behaviour attributable to somatic variation, other than to observe that the
metastatic stage of cSCC has a high mutational burden with prominent amplification. Within
our patient group, there was a wide variation in age, comorbid disease and
immunocompetency, all of which potentially confound a direct line between any given
genomic event and a clinical effect. So it would be fair to say that small numbers in this study
have not helped overcome the challenge of drawing specific conclusions with regard to
clinicopathologic behaviour.

Studies such as this need to be based on a watertight and meticulously archived tumour bank.
It is very challenging, even for a dedicated clinical team, to annotate and care for specimens
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to that level required of such a project. At every stage, we have been reminded of the absolute
requirement for record keeping and sample movement rigour, and have, on occasions, needed
to repeat experiments and retrace our steps, with time and money sacrificed. During this
project, the establishment of a highly sophisticated and research enabling tumour bank
(CONCERT) has taken over the ongoing collection and curation of our precious clinical
specimens and combines this with a prospective clinicopathologic database.

A single sequencing facility and team would have reduced opportunities for error and overall
would have reduced the work of sample delivery and downstream processing. Whilst the
AFP at ANU were as helpful and accommodating as the geographic dislocation allowed, the
delivery of tissues overseas to Macrogen did incur delay and further handling steps.
Subsequent delivery of raw data to allow for alignment, variant calling and eventual
bioinformatics analysis was more cumbersome than would have been afforded had we done
all the sequencing and processing at the KCCG, or any other single quality assured
sequencing provider.

I would have spent more time and consulted more widely in the establishment of an exact
protocol for cellularity estimation. I failed to discuss this process with other groups who may
have been in the position to help with a protocol to diminish the rate of poor tumour
cellularity and subsequent unusable sequencing effort. We had designed a system that relied
too heavily on potentially inexact and subjective measures, based on tissue samples that may
not have eventually matched exactly that which was subsequently used for DNA extraction
and sequencing. The protocol we eventually landed on was to take a small block of tissue
either side of that to be sequenced (30mg blocks) and to then have a Specialist Pathologist
give a tissue cellularity. If the tissue is assessed at >50%, the extracted DNA should then be
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submitted to a SNP array to confirm the suitability for WGS. One WGS undertaken on low
cellularity (unusable) tissue would pay for 15 SNP arrays. This modification of process has
educated a subsequent round of WGS of DNA extracted from primary cSCC.

Despite the learning curve associated with the technical and cognitive gains required, this
project has been transformative. It has allowed me to further understand the biology of a
challenging disease, to appreciate the scientific method and to build a strong collaboration of
interested clinicians and scientists to progress this work.
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Appendix 4 Gene List
AHNAK, BMP1, CALD1, CDH2 , COL1A2, COL3A1, COL5A2, FN1, FOXC2, GNG11, GSC,
IGFBP4, ITGA5, ITGAV, MMP2 MMP3, MMP9, MSN, SERPINE1, SNAI1, SNAI2, SNAI3,
SOX10, SPARC, STEAP1, TCF4, TIMP1, TMEFF1, TMEM132A, TWIST1, VCAN, VIM,
VPS13A, WNT5A, WNT5B, CAV2, CDH1 , DSP, FGFBP1, IL1RN, KRT19, MITF, MST1R,
NUDT13, PPPDE2, RGS2, SPP1, TFPI2, TSPAN13, AKT1,, CAV2, CDH2 CTNNB1, FN1,
FZD7, GNG11, GSK3B, IGFBP4, ILK, ITGA5, MAP1B, MITF, RGS2, SNAI1, SNAI2,
SPARC, TCF4, TGFB1, TGFB2, TGFB3, TIMP1, TMEFF1, TSPAN13, VIM, VPS13A,
WNT5A, AKT1, BMP2, BMP7, CTNNB1, DSP, ERBB3, F11R, FZD7, GSC, KRT14, MITF,
MST1R, NODAL, NOTCH1, PTP4A1, SMAD2, TGFB2, TGFB3, TMEFF1, TWIST1, VCAN,
WNT11, WNT5A, WNT5B, CTNNB1, PPP3R1, RAC1, SMAD2, SOX10, TGFB1, TGFB2,
TGFB3, TWIST1, WNT11, WNT5A, AKT1, BMP2, BMP7, CAV2, CTNNB1, EGFR, ERBB3,
FGFBP1, HIF1A, IGFBP4, ILK, MST1R, NODAL, PDGFRB, TGFB1, TGFB2, TGFB3,
TIMP1, VCAN, CAV2, EGFR, FN1, ITGB1, MSN, MST1R, NODAL, PDGFRB, RAC1,
STAT3, TGFB1, VIM, BMP2, BMP7, CDH1, CDH2 , CTGF, CTNNB1, DSC2, EGFR,
ERBB3, F11R, FN1, ILK, ITGA5, ITGAV, ITGB1, PTK2, RAC1, SPP1 , TGFB1, TGFB2,
TIMP1, VCAN, CAV2, ESR1 , KRT19, TGFB3, NOTCH1, EGFR, ERBB3, PDGFRB, RGS2,
SPARC, BMP2, BMP7, , SMAD2, SMAD4, TGFB1, TGFB2, TGFB3 CCT3, CENPF,
KCNK1, CCL14, GREB1, ADH1B, ANLN RELN AAMP ABI3BP ACHE ACTG2 ACVR1
ACVR1C ACVRL1 ADAM15 ADAM17 ADAM28 ADAM8 ADAM9 ADAMTS1 ADAMTS12
ADAMTS8 ADAP1 ADD1 ADM2 ADRA2B AEBP1 AGGF1 AGR2 AGRN AGT AKAP12
AKAP2 AKT1 AKT2 AKT3 ALB ALDOA ALOX5 AMH ANG ANGPT1 ANGPT2 ANGPTL2
ANGPTL4 ANPEP ANXA2 AP1M2 APC APOD APOE APOH AQP1 ARAP2 AREG
ARHGAP32 ARHGDIB ASPN ATPIF1 B3GNT3 BAD BAG2 BAI1 BAI3 BCAS1 BGN BICC1
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BMP4 BMP5 BMP7 BMPER BMPR1A BMPR1B BMPR2 BNC2 BRMS1 BTG1 C1S C3
C3AR1 CADM1 CALCRL CAMK2A CAMK2B CAMK2D CAMP CASP8 CAV1 CBLC
CCBE1 CCDC80 CCL11 CCL21 CCL5 CCL7 CCL8 CCR2 CCR3 CD163 CD24 CD2AP
CD34 CD36 CD44 CD46 CD82 CDC42 CDH1 CDH11 CDH13 CDH2 CDK14 CDKN1A
CDKN2A CDS1 CEACAM1 CEACAM5 CEACAM6 CEP170 CEP295 CFP CGN CHAD
CHD4 CHI3L1 CHP1 CHP2 CHRDL1 CHRNA7 CIB1 CKMT1A CLDN1 CLDN3 CLDN4
CLDN7 CLEC2B CLEC3B CLIC4 CLU CMA1 CNN1 COL18A1 COL4A1 COL4A2 COL4A6
COL5A1 COL6A1 COL6A2 COL6A3 COL7A1 COMP CREBBP CRIP2 CRISPLD2 CSF2RB
CSPG4 CST7 CTNNB1 CTNND1 CTSG CTSH CTSK CTSL CUL1 CX3CL1 CXADR
CXCL10 CXCL11 CXCL12 CXCL13 CXCL17 CXCL8 CXCR2 CXCR3 CXCR4 CYB561
CYBB CYP1B1 DAG1 DCC DCN DDR2 DENND5A DENR DESI1 DICER1 DLC1 DLG1
DLL4 DPT DPYSL3 DSC2 DST ECM1 ECM2 ECSCR EDN1 EGF EGFL7 EGFR EGLN2
EGLN3 EIF2AK3 EIF4E2 EIF4EBP1 ELF3 ELK3 EMCN EMILIN1 EMILIN3 EMP3 ENO1
ENO2 ENO3 ENPEP ENPP2 EP300 EPAS1 EPCAM EPHA1 EPHA2 EPHB1 EPHB3
EPHB4 EPN3 EPS8L1 ERBB2 ERBB2IP ERBB3 EREG ERMP1 ESRP1 ETV4 EVI2A EVPL
F11R F3 FAM174B FAP FASLG FBLN1 FBLN5 FBN1 FBN2 FBP1 FERMT2 FGF18 FGF2
FGF9 FGFR1 FGFR2 FGFR3 FGFR4 FGL2 FHL1 FIGF FLI1 FLT1 FLT4 FMOD FN1
FOXO4 FRAS1 FREM1 FREM2 FST FSTL1 FUT3 FXYD6 GALNT7 GATA4 GDF15 GDF5
GDF6 GIMAP4 GIMAP6 GJA5 GLYR1 GPI GPR124 GPR56 GPX1 GREM1 GRHL2 GSN
GTF2I GZMK HAPLN1 HAS1 HDAC5 HDHD3 HEG1 HGF HIF1A HIPK1 HIPK2 HK2
HK3 HKDC1 HLA-DPB1 HMOX1 HOXA5 HOXA7 HOXB13 HOXB3 HPSE HRAS
HSD17B12 HSP90B1 HSPB1 HSPG2 HUNK IBSP ICAM1 ID1 ID2 ID4 IFNG IGF1
IGFBP4 IGFBP7 IL10RA IL11 IL13RA2 IL15 IL18 IL1A IL1B IL1RL1 IL1RN IL6 ILK
INHBA INHBE IRF6 ISL1 ISLR ITGA1 ITGA11 ITGA2 ITGA3 ITGA5 ITGA6 ITGA7 ITGA8
ITGA9 ITGAM ITGB1 ITGB1BP1 ITGB2 ITGB3 ITGB4 ITGB6 ITGB7 ITGB8 ITM2A JAG1
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JAM2 JAM3 JUN KCNJ8 KDM1A KDR KIAA1462 KISS1 KLK3 KRAS KRIT1 KRT1 KRT14
KRT19 KRT7 LAD1 LAMA1 LAMA3 LAMA4 LAMA5 LAMB3 LAMC1 LAMC2 LDHA
LEFTY1 LGALS1 LHFP LIFR LLGL2 LOX LOXL2 LRG1 LTBP4 LUM LY96 MAF MAP2K1
MAP2K2 MAP2K4 MAP3K7 MAPK1 MAPK3 MAPKAPK3 MCAM MED1 MED23 MEG3
MEOX2 MET MFAP4 MGAT5 MGP MISP MMP1 MMP10 MMP12 MMP13 MMP14
MMP17 MMP2 MMP24 MMRN2 MPDZ MRC1 MS4A4A MS4A6A MT3 MTA1 MTBP
MTDH MTOR MUC1 MYC MYCL MYH11 MYLK MYO1D MYO5C NAA15 NAP1L3
NCAM1 NCL NDNF NDP NDRG1 NF1 NF2 NFAT5 NFATC2 NFKB1 NID2 NME1 NME4
NODAL NOS2 NOS3 NOTCH1 NOTCH2 NOX5 NPR1 NR3C1 NR4A1 NR4A3 NRCAM
NRP1 NRP2 NRXN1 NRXN3 NTRK1 OAS1 OCLN OGN OLFML2B OVOL2 P3H1 P3H2
PCOLCE PDCD10 PDCL3 PDGFA PDGFC PDGFRB PDK1 PDPN PEBP4 PECAM1
PFKFB1 PFKFB4 PGK1 PIK3CA PIK3CD PIK3CG PIK3R1 PIK3R2 PIK3R5 PIK3R6
PITX2 PKM PKN1 PKNOX1 PLA2G10 PLA2G2A PLA2G2D PLA2G3 PLAU PLAUR
PLCG1 PLCG2 PLEKHO1 PLS1 PLXDC1 PLXNC1 PLXND1 PMP22 PNPLA6 POPDC3
POSTN PPFIBP2 PPL PPP1R16B PPP2CB PPP2R1A PPP3R1 PRELP PRF1 PRKCB
PRKCG PRKCZ PROK2 PROM1 PRR15L PRSS22 PRSS8 PTEN PTGDS PTGIS PTGS2
PTK2 PTK2B PTK6 PTPRB PTPRC PTPRM PTRF PTTG1 PTX3 PXDN PYCARD QKI
RAB25 RAC1 RAC2 RAF1 RAMP1 RAMP2 RB1 RBL1 RBL2 RBM47 RBPJ RBX1 RELN
RGCC RHOA RNH1 ROBO4 ROCK1 ROCK2 RORA RORB RPS27A RPS6KB1 RPS6KB2
RRAS RTN4 RUNX1 RUNX1T1 S100A14 S100A7 S1PR1 SACS SAMSN1 SCG2 SCNN1A
SDC4 SELE SEMA3E SERINC5 SERPINA1 SERPINF1 SERPING1 SERPINH1 SET SETD2
SFRP1 SFRP2 SH2B3 SH2D3A SH3YL1 SHB SIRT1 SKP1 SLC12A6 SLC2A1 SLC35A3
SLC37A1 SLC44A4 SLIT2 SLPI SMAD1 SMAD2 SMAD3 SMAD4 SMAD5 SMAD9 SMC3
SMOC1 SMURF1 SMURF2 SNRPF SOD1 SOS SORD SOX17 SOX2 SOX9 SP1 SPARC
SPARCL1 SPDEF SPHK2 SPINK5 SPINT1 SPOCK3 SPP1 SRC SRF SRGN SRPK2 SRPX2
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SSTR2 ST14 STAB1 STAB2 STAT1 STAT3 SULF1 SV2B SYK SYNE1 TACSTD2 TAL1 TBX1
TBX4 TBXA2R TCEB1 TCEB2 TCF20 TCF3 TCF4 TDGF1 TEK TF TFDP1 TFPI2 THBS1
THBS2 THBS4 THY1 TIE1 TIMP1 TIMP2 TIMP4 TJP2 TJP3 TLR4 TMC6 TMEM100
TMEM30B TMPRSS2 TMPRSS4 TMPRSS6 TNC TNF TNFRSF12A TNFRSF1A TNFSF10
TNFSF12 TNFSF13 TNMD TNN TNS1 TNXB TOM1L1 TP53 TPM2 TPSB2 TPSD1 TSHR
TSPAN1 TWIST1 TWIST2 TXNIP TYMP UBA52 UTS2 VAMP8 VASH1 VAV2 VAV3 VCAM1
VCAN VEGFA VEGFB VEGFC VEZF1 VHL VIM VIT VPS13A VSIG4 VWA1 VWA2 WARS
WIPF1 WNT5A WNT5B WWTR1 ZC3H12A ZCCHC24 ZEB1 ZEB2 ZFPM2 ZFYVE16
ZFYVE9 AGK AMMECR1L CC2D1B CNOT10 CNOT4 COG7 DDX50 DHX16 DNAJC14
EDC3 EIF2B4 ERCC3 FCF1 GPATCH3 HDAC3 MRPS5 MTMR14 NOL7 NUBP1
PRPF38A SAP130 SF3A3 TLK2 TMUB2 TRIM39 USP39 ZC3H14 ZKSCAN5 ZNF143
ZNF346, CDH2 , FN1, FOXC2, GNG11, GSC, IGFBP4, ITGA5, ITGAV , MSN, SOX10,
SPARC, STEAP1, TCF4, TIMP1, TMEFF1, TMEM132A, TWIST1, VCAN, VIM, VPS13A,
WNT5A, WNT5B, CAV2, CDH1 , DSP, FGFBP1, IL1RN, KRT19, MITF, MST1R, NUDT13, ,
RGS2, SPP1, TFPI2, TSPAN13, , AKT1, , CAV2, CDH2 CTNNB1, FN1, FZD7, GNG11,
GSK3B, IGFBP4, ILK, ITGA5, MAP1B, MITF, RGS2, SPARC, TCF4, TGFB1, TGFB2,
TGFB3, TIMP1, TMEFF1, TSPAN13, VIM, VPS13A, WNT5A, AKT1, BBMP2,
BMP7CTNNB1, DSP, ERBB3, F11R, FOXC2, FZD7, GSC, KRT14, MITF, MST1R, NODAL,
NOTCH1, PTP4A1, SMAD2, SOX10, TGFB2, TGFB3, TMEFF1, TWIST1, VCAN, WNT11,
WNT5A, WNT5B, CTNNB1, FOXC2, PPP3R1, RAC1, SMAD2, SOX10, TGFB1, TGFB2,
TGFB3, TWIST1, WNT11, WNT5A, AKT1, BMP2, BMP7, CAV2, CTNNB1, EGFR, ERBB3,
FGFBP1, FOXC2, HIF1A, IGFBP4, ILK, MST1R, NODAL, PDGFRB, TIMP1, VCAN,
CAV2, EGFR, FN1, ITGB1, MSN, MST1R, NODAL, PDGFRB, RAC1, STAT3, TGFB1, VIM,
BMP2, BMP7, CDH1, CDH2 , COL5A2, CTGF, CTNNB1, DSC2, EGFR, ERBB3, F11R,
FN1, FOXC2, ILK, ITGA5, ITGAV, ITGB1, MMP3, PTK2, RAC1, SPP1 , TGFB1, TGFB2,
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TIMP1, VCAN, CAV2, ESR1 , KRT19, TGFB3, PDGFRB, RGS2, SPARC, SMAD4, CCT3,
CENPF, KCNK1, CCL14, GREB1, ADH1B, ANLN RELN PCLO, CSMD3, MUC16, ST18,
USH2A, AMPH, FAT4, PDE1C, SHANK1, ABCA13, APOB, THSD7B, CYP2C8, DNAH10,
SEMA3D, IL1RAPL1
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Appendix 5 Nanostring Pancancer Progression Panel Gene
List
ZFYVE9,ZFYVE16,ZFPM2,ZEB2,ZEB1,ZCCHC24,ZC3H12A,WWTR1,WNT5B,WNT5A,WIPF1,WAR
S,VWA2,VWA1,VSIG4,VPS13A,VIT,VIM,VHL,VEZF1,VEGFC,VEGFB,VEGFA,VCAN,VCAM1,VAV3,
VAV2,VASH1,VAMP8,UTS2,UBA52,TYMP,TXNIP,TWIST2,TWIST1,TSPAN1,TSHR,TPSD1,TPSB2,
TPM2,TP53,TOM1L1,TNXB,TNS1,TNN,TNMD,TNFSF13,TNFSF12,TNFSF10,TNFRSF1A,TNFRSF1
2A,TNF,TNC,TMPRSS6,TMPRSS4,TMPRSS2,TMEM30B,TMEM100,TMC6,TLR4,TJP3,TJP2,TIMP
4,TIMP2,TIMP1,TIE1,THY1,THBS4,THBS2,THBS1,TGFBR2,TGFBI,TGFB2,TGFB1,TFPI2,TFDP1,TF
,TEK,TDGF1,TCF4,TCF3,TCF20,TCEB2,TCEB1,TBXA2R,TBX4,TBX1,TAL1,TACSTD2,SYNE1,SYK,SV
2B,SULF1,STAT3,STAT1,STAB2,STAB1,ST14,SSTR2,SRPX2,SRPK2,SRGN,SRF,SRC,SPP1,SPOCK3,
SPINT1,SPINK5,SPHK2,SPDEF,SPARCL1,SPARC,SP1,SOX9,SOX2,SOX17,SORD,SOD1,SNRPF,SNA
I3,SNAI2,SNAI1,SMURF2,SMURF1,SMOC1,SMC3,SMAD9,SMAD5,SMAD4,SMAD3,SMAD2,SM
AD1,SLPI,SLIT2,SLC44A4,SLC37A1,SLC35A3,SLC2A1,SLC12A6,SKP1,SIRT1,SHB,SH3YL1,SH2D3A
,SH2B3,SFRP2,SFRP1,SETD2,SET,SERPINH1,SERPING1,SERPINF1,SERPINE1,SERPINA1,SERINC5
,SEMA3E,SELE,SDC4,SCNN1A,SCG2,SAMSN1,SACS,S1PR1,S100A7,S100A14,RUNX1T1,RUNX1,
RTN4,RRAS,RPS6KB2,RPS6KB1,RPS27A,RORB,RORA,ROCK2,ROCK1,ROBO4,RNH1,RHOA,RGCC
,RELN,RBX1,RBPJ,RBM47,RBL2,RBL1,RB1,RAMP2,RAMP1,RAF1,RAC2,RAC1,RAB25,QKI,PYCA
RD,PXDN,PTX3,PTTG1,PTRF,PTPRM,PTPRC,PTPRB,PTK6,PTK2B,PTK2,PTGS2,PTGIS,PTGDS,PTE
N,PRSS8,PRSS22,PRR15L,PROM1,PROK2,PRKCZ,PRKCG,PRKCB,PRF1,PRELP,PPP3R1,PPP2R1A,
PPP2CB,PPP1R16B,PPL,PPFIBP2,POSTN,POPDC3,PNPLA6,PMP22,PLXND1,PLXNC1,PLXDC1,PL
S1,PLEKHO1,PLCG2,PLCG1,PLAUR,PLAU,PLA2G3,PLA2G2D,PLA2G2A,PLA2G10,PKNOX1,PKN1
,PKM,PITX2,PIK3R6,PIK3R5,PIK3R2,PIK3R1,PIK3CG,PIK3CD,PIK3CA,PGK1,PFKFB4,PFKFB1,PEC
AM1,PEBP4,PDPN,PDK1,PDGFRB,PDGFC,PDGFA,PDCL3,PDCD10,PCOLCE,P3H2,P3H1,OVOL2,
OLFML2B,OGN,OCLN,OAS1,NTRK1,NRXN3,NRXN1,NRP2,NRP1,NRCAM,NR4A3,NR4A1,NR3C1
,NPR1,NOX5,NOTCH1,NOS3,NOS2,NODAL,NME4,NME1,NID2,NFKB1,NFATC2,NFAT5,NF2,NF
1,NDRG1,NDP,NDNF,NCL,NCAM1,NAP1L3,NAA15,MYO5C,MYO1D,MYLK,MYH11,MYCL,MYC,
MUC1,MTOR,MTDH,MTBP,MTA1,MT3,MS4A6A,MS4A4A,MRC1,MPDZ,MMRN2,MMP9,MMP
3,MMP24,MMP2,MMP17,MMP14,MMP13,MMP12,MMP10,MMP1,MISP,MGP,MGAT5,MFA
P4,MET,MEOX2,MEG3,MED23,MED1,MCAM,MAPKAPK3,MAPK3,MAPK1,MAP3K7,MAP2K4,
MAP2K2,MAP2K1,MAF,LY96,LUM,LTBP4,LRG1,LOXL2,LOX,LLGL2,LIFR,LHFP,LGALS1,LEFTY1,L
DHA,LAMC2,LAMC1,LAMB3,LAMA5,LAMA4,LAMA3,LAMA1,LAD1,KRT7,KRT19,KRT14,KRT1,K
RIT1,KRAS,KLK3,KISS1,KIAA1462,KDR,KDM1A,KCNJ8,JUN,JAM3,JAM2,JAG1,ITM2A,ITGB8,ITG
B7,ITGB6,ITGB4,ITGB3,ITGB2,ITGB1BP1,ITGB1,ITGAM,ITGA9,ITGA8,ITGA7,ITGA6,ITGA5,ITGA
3,ITGA2,ITGA11,ITGA1,ISLR,ISL1,IRF6,INHBE,INHBA,ILK,IL6,IL1RN,IL1RL1,IL1B,IL1A,IL18,IL15,I
L13RA2,IL11,IL10RA,IGFBP7,IGFBP4,IGF1,IFNG,ID4,ID2,ID1,ICAM1,IBSP,HUNK,HSPG2,HSPB1,
HSP90B1,HSD17B12,HRAS,HPSE,HOXB3,HOXB13,HOXA7,HOXA5,HMOX1,HLADPB1,HKDC1,HK3,HK2,HIPK2,HIPK1,HIF1A,HGF,HEG1,HDHD3,HDAC5,HAS1,HAPLN1,GZMK,G
TF2I,GSN,GRHL2,GREM1,GPX1,GPR56,GPR124,GPI,GLYR1,GJA5,GIMAP6,GIMAP4,GDF6,GDF
5,GDF15,GATA4,GALNT7,FXYD6,FUT3,FSTL1,FST,FREM2,FREM1,FRAS1,FOXO4,FOXC2,FN1,F
MOD,FLT4,FLT1,FLI1,FIGF,FHL1,FGL2,FGFR4,FGFR3,FGFR2,FGFR1,FGF9,FGF2,FGF18,FERMT2,
FBP1,FBN2,FBN1,FBLN5,FBLN1,FASLG,FAP,FAM174B,F3,F11R,EVPL,EVI2A,ETV4,ESRP1,ERMP
1,EREG,ERBB3,ERBB2IP,ERBB2,EPS8L1,EPN3,EPHB4,EPHB3,EPHB1,EPHA2,EPHA1,EPCAM,EP
AS1,EP300,ENPP2,ENPEP,ENO3,ENO2,ENO1,EMP3,EMILIN3,EMILIN1,EMCN,ELK3,ELF3,EIF4E
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BP1,EIF4E2,EIF2AK3,EGLN3,EGLN2,EGFR,EGFL7,EGF,EDN1,ECSCR,ECM2,ECM1,DST,DSC2,DPY
SL3,DPT,DLL4,DLG1,DLC1,DICER1,DESI1,DENR,DENND5A,DDR2,DCN,DCC,DAG1,CYP1B1,CYBB
,CYB561,CXCR4,CXCR3,CXCR2,CXCL8,CXCL17,CXCL13,CXCL12,CXCL11,CXCL10,CXADR,CX3CL1,
CUL1,CTSL,CTSK,CTSH,CTSG,CTNND1,CTNNB1,CST7,CSPG4,CSF2RB,CRISPLD2,CRIP2,CREBBP,
COMP,COL7A1,COL6A3,COL6A2,COL6A1,COL5A2,COL5A1,COL4A6,COL4A2,COL4A1,COL3A1,
COL1A2,COL1A1,COL18A1,CNN1,CMA1,CLU,CLIC4,CLEC3B,CLEC2B,CLDN7,CLDN4,CLDN3,CLD
N1,CKMT1A,CIB1,CHRNA7,CHRDL1,CHP2,CHP1,CHI3L1,CHD4,CHAD,CGN,CFP,CEP295,CEP170
,CEACAM6,CEACAM5,CEACAM1,CDS1,CDKN2A,CDKN1A,CDK14,CDH2,CDH13,CDH11,CDH1,C
DC42,CD82,CD46,CD44,CD36,CD34,CD2AP,CD24,CD163,CCR3,CCR2,CCL8,CCL7,CCL5,CCL21,C
CL11,CCDC80,CCBE1,CBLC,CAV1,CASP8,CAMP,CAMK2D,CAMK2B,CAMK2A,CALD1,CALCRL,CA
DM1,C3AR1,C3,C1S,BTG1,BRMS1,BNC2,BMPR2,BMPR1B,BMPR1A,BMPER,BMP7,BMP5,BMP
4,BICC1,BGN,BCAS1,BAI3,BAI1,BAG2,BAD,B3GNT3,ATPIF1,ASPN,ARHGDIB,ARHGAP32,AREG,
ARAP2,AQP1,APOH,APOE,APOD,APC,AP1M2,ANXA2,ANPEP,ANGPTL4,ANGPTL2,ANGPT2,AN
GPT1,ANG,AMH,ALOX5,ALDOA,ALB,AKT3,AKT2,AKT1,AKAP2,AKAP12,AHNAK,AGT,AGRN,AG
R2,AGGF1,AEBP1,ADRA2B,ADM2,ADD1,ADAP1,ADAMTS8,ADAMTS12,ADAMTS1,ADAM9,AD
AM8,ADAM28,ADAM17,ADAM15,ACVRL1,ACVR1C,ACVR1,ACTG2,ACHE,AAMP
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